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Expansion of the CGG repeat region of the FMR1 gene from less than 45 repeats to between 
55 and 200 repeats is known as the FMR1 premutation. Carriers of the FMR1 premutation 
may develop a neurodegenerative disease called fragile X-associated tremor/ataxia syndrome 
(FXTAS), which involves progressive symptoms of tremor, ataxia and cognitive decline. 
Evidence also suggests that premutation carriers experience other psychiatric difficulties 
throughout their lifespan.  
The present study aimed to investigate and delineate neurodegenerative and 
neurodevelopmental aspects of the premutation utilising primarily fMRI, clinical 
assessments and molecular measurements in 17 premutation carrier participants and 17 age-
matched control participants, aged between 20 and 70 years. The functional imaging 
protocol included a motor task and an emotional processing task. A battery of clinical and 
neuropsychological tests outside of the scanner and blood-based measurements of FMR1 
CGG repeat length, FMRP levels and FMR1 mRNA levels were also carried out.  
In the motor task, premutation carriers demonstrated significantly less cerebellar activation 
than controls during sequential versus random finger tapping (FWEcorr<0.001). In addition, 
there was a significant age by group interaction in the hippocampus, inferior parietal cortex 
and temporal cortex originating from a more negative relationship between brain activation 
and age in the carrier group compared to the controls (FWEcorr<0.001). Quantative real-time 
PCR analysis revealed that mean age-matched FMR1 mRNA levels display a trend towards 
being higher in carriers and clinical testing of motor skills additionally showed significantly 
worse tremor and co-ordination scores in non-FXTAS carriers. No significant associations 
were seen between these measurements and neuroimaging data. 
During the emotional processing task, carriers exhibited significantly lower activation 
compared to controls (FWEcorr<0.001) at the bilateral superior parietal lobe, bilateral 
Brodmann Area (BA) 17 (V1), right intraparietal area and right BA18 (V2) when comparing 
high arousal and low arousal conditions. Group by age interaction analyses indicated no 
significant between group differences at a whole brain level. Clinical assessment revealed 
that carriers displayed significantly worse symptoms of obsessive-compulsiveness, anxiety, 
global severity of psychiatric symptoms, facial emotion recognition and autistic traits 
compared to controls and FMRP levels were comparable between groups. No significant 
associations were seen between these measurements and neuroimaging data. 
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Here, we present for the first time functional imaging-based evidence for early movement-
related neurodegeneration in Fragile X premutation carriers. These changes pre-exist the 
diagnosis of FXTAS and are greatest in older carriers suggesting that they may be indicative 
of FXTAS vulnerability. Additionally, we show significantly altered emotional processing at 
neuropsychological, clinical and functional neuroimaging levels in carriers compared to 
controls, which appear to display stability over age. Overall, we present new evidence in 
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Chapter 1: An introduction to the Fragile X premutation  
1.1 Neurodegeneration in the Fragile X premutation and the neurological clinical 
presentation of FXTAS 
The Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) is one of the most prevalent 
neurodegenerative movement diseases with a known single gene causation (Tassone & Berry-Kravis 
2010). The syndrome develops in approximately 40% of males and 8-16% of females who carry a 
repeat expansion mutation of the FMR1 gene, which is known as the FMR1 premutation. Specifically, 
the Fragile X premutation is an enlargement of the non-translated 5’ CGG repeat island of FMR1 to 
between 55-200 repeats. The normal repeat range in the general population is anywhere up to 55 
repeats (Dombrowski et al. 2002; Coffey et al. 2008). As of yet, there is no evidence-based, targeted 
treatment for FXTAS. However, treatment of the associated symptoms have proven effective for some 
affected people (Hall et al. 2006). 
FXTAS presents classically as a late-onset disorder, usually in males above the age of 50 years. 
Patients typically experience progressive symptoms of gait ataxia, kinetic tremor and mild 
Parkinsonism. As the disease advances, tremor usually increases in amplitude, causing patients 
difficulty with every day activities that require fine motor control, such as eating and writing 
(Tassone, Adams, Elizabeth M Berry-Kravis, et al. 2007). Gait instability gradually worsens such that 
falling and loss of balance subsequently become more frequent in the later stages of the disease, often 
resulting in injury and causing FXTAS individuals to eventually become bed bound (Leehey et al. 
2008). Features of Parkinsonism are also an important part of the FXTAS phenotype, with patients 
typically experiencing rigidity and hypomimia. Although these Parkinsonian symptoms are usually 
characterised as mild, it is estimated that over a quarter of FXTAS patients are initially misdiagnosed 
with Parkinson disease (Hall et al. 2005). Autonomic dysfunction, peripheral neuropathy and changes 
to normal endocrine functioning are also commonly found in patients with FXTAS (Tassone & Berry-
Kravis 2010). Neuropathic signs in particular are thought to be linked to the presence of ataxia and 
increased severity has been found to positively correlate with larger CGG repeat expansions (Berry-
Kravis, Goetz, et al. 2007). Moreover, electrophysiological findings in males both with and without 
FXTAS are found consistently to be abnormal, although this is much less significant in carriers 
without other neurological symptoms (Soontarapornchai et al. 2008). Autonomic dysfunction is 
frequently reported by older premutation carriers, with the majority of men with FXTAS experiencing 
urinary incontinence and some presenting with orthostatic hypotension (Jacquemont et al. 2003a).  
Progressive cognitive decline also forms a major part of the FXTAS diagnosis. Approximately 40% of 
males with FXTAS will develop full dementia, although this frequency is likely to be an 
underestimate for those with late-stage FXTAS (Bourgeois et al. 2007). The percentage of women 
that develop dementia however is thought to be significantly lower (Hagerman et al. 2004). Clinical 
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reports have also suggested that subtle cognitive impairments may precede the onset of motor 
dysfunction in many FXTAS cases (Bourgeois et al. 2006). 
The cognitive impairment in FXTAS is both cortical and subcortical, with involvement of the frontal 
and hippocampal structures and both cerebral and cerebellar white matter.  This presents as deficits in 
attentional control, working memory, declarative learning and memory and information processing 
speed, which gradually worsen (Seritan et al. 2008). Many of these types of cognition come under the 
umbrella of executive functioning, which is the subset of cognitive processes that regulate planning, 
judgements, selective attention focussing and multi-tasking. In FXTAS, cognitive decline is primarily 
driven by executive dysfunction, and other deficits are thought to be largely secondary (Brega et al. 
2008). An integral part of executive functioning is the autonomous initiation of purposeful behaviour 
and the inhibition of inappropriate activity. Dysregulation of this type of executive functioning, 
namely disinhibition, is a prominent deficit in individuals with FXTAS, and is one of the earliest signs 
of cognitive impairment for those with the Fragile X premutation. Evidence indicates that age plays a 
large a role in disinhibition for premutation carriers both with and without FXTAS, as the trajectory of 
inhibitory control appears to worsen over time (Cornish et al. 2008). Marked impairment in non-
verbal intelligence, as measured by IQ scores, is also commonly seen in individuals with FXTAS, 
whereas verbal IQ functioning is much less affected (Hagerman et al. 2001). The executive 
functioning system is distributed widely across the whole brain, with many areas that feed into and 
out of it, nevertheless, given its integrative role of structuring goal-directed behaviour, the prefrontal 
cortex has been implicated as a region of interest for dysexecutive syndromes such as FXTAS (Yang 
et al. 2013).   
It is notable that the phenotype of FXTAS is highly variable. Patients often present with varying 
degrees of disordered movement and cognitive impairment, with progression of the disease being 
extremely fast in some cases and much slower in others (Tassone & Berry-Kravis 2010). The reasons 
for such heterogeneity are unclear, however it is likely that both genetic and environmental factors 
play a role.  
1.2 Neurodevelopmental disorders in Fragile X premutation carriers 
Neurodevelopmental disorders such as autistic traits and psychiatric problems (including anxiety, 
depression, obsessive-compulsive behaviour and irritability) have been identified in Fragile X 
premutation carriers throughout their lifespan (Dorn et al. 1994). The manifestation of these disorders 
seems to be irrespective of FXTAS development, and it is possible that these neurodevelopmental 
abnormalities are functionally separate to neurodegeneration in carriers, representing a stable 
phenotype (Hagerman & Hagerman 2013).  
Psychiatric checklist questionnaires have revealed that both male and female asymptomatic 
premutation carriers scored higher than control subjects for obsessive-compulsiveness and overall 
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symptom severity. Males and females with FXTAS exhibited a more severe psychiatric phenotype, 
with elevated scores for somatization, obsessive-compulsiveness, depression and overall symptom 
severity (Hessl et al. 2005). It is unclear however, whether this heightened level of psychiatric 
symptomatology is inherently part of FXTAS or whether existing problems are exacerbated by 
cognitive dysfunction and physical illness. Notably, whilst carriers commonly exhibit increased 
prevalence of symptoms of psychiatric disturbance, research does not suggest a link between the 
Fragile X premutation and clinically significant psychiatric illness (Bacalman et al. 2006). Carrier 
mothers that have a child with Fragile X Syndrome are especially affected with psychiatric 
symptomatology, with one study reporting a 55.7% lifetime incidence of mood disorders in this subset 
of individuals, of which 19.7% were classified as major depression disorder and 41% were classified 
as anxiety disorders. It is likely in these cases that stress and the lifestyle demands of caring for a 
disabled child with Fragile X play a large role in augmenting psychiatric difficulties (Franke et al. 
1998). Recent evidence has also shown that premutation carriers have a significantly heightened risk 
of developing a social phobia, with lifetime prevalence in both male and female carriers being 
estimated at 34.2% compared with 12.6% in the general population (Bourgeois et al. 2011). Again, 
research is suggestive that these findings into social phobias in carriers may be a result of the 
interacting effects of social stress and genetic risk, given that approximately 18% of female carriers 
with a Fragile X child suffer from a social phobia, compared to 5.9% of female carriers without a 
Fragile X child (Franke et al. 1998).  
The frequency of autism spectrum disorder (ASD) within in the Fragile X premutation carrier 
population has also been found to be significantly higher than in the general population, with an 
estimated 10-20% of carrier males and 1-7% of carrier females meeting the criteria for ASD, 
compared to less than 1% of males and females in the general population (Besterman et al. 2014; 
Hagerman & Hagerman 2016). Studies have shown that social deficits consistent with ASD in 
particular, such as poor social cognition, lowered accuracy in social perception and marked difficulty 
with interpersonal skills are frequently observed in carriers from a young age (Cornish et al. 2005). 
Much like the neurodegenerative aspects of the Fragile X premutation, the psychiatric and 
neurodevelopmental problems experienced by some carriers are notably broad and heterogeneous. 
The genetic risk appears to be inclusive of many types of disorder or elevated symptomatology, and it 
is likely that environmental and socio-economic factors play a part in determining manifestation.  
1.3 Molecular pathology of the premutation and FXTAS 
In full Fragile X Syndrome, a CGG repeat expansion of the FMR1 gene to above 200 repeats causes 
the gene to become heavily methylated, silencing its protein output by inhibiting transcriptional 
access to the gene (Brasa et al. 2016). However, in the Fragile X premutation, with an expansion of 
between 55-200 CCG repeats, the gene still produces a functional FMRP transcript. FMRP is 
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primarily a transcriptional regulator, and is at its highest concentrations within the brain, where it is an 
important regulator of synaptic plasticity and maturation (Tassone & Berry-Kravis 2010; Harlow et al. 
2010). High FMRP expression levels are also observed in lymphocytes, placenta, teste, lung and 
kidney tissue (Hinds et al. 1993).  
Studies into the molecular markers of the Fragile X gene have shown that FMR1 mRNA levels are 
increased up to 8-fold the normal level in premutation carriers (Tassone, Hagerman, Taylor, Gane, et 
al. 2000). The reasons for this increase are as yet unclear, although it is highly likely that the 
expansion of the CGG repeat island alters the genetic chromatin structure, allowing improved access 
for transcriptional modulators of FMR1 (Li & Jin 2012). Despite the premutation allele producing a 
functional protein transcript, it has also been shown that FMRP levels are slightly lower in carriers, 
especially when the numbers of CGG repeats are higher (Li & Jin 2012; J. M. Wang et al. 2012; 
Berry-Kravis & Hall 2011). The causation of these lower FMRP levels are uncertain, as given that 
FMR1 mRNA levels are higher it would be reasonable to expect that FMRP levels would also be 
increased. However, it has been suggested that falls in FMRP may result from deficits in the mRNA 
translational efficiency, as an expanded CGG repeat island impedes ribosomal subunit migration to 
the start codon (Li & Jin 2012). It seems likely when considering the role of FMRP in both healthy 
brain development and Fragile X Syndrome, that small decreases in FMRP in carriers may be the 
driving force behind neurodevelopmental abnormalities, in particular autistic traits. Nevertheless, it is 
widely accepted that it is the large increases in FMR1 mRNA that are the major causative factor in the 
development of FXTAS (Garcia-Arocena & Hagerman 2010).   
The characteristic neuropathological hallmark of FXTAS is the presence of intranuclear inclusions, 
the formation of which is thought to be driven by an excess of FMR1 mRNA. Studies investigating 
how high levels of FMR1 mRNA may cause neurotoxicity in FXTAS have shown that intranuclear 
inclusions in neurones and astrocytes are formed regardless of the presence of encoding regions of the 
FMR1 gene but do not form without the CGG repeat expansion (Hagerman & Hagerman 2004). 
Intranuclear inclusions that contain FMR1 mRNA are found throughout the brain and brainstem of 
FXTAS patients (Greco et al. 2002; Greco et al. 2005). Exactly how these inclusions develop however 
is undetermined, but in keeping with the gain-of-function theory, the favoured opinion is that excess 
mRNA begins to sequester mRNA binding proteins, including histones, heat shock proteins and 
cytoskeletal proteins. In particular, neurofilament isoforms A and C have been shown to play a role in 
the formation of intranuclear inclusions, which is likely to cause neurofilament and trafficking 
dysregulation within neurones and could be a major contributing factor to peripheral neuropathy in 
carriers. Additionally, the direct effects of accumulation within cells are not the only facets to 
consider, as knock-on effects of sequestration such as inhibition of normal mRNA binding protein 
functions are entirely probable (Tassone, Hagerman, Taylor, Gane, et al. 2000; Greco et al. 2005).   
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Repeat Associated non-AUG initiated (RAN) translation has also been implicated in the molecular 
pathology of FXTAS. RAN translation is the process by which a protein is translated from outside of 
the open reading frame of a gene in association with an island of repeated base sequences, and here 
the expanded CGG repeat region triggers the production of a polyglycine-containing protein known as 
FMRpolyG (Oh et al. 2015). This protein product has been demonstrated to be toxic in multiple 
human cell lines, and accumulates in intranuclear inclusions in cell culture, mouse models of FXTAS 
and human patients. Evidence suggests that FMRpolgG is a significant contributor to 
neurodegeneration in premutation carriers as intranuclear inclusions in FXTAS are ubiquitin-positive 
in pathology studies, and the effects of this combined with RNA toxicity may be additive or 
synergistic. Moreover, RAN translation has become a more prominent focus in neurodegeneration 
research as a whole, as similar repeat associated proteins initiated outside of the open reading frame 
have been implicated in amyotrophic lateral sclerosis and frontotemporal dementias (Todd et al. 2013; 
Todd et al. 2010). 
Recent findings have also found that antisense transcription plays a role in the molecular pathology of 
FXTAS. The antisense transcript ASFMR1 overlaps the CGG repeat island of the FMR1 gene, is 
transcribed in an antisense orientation and has been recently suggested to subsidise phenotypic 
variations associated with disorders arising from the expansion of FMR1 (Khalil et al. 2008). The 
premutation allele causes ASFMR1 mRNA to be upregulated, in a similar way to original FMR1 
mRNA upregulation, and both are silenced by the full Fragile X mutation. Alternative splicing of this 
gene product has been identified in carriers of the premutation, again suggestive of a 
neurodegenerative role in FXTAS (Ladd et al. 2007).  
Despite a lack of exact molecular understanding of how toxic RNA gain-of-function, RAN translation 
and antisense transcription contribute to phenotypes of the premutation and FXTAS, it is likely that 
combined downstream effects of these genetic changes cause severe cellular stress and subsequent 
programmed cell death. This manifests at a tissue and whole brain level as the classical radiological 
findings and symptomatic presentation of FXTAS. 
1.4  Genotype and phenotype relationships 
Molecular measurements from the FMR1 gene have been shown in a wealth of studies to have 
associations with various phenotypic features of FXTAS.  
One of the most commonly drawn conclusions from study data is that occurrence and severity of 
FXTAS are associated with larger CGG repeat sizes in the FMR1 gene (Leehey et al. 2008; Tassone, 
Adams, Elizabeth M Berry-Kravis, et al. 2007; Allen et al. 2008b). Of motor and nerve conduction 
symptomatology, it has been demonstrated that age of onset for tremor and ataxia, and peripheral 
neuropathy measurements are significantly correlated with size of the CGG repeat region (Tassone, 
Adams, Elizabeth M. Berry-Kravis, et al. 2007; Berry-Kravis, Goetz, et al. 2007). Cognitive FXTAS 
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phenotypes have also shown significant associations with CGG repeat length, with poorer scores of 
intelligence as measured by the Full Scale Intelligence Quotient (FSIQ), perceptual organisation, 
processing speed and executive functioning as measured by the Behavioural Dyscontrol Scale, the 
Controlled Oral Word Association Test and the Symbol Digit Modalities Test all demonstrating a 
significant association with larger repeat sizes (Hessl et al. 2005; Cohen et al. 2006; Grigsby et al. 
2007). Poorer scoring for inhibitory control and cognitive impairment as measured by the Mattis 
Dementia Rating Scale also showed a relationship to a larger number of CGG repeats (Cornish et al. 
2008; Sévin et al. 2009). Repeat size however has not proven to be a significant indicator of 
psychiatric illness or elevated psychiatric symptoms in premutation carriers, with no significant 
association with somatization, obsessive-compulsiveness, interpersonal sensitivity, depression, 
anxiety, hostility, phobic anxiety, paranoid ideation or psychoticism (Hessl et al. 2005). When 
considering radiological changes associated with FXTAS however, repeat size again shows some 
significant correlations. Voxel density of cerebellum, amygdala-hippocampal complex and thalamus 
and whole brain, cerebral, cerebellar and ventricular volume all significantly associated with length of 
the CGG repeat region, as may be expected given the phenotypic correlation between higher repeat 
sizes and more severe FXTAS symptomatology (Moore et al. 2004; Loesch et al. 2005; Cohen et al. 
2006; Adams et al. 2007). In keeping with these findings, CGG repeat size also showed a positive 
correlation with percentages of neurons and astrocytes in brain pathology samples with intranuclear 
inclusions (Greco et al. 2006). 
As demonstrated by the literature, CGG repeat size shows many significant phenotypic relationships. 
Investigation into these associations is very much supported by accurate genetic analysis techniques in 
determining base pair sequences, meaning that measurements obtained from peripheral blood samples 
are precise representations of repeat sizes (Tassone et al. 2008; Tzeng et al. 2005). It is also of note 
that for the development of some premutation or FXTAS phenotypes, those which show no or 
inconsistent relationships with CGG repeat length, that repeat expansion size may have little to no 
effect magnitude. However, more investigation into the molecular biology of the expanded FMR1 
CGG repeat island is required.  
Measurements of FMR1 mRNA also show some relationships to FXTAS and premutation 
phenotypes, as may be expected given the higher levels of FMR1 transcription in carriers and links to 
gain-of-function toxicity. In premutation carriers only, levels of FMR1 mRNA were observed to 
correlate with scores of peripheral neuropathy and nerve conduction (Berry-Kravis, Goetz, et al. 2007; 
Soontarapornchai et al. 2008). Significant associations were not identified however between mRNA 
levels and FXTAS rating scores (Tassone, Adams, Elizabeth M Berry-Kravis, et al. 2007). Cognitive 
measurements also showed no associations (Hessl et al. 2005; Cohen et al. 2006). Measures of 
psychiatric symptoms did show a relationship with FMR1 mRNA levels, with somatization, 
obsessive-compulsiveness, interpersonal sensitivity, depression, anxiety, hostility, paranoid ideation 
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and psychoticism, but not phobic anxiety, exhibiting a significant correlation (Hessl et al. 2005). Most 
radiological features showed no significant association, except for hippocampal volume (Cohen et al. 
2006; Adams et al. 2007; Moore et al. 2004).    
It may be considered a somewhat surprising finding that almost all psychiatric measurements 
significantly associated with FMR1 mRNA, as psychiatric symptomatology in carriers is thought to be 
primarily neurodevelopmental, and therefore would not be likely to correlate with a build-up of high 
levels of mRNA. However, given that many patients with neurodegeneration experience worsening 
psychiatric problems, it is likely that these significant associations are related to FXTAS pathology 
and are not developmental in nature (Kazui et al. 2016; Ismail et al. 2016). Studies to replicate these 
findings would also be beneficial to establish to robustness of such correlations. In addition, phobic 
anxiety did not show a relationship with FMR1 mRNA, despite being reported as significantly worse 
in a FXTAS sample, and this may be due to it being a more stable, life-long trait in carriers (Hessl et 
al. 2005). Additionally, lack of associations between radiological changes associated with FXTAS and 
FMR1 mRNA levels in some studies are also rather unexpected when considering the RNA gain-of-
function toxicity hypothesis (Moore et al. 2004; Qurashi et al. 2011). This may be due to some 
radiological changes during the disease not being driven, at least primarily, by changes in RNA, 
however it is more likely that peripheral measurements of FMR1 mRNA are not accurately 
representing brain expression. Implication of the hippocampus however may be indicative of a limbic 
vulnerability to the onset of molecular pathology and inclusion formation in FXTAS, in a similar 
manner to other neurodegenerative diseases and mechanisms of aggregate development (Hochgräfe et 
al. 2013; Nunomura et al. 2012; Kandiah et al. 2014). These studies demonstrate the complex nature 
of linking FXTAS pathology or premutation traits to FMR1 mRNA levels, as results show 
inconsistency of expected correlations with neurodegenerative and neurodevelopmental traits. Aside 
from a complexity of molecular pathology that is not yet established, it may be possible that the 
reason for these discrepancies is that blood-based molecular measurements are not necessarily 
reflective of distinct expression profiles in the brain, or indeed may only reflect some areas of FMR1 
expression in the brain but not others.   
Fewer studies have investigated FMRP levels in addition to FMR1 mRNA and CGG repeat length, 
most likely due to the more difficult methodology of isolating and quantifying protein levels without 
brain tissue. Nevertheless, in studies that have investigated FMRP quantity and phenotypic 
relationship, no association was found between FMRP and cognition as measured by the FSIQ or any 
psychiatric symptom (Hessl et al. 2005; Cohen et al. 2006). A significant association was identified 
however between lower voxel density of the cerebellum, amygdala-hippocampal complex and 
thalamus in carriers and FMRP levels (Moore et al. 2004). 
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When considering the data that carriers have slightly lower levels of FMRP and the wealth of existing 
knowledge of the importance of FMRP during brain development, it may be expected that carriers 
have cognitive and neurodevelopmental differences that are driven in part by FMRP (Primerano et al. 
2002; Lozano, Rosero, et al. 2014). However, findings have shown a lack of relationship between 
these variables as measured by the FSIQ and psychiatric checklists (Hessl et al. 2005; Cohen et al. 
2006). Again, the reason for the lack of significant findings may be the difficulty in using peripheral 
blood for molecular investigation, but also, given that changes in FMRP in carriers are moderate at 
best and notably variable, it is likely that modest effect sizes may be missed. A significant association 
between the radiological measurements of voxel density at the cerebellum, amygdala-hippocampal 
complex and thalamus and FMRP has been established, and this brain phenotype exhibited no 
relationship to FMR1 mRNA levels (Moore et al. 2004). This finding of lower brain voxel density in 
carriers therefore could possibly be considered to be linked to changes in regional brain structural 
integrity due to the vital role FMRP plays in early synaptic plasticity.    
Overall, the use of regression analyses for establishing genotypic and phenotypic relationships in 
FXTAS and the premutation has been important for the field. However, a number of limitations, as 
previously discussed, may mean that underlying molecular pathology and its association to various 
clinical, cognitive, psychiatric or radiological phenotypes may be being understated. 
1.5 The epidemiology of the Fragile X premutation and FXTAS  
The prevalence of the Fragile X premutation is estimated to be between 1/150 to 1/300 in females and 
between 1/400 to 1/850 in males (Tzeng et al. 2005; Dombrowski et al. 2002; Hagerman & Hagerman 
2016). Within the premutation population, it is estimated that over a third of males over the age of 50 
exhibit both tremor and ataxia, meeting the criteria for a diagnosis of probable FXTAS. Penetrance 
further increases with age, with over half of premutation males showing signs of FXTAS above the 
age of 70 (Sébastien Jacquemont et al. 2004). Penetrance of FXTAS in female carrier populations 
appears to be significantly lower, in addition to symptoms of the disease often being much milder. It 
is estimated that approximately 8% of women who carry the premutation allele and are over the age of 
40 exhibit signs of FXTAS (Coffey et al. 2008).  
By combining data on the frequency of the FMR1 premutation allele in the general population, and 
considering incomplete FXTAS penetrance within this group, FXTAS is estimated to affect 1/4,000 
males over the age of 50 within the general population (Dombrowski et al. 2002). Direct population-
based studies on FXTAS have yet to be conducted, given the rarity of the disease and the regularity of 
misdiagnoses of FXTAS as other types of movement disorder and cognitive neurodegeneration. In 
addition, other epidemiological facets of carrier status are yet to be defined, such as mortality rates or 
expansion quantifications of the CGG repeat island. Further epidemiological study into these aspects 
of the Fragile X premutation are likely to reveal significant and medically relevant insights into the 
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nature of carrier status and FXTAS, and may indeed demonstrate that FMR1 repeat-associated 
disorders are not as uncommon as originally thought. 
Since the Fragile X-associated Tremor/Ataxia Syndrome was identified in 2001, awareness of 
individuals and families affected by the condition has continued to increase, as has the understanding 
of the lifelong neurodevelopmental issues that also may affect carriers. The presence of the 
premutation allele is an important factor for families to consider, if, indeed, they are aware of it. This 
is because the premutation allele is known to expand in the CGG repeat island region over maternal 
transfer (Nolin et al. 2003). If the CGG repeat length exceeds the premutation range, which as 
previously mentioned, is between 55-200 repeats, and becomes longer than 200 repeats, then the 
FMR1 gene becomes heavily methylated, inhibiting access for transcriptional regulator proteins and 
obstructing transcription. This DNA methylation silences the gene, blocking protein output and causes 
a severe neurodevelopmental disorder called Fragile X Syndrome, which is characterised by major 
intellectual disability, global developmental delay and autistic traits (Penagarikano et al. 2007). For 
reasons that are as yet unclear, the premutation allele does not tend to expand over paternal transfer. 
Therefore, given the sex-linked nature of the FMR1 gene, males with the premutation will always pass 
on a stable carrier allele to their daughters, but never to their sons. Females with the premutation 
however, will have a 50% chance of passing on the allele to a child of either sex, with the likely 
possibility that the CGG repeat island of FMR1 will also expand and the child will have Fragile X 
Syndrome (Nolin et al. 1996).  
Penetrance of Fragile X-associated disorders differs significantly between men and women, and this is 
clearly seen in the premutation. Because of the presence of a second, functioning FMR1 allele in 
women, the effects of the mutated allele are somewhat masked. This is not the case for males, who 
carry only one copy of FMR1. Within the female carrier population however, there is significant 
heterogeneity of phenotype (Hagerman et al. 2004; Franke et al. 1998). This heterogeneity stems from 
the natural process of X-inactivation within female cells, where one of the two X chromosomes in 
each cell is silenced at random to provide dosage compensation of X-related genes. X-inactivation in 
females with the premutation means that percentages of the active premutation allele can vary 
significantly between women, meaning that the severity of Fragile X premutation carrier 
symptomatology fluctuates to a large degree (Nolin et al. 2003; Nolin et al. 1996). In a similar way, 
X-inactivation plays a large role in protecting many girls and women with the full mutation from 
serious intellectual disability and autism, as females inheriting an FMR1 CGG repeat length greater 
than 200 will have a 50-70% risk of showing features of Fragile X Syndrome, compared to virtually 
100% of males (Keysor & Mazzocco 2002). 
Taking into account the aforementioned problems in assessing the epidemiological presence of 
FXTAS and the Fragile X premutation, it is possible that their prevalence may be larger than current 
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data suggests. It is therefore of importance that the field pursue population, such as newborn,  
screening and understanding of the effects of carrying the premutation, in the hope that targeted 
treatments may be developed in the future and benefit a larger-than-expected clinical group.   
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Chapter 2: A systematic review of neuroimaging findings in Fragile X premutation carriers 
2.1 Introduction 
The neuroimaging techniques employed in premutation research to date have been magnetic 
resonance based structural, diffusion tensor and functional imaging. Neuroimaging has played a vital 
part in advancing our knowledge and understanding of the premutation and FXTAS. Much of the 
current research has served to elucidate FXTAS diagnostic criteria and to begin to unravel the 
complex pathology of both neurodevelopmental abnormalities and neurodegeneration in carriers. It is 
likely that in the future, neuroimaging studies will start to reveal more sophisticated measurements of 
subtle changes in the brain, allowing a greater understanding of the disease process and directing 
clinicians towards a clearer understanding of prognosis.   
Structural magnetic resonance imaging (MRI) is a technique that images parts of the body, in this case 
the brain, using contrasts created by the magnetic properties of water molecules in the body. It is a 
favoured method of neuroimaging as it is safe and non-invasive, however an MRI scan is both costlier 
and more time-consuming than other types of medical imaging and can exacerbate anxiety and 
claustrophobia in patients or research participants (Eshed et al. 2007). Nevertheless, given that MRI 
has high-quality image resolution and effectively differentiates between tissue types within the brain, 
such as white matter and grey matter, it is one of the most utilised imaging modalities for medical 
research (Bigler 2015).  
Diffusion tensor imaging (DTI) is a structural MRI technique that utilises the diffusion and movement 
of water molecules to produce contrasted brain images. As water molecules will not diffuse freely in 
brain tissue, the nature of their motion can reveal detailed insights into brain tissue architecture. The 
variation in the restriction of the diffusion of water molecules means that structural integrity of 
neuronal tracts can be reliably investigated in both control and patient groups. The drawbacks of this 
valuable experimental technique include the fact that DTI scans are very noisy and can cause 
discomfort for participants, especially in those who are claustrophobic or anxious. In combination 
with a long scan time to obtain detailed and usable DTI data, this means that participants can be prone 
to not completing the scan. However, these issues can be fairly easily managed with appropriate 
preparation and explanation for subjects undergoing a DTI scan (Garin-Muga & Borro 2014; Assaf & 
Pasternak 2008).  
Functional MRI (fMRI) is a technique utilised in premutation research that measures functional brain 
activity by monitoring changes that are associated with blood flow. The technique is based upon a 
contrast known as the blood-oxygen-level dependant (BOLD) response, which is reliant on the MRI 
scanner identifying changes in the magnetic properties of blood in the brain. Because neuronal 
activity and blood flow are tightly coupled, when neuronal populations are active, blood flow to those 
specific areas increases (Buxton 2013). Consequently, fMRI can reliably display active regions of the 
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brain in response to sets of stimuli and is a frequently employed method in psychiatric and neurology 
research. There are however some problematic aspects to the use of functional imaging, one 
prominent issue being that head movement during scanning can result in artificial changes in 
activation signals in the brain. Another issue is ambiguous baseline conditions during testing, given 
that the brain is constantly active. This means that experimental design must carefully take baseline 
activity into account, and control or rest conditions within a task must be appropriate to the test 
conditions to minimise physiological noise. This type of problematic and unwanted brain activity 
must also be taken into consideration during image processing and data analysis. Task design is also a 
critical part of experimental legitimacy, and poorly designed scanner tasks can be significantly 
detrimental to valid results. For example, a task utilising a blocked design – one which groups stimuli 
together to allow for an additive hemodynamic response – must use a baseline condition suited to the 
task stimuli, and awareness of the fact that participants may experience boredom or predict parts of 
the task when blocks are not randomised is important. In contrast to block design, an event-related 
design of a scanner task may be used to minimise aspects of boredom and task prediction. This type of 
design uses short, randomised presentation of stimuli, and as such is considered to be a more realistic 
test of brain activation. However, as the BOLD response to stimuli presented in this manner is 
inherently low and event-related designs lack the robust statistical power that a block design 
possesses. If these issues are properly taken into account and managed however, fMRI can be a very 
insightful and useful imaging technique (Glover 2011; Eklund et al. 2016).  
Here, the aforementioned imaging techniques utilised in investigation into individuals with the Fragile 
X premutation are reviewed with respect to the current published literature.  
2.2 Methods 
Medline, EMBASE and PsychINFO were searched for all English language studies published 
between January 1990 and December 2013 that reported imaging data in fragile X premutation 
carriers. Terms included in the search were as follows: “Fragile X” “Fragile X premutation” 
“premutation carriers” and related terms combined using the AND operator with “magnetic resonance 
imaging”. All abstracts resulting from the search were assessed for inclusion. There were 422 
abstracts identified during the search, of which 385 were excluded due to lack of relevance to 
neuroimaging and/or the Fragile X premutation. There were 37 articles that remained, which were 
then assessed according to inclusion criteria individually in full text. Primary research articles were 
considered for inclusion if they were published by an English language peer-reviewed journal, used 
sample groups of fragile X premutation carriers with or without FXTAS and compared the group(s) to 
a group of healthy controls and included structural, functional or diffusion tensor MRI methodology. 




Figure 2.1. Inclusion and exclusion process of relevant literature. 
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2.3 Results   
Studies utilising structural MRI techniques have identified substantial radiological changes in 
premutation carrier populations both with and without FXTAS in comparison to control subjects. A 
number of these structural brain abnormalities form important diagnostic criteria for FXTAS and can 
be particularly useful in differentiating between FXTAS and other similar neurological diseases.  
To date, a total of 12 studies have used structural MRI in premutation carrier groups (these are 
summarised in Table 2.1). Of these studies, eleven utilised quantitative measurements and one used 
qualitative analysis techniques. A notable finding of these studies involves a hallmark radiological 
feature of FXTAS, which is a region of increased T2 signal intensity at the middle cerebellar 
peduncles (MCPs), commonly known as the MCP sign. The MCP sign is a primary diagnostic 
criterion for FXTAS, and its pathological basis is thought to originate from the development of 
spongiosis in the deep cerebellar white matter (Berry-Kravis, Abrams, et al. 2007). However, it is 
worth noting that presence of an MCP sign is not completely indicative of FXTAS, as it has been 
reported in other neurodegenerative disorders, such as multiple system atrophy. Similarly, it is 
estimated that the MCP sign is only present in 60% of male individuals with FXTAS and 13% of 
female individuals with FXTAS (Adams et al. 2007). The MCP sign was identified in FXTAS groups 
in all of the four studies that investigated this region. Cerebellar and cerebral atrophy is also found in 
virtually all patients with FXTAS, with 9 out these 12 studies both quantitatively and qualitatively 
identifying such volume loss. Carrier populations both with and without diagnosed FXTAS exhibited 
statistically significant decreases in volumes of the total brain, cerebrum, cerebellum and brain stem 
(Loesch et al. 2005; Cohen et al. 2006).  Mild to moderate loss of volume was observed in 75% of 
carriers with signs of FXTAS, and 20% of patients showed loss of volume that was characterised as 
severe (Jacquemont et al. 2003a). Radiological findings were less pronounced and less frequent in 
FXTAS patients with milder symptomatology (Juncos et al. 2011). The corpus callosum is also an 
area of interest in FXTAS disease pathology, with thinning apparent from both qualitative and 
quantitative volumetric analysis in the majority of patients with a diagnosis (Brunberg et al. 2002). 
Changes in hippocampal and amygdala volume have also been noted in multiple studies, however 
these are less significant and findings have not been reliably replicated between research groups 
(Loesch et al. 2005; Cohen et al. 2006; Selmeczy et al. 2011). 
Table 2.1: Structural Imaging Studies 
Study Participants Methodology Significant findings 
(Brunberg et 
al. 2002)  
17 male PMCs with 
signs of FXTAS 
(mean age 68) and 




15/17 PMCs showed symmetrically decreased 
T1 and increased T2 signal intensities in 
cerebellar white matter 
14/17 PMCs exhibited the MCP sign 
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Cerebellar cortical atrophy was present in 16/17 
PMCs and cerebral atrophy was present in all 
PMC participants 
The corpus callosum was thinned in 14/16 PMCs 
and MCPs were atrophic compared to the control 
group 
(Jacquemont 
et al. 2003b)  
20 male PMCs with 
FXTAS (aged >50 












Mild to moderate loss of cerebral cortical 
volume was present in 75% of patients. The 
volume loss was severe in 20% 
Increased T2 signal intensity in the 
subependymal and deep white matter of the 
frontal and parietal lobes was seen in 75% of 
patients 
(Moore et al. 
2004) 
20 male PMCs and 












The PMC group had significantly less voxel 
density in several brain areas including the 
cerebellum, thalamus and amygdalo-
hippocampal complex 
Aging, increased CGG repeat size and decreased 
FMRP were all associated with decreased voxel 
density 
Regional grey and white matter density is 
significantly affected in PMCs 
(Loesch et al. 
2005) 
12 male PMCs 
(mean age 62.15) 
and 11 male 
matched controls 










repeat size and 
FMR1 mRNA) 
Variable MRI changes in PMCs classified as 
being 'neurologically affected', including 
cerebral, cerebellar atrophy and the MCP sign 
(Cohen et al. 
2006)  
11 male PMCs 
without FXTAS, 25 
male PMCs with 








No differences in radiological findings between 
unaffected PMCs and controls, except for a 
reduction in brainstem volume (the brainstem-
cerebellar region extended from one slice 
inferior to the anterior commissure to the most 













repeat size and 
FMR1 mRNA) 
the inferior border of the cerebellar vermis was 
used as a tracing cut-off) 
Differences in all brain region volumes 
measured, except for hippocampus, between 
FXTAS affected and control groups 
CGG repeat length was associated with the 
volume of many areas including the cerebellum, 
ventricle and whole brain white matter 
hyperintensity 
IQ scores were significantly associated with 
volumes of multiple regions including whole 
brain, cerebrum, cerebellum, hippocampus, 
ventricles and whole brain white matter 
hyperintensity 
Higher CGG repeat lengths were correlated with 
lower IQ scores 
(Adams et al. 
2007) 
15 female PMCs 
with FXTAS (age 
59.5±10.3 years), 
20 unaffected PMC 
females (age 43.3 ± 
11.2 years), and 11 
matched female 
controls (age 51.0 ± 
10.3 years). 36 
male PMCs with 
FXTAS (age 65.0 ± 
5.6 years), 25 
unaffected PMC 
males (age 53.5 ± 
12.5 years) and 39 
matched male 
controls (age 58.0 ± 









repeat size and 
FMR1 mRNA) 
Less pronounced reductions of cerebellar 
volumes and less involvement of the MCP sign 
was seen in female PMCs compared to male 
PMCs 
Reduced brain volumes and increased white 
matter disease in PMC females compared to 
control females 
Significant associations between reduced 
cerebellar volume, increased severity of FXTAS 




(Loesch et al. 
2008)  
24 male PMCs, 
aged above 33 




PMCs showed significant decrease in total brain 
and cerebrum volumes 
Volumes of right, left and total hippocampus 
were significantly increased in PMCs 
Significant correlation with decreased brain 
volume and increasing CGG repeat size 
(Adams et al. 
2010)   
16 female PMCs 
with FXTAS (age 
57.5 ± 12.46 years), 
17 unaffected PMC 
females (age 44.94 
± 11.23 years), and 
8 matched female 
controls (age 50.63 
± 11.43 years). 34 
male PMCs with 
FXTAS (age 66.44 
± 6.77 years), 21 
unaffected PMC 
males (age 52.38 ± 
12.11 years) and 30 
matched male 
controls (age 57.2 ± 













Significant negative correlation between total 
hippocampal volume and anxiety in female 
PMCs with and without FXTAS. This was 
driven by the significant negative correlation 
between right hippocampal volume and anxiety 
In male PMCs with and without FXTAS, only 
paranoid ideation negatively correlated with 
hippocampal volume 
Female PMCs also demonstrated a negative 
association between hippocampal volume and 
severity of anxiety-related symptoms 
Negative association between CGG repeat size 
and hippocampal volume, but this was not 
significant after adjustment 
(Selmeczy et 
al. 2011)  
49 PMC males 
(mean age 48.5 
years) and 48 
matched controls 













No significant differences between groups in 
amygdala volumes 
Significant negative correlation between 
amygdala volume and the lower range of CGG 




(Juncos et al. 
2011)  
50 male PMCs, 
with and without 
FXTAS (mean age 













The majority of PMCs exhibited general volume 
loss and the MCP sign 
CGG repeat size did not seem to correlate with 
FXTAS severity 
Radiological changes were less severe and less 
frequent in participants with milder FXTAS 
symptomatology 
(Hashimoto, 
Javan, et al. 
2011)  
31 male PMCs with 
FXTAS, 24 male 
PMCs without 
FXTAS and 28 
male matched 
controls (aged 











Grey matter loss in cortical and subcortical 
regions was seen in FXTAS patients 
Significant associations between grey matter loss 
in the left amygdala and increased levels of 
obsessive-compulsive and depressive traits. Also 
significant associations seen between decreased 
grey matter in the left inferior frontal cortex and 
anterior cingulate cortex and poor working 
memory 
Significant negative effect of CGG repeat size on 




et al. 2013)  
11 male PMCs 
without FXTAS, 36 
male PMCs with 
FXTAS and 14 











FXTAS group showed significant atrophy in the 
bilateral thalamus and putamen, left caudate and 
right pallidus compared to controls 
FXTAS group also showed significant DWI 
hypointensity in the bilateral thalamus, caudate, 
putamen and right pallidus compared to controls 
Volume measurements of the bilateral thalamus 
and putamen, and left caudate showed significant 
negative correlation with FXTAS stage 
Abbreviations 
PMC: premutation carrier; FXS: Fragile X Syndrome MCP: middle cerebellar peduncle 
 
Four DTI studies in Fragile X premutation carriers have been published to date (these are summarised 
in Table 2.2).  
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Patients with FXTAS demonstrated significantly lower structural connectivity in motor, limbic, 
association and callosal white matter fiber tract categories (J. Y. Wang et al. 2012). As might be 
expected, motor fiber tracts were of particular interest, with carriers with established FXTAS 
displaying reductions in connectivity at the descending motor tract, the MCP, the superior cerebellar 
peduncle and the anterior body of the corpus callosum (Wang, Hessl, et al. 2013). Patients with 
FXTAS were also found to have reduced fractional anisotropy (FA) in multiple white matter tracts, 
including the MCPs, the superior cerebellar peduncles, the cerebral peduncle, the fornix and the stria 
terminalis. In this study, in carrier groups both with and without FXTAS, both axial and radial 
diffusivities were found to be significantly higher than controls at the MCPs (Hashimoto, Srivastava, 
et al. 2011).  
Table 2.2: Diffusion Tensor Imaging Studies 
Study Participants Methodology Significant findings 
(Hashimoto, 
Srivastava, 
et al. 2011)  
35 PMC males with 
FXTAS, 16 PMC males 
without FXTAS and 20 
matched male controls. 
Participants aged 
between 40 and 79 years. 
Structural MRI: 
Diffusion tensor 






FMRP and FRM1 
mRNA) 
 
FXTAS group showed significant 
reductions in fractional anisotropy (FA) in 
multiple white matter tracts including the 
MCPs, superior cerebellar peduncle, 
cerebral peduncle, the fornix and stria 
terminalis 
Axial and radial diffusivities were 
significantly elevated in the MCP in both 
premutation groups 
U-shaped relationship between CGG 
repeat size and axial and radial 
diffusivities in the MCP 
(J. Y. Wang 
et al. 2012)  
15 PMCs aged under 45 
years and 19 matched 
controls under 45 years 
(younger groups). 15 
PMCs aged over 45 
years with FXTAS, 11 
PMCs aged over 45 
years without FXTAS 
and 15 matched controls 
aged over 45 years (older 
groups). Participants 





Carriers with FXTAS showed reduced 
structural connectivity relative to controls 
in motor, limbic, association and callosal 
fiber tract catagories  
Carriers with FXTAS also showed greater 
age-related decline in structural 
connectivity in limbic, association and 
callosal fiber tracts 
Only groups with lesions in the MCP and 
corpus callosum exhibited significantly 




et al. 2013)  
30 PMC males and 37 
male matched controls 
aged between 20-70 
years. All participants 
















Grey matter voxel based morphometry 
showed a lower grey matter volume in the 
anterior lobule VI of the cerebellum and 
bilateral thalamus in PMCs 
Radial diffusivity was increased at the 
MCPs, hippocampal fimbria/fornix and 
stria terminalis bilaterally 
MCP radial diffusivity showed interaction 
with age and CGG repeat size 
(Wang, 
Hessl, et al. 
2013)  
36 male PMCs with 
FXTAS, 26 male PMCs 
without FXTAS and 34 
male controls. PMCs 






values of FA, MD 
and average DWI 
Molecular 
measures (CGG 
repeat size and 
FRM1 mRNA) 
FXTAS group had significantly lower 
tract volume at the descending motor tract, 
the MCP, the superior cerebellar peduncle 
(SCP) and the anterior body of the corpus 
callosum 
CGG repeat length correlated negatively 
with the SCP tract volume in both PMC 
groups 
CGG repeat length also correlated 
negatively with SCP FA in the FXTAS 
group 
Abbreviations 
PMC: premutation carrier; MCP: middle cerebellar peduncle, FA: fractional anisotropy, MD: mean 
diffusivity, DWI: diffusion-weighted image  
  
To date, there have been 7 publications of fMRI data in premutation carriers (these are summarised in 
Table 2.3). These considered multiple different types of cognition and processing, with one 
investigating numerical processing, two investigating social processing and four investigating various 
aspects of memory. In one study into working memory, premutation carrier groups both with and 
without FXTAS generally performed equally well in the scanner tasks compared to the control group. 
However, both premutation groups showed significant differences in activation during the task, with 
the right ventral part of the inferior frontal cortex (vIFC) and the left dorsal part of the inferior frontal 
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cortex and premotor cortex (dIFC/PMC) exhibiting a reduction in activation (Hashimoto, Backer, et 
al. 2011). Tasks requiring associative memory recall showed that carriers had reduced left 
hippocampal activation in comparison to controls, in addition to increased parietal activation patterns 
(Koldewyn et al. 2008). Premutation carriers also displayed a low level of temporoparietal activation 
during temporal working memory retrieval compared to spatial working memory retrieval, whereas 
controls exhibited higher levels (Kim et al. 2014). In a study involving a magnitude estimation task 
carried out in the scanner, the premutation group were found to have significantly decreased lower 
fronto-parietal activation, particularly at the bilateral inferior parietal lobule and the left inferior 
frontal gyrus (Kim et al. 2013). Emotional processing tasks have also reliably shown premutation 
carrier group activation differences in comparison to controls, with two studies finding a reduction in 
amygdala activation in response to emotional stimuli. In particular, the right and overall amygdala 
activations appear significantly lower (Hessl et al. 2007; Hessl et al. 2011). One study found 
additional significant reductions of activation at the bilateral superior temporal sulcus, the bilateral 
orbital gyrus and the bilateral insula during emotional processing, whereas these areas were reliably 
activated in the control population (Hessl et al. 2011).  
Table 2.3: Functional Imaging Studies 
Study Participants Methodology Significant findings 
(Hessl et al. 2007)  12 PMC males 
(mean age 42.9 
years) and 13 male 
matched controls 















startle and skin 
conductance 
paradigms 
In PMCs, psychological symptoms 
were significantly associated with 
decreased right amygdala volume 
PMCs showed an overall decrease in 
amygdala activation and varied 
activation patterns 
Unlike in controls, PMCs showed no 
significant activation in the bilateral 
superior temporal sulcus, bilateral 
orbital gyrus and bilateral insula 
PMCs showed a greater overall 
activation in response to calm faces 
(Koldewyn et al. 
2008)  
11 PMC males 
(mean age 42.9 




Groups did not differ in hippocampal 
volume 















memory recall task 
hippocampal activation and increased 
right parietal activation during 
memory recall task compared to 
controls 
Left hippocampal activation was 
negatively correlated with both 
FMR1 mRNA levels and psychiatric 
symptomatology in the PMC group 
 
(Hashimoto, 
Backer, et al. 
2011)  
15 PMCs with 
FXTAS, 15 PMCs 
without FXTAS and 
12 matched 
controls. Males and 
females aged 
between 33 and 75 
years. 
Functional MRI and 
working memory task 
 
All groups performed equally on 
working memory task 
All groups had significant activation 
in bilateral hippocampus, inferior 
frontal cortex, premotor cortex, 
anterior cingulate cortex and 
supplementary motor area 
The right vIFC and left dIFC/PMC 
showed reduced activation in both 
PMC groups 
Regression analysis showed a 
significant negative effect of mRNA 
levels on vIFC activity 
(Hessl et al. 2011)  23 PMC males 
(mean age 32.9 
years) and 25 
matched controls 




repeat size, FMR1 





PMCs had significantly smaller right 
and left amygdala volumes 
PMCs had reduced right amygdala 
activation during emotional 
processing task  
Regression analysis revealed reduced 
FMRP levels to be a primary factor in 
the reduced amygdala activation  
There was no difference between 
groups on task accuracy 
(J. M. Wang et al. 
2012)  
24 PMC males 
(mean age 32.6 
years) and 25 male 
Molecular measures 
(CGG repeat size, 
FMR1 mRNA and 
FMRP was 23% reduced in PMCs 
No difference in hippocampal/total 













Both groups had similar performance 
on encoding task 
No significant difference in activation 
amount or pattern between groups 
Functional connectivity analysis 
revealed that PMCs had significantly 
lower connectivity with the right 
prefrontal cortex and the right 
parahippocampal gyrus. This 
correlated with reduction in FMRP 
(Kim et al. 2013)  16 female/12 male 
PMCs (mean age 
32.3 years) and 14 
female/15 male 










The PMC group showed significantly 
reduced activation in the bilateral 
inferior parietal lobule and the left 
inferior frontal gyrus compared to 
controls for the distance effect in the 
task 
CGG repeat size was a primary factor 
in reduced fronto-parietal activation 
in the PMC group 
(Kim et al. 2014) 20 asymptomatic 
PMCs (mean age 
30.4 years, 
female:10) and 20 
controls (mean age 









The control group showed 
significantly greater activation at the 
right temporoparietal junction during 
temporal WM retrieval than in spatial 
WM retrieval. PMCs failed to show 
this increase at the temporoparietal 
junction during spatial compared to 
temporal WM retrieval 
Elevated FMR1 mRNA predicted 
reduced temporoparietal activation in 
PMCs 
Abbreviations 
PMC: premutation carrier; vIFC: ventral part of the inferior frontal cortex; dIFC/PMC: dorsal part 
of the inferior frontal cortex and premotor cortex; FXS: Fragile X Syndrome; MCP: middle 





Despite being integral to the FXTAS diagnosis criteria, structural MRI studies into FXTAS and the 
premutation reveal that MCP sign is not a solid indicator of the disease, as it is present in only 
approximately 60% of cases. Combined with its non-exclusivity, the radiological presence of the 
MCP sign can serve only as a likely indicator of FXTAS, but does not provide a definitive diagnosis 
(Loesch et al. 2008). Additionally, evidence is highly suggestive that asymptomatic carriers also 
exhibit milder and more infrequent radiological abnormalities, and while this strongly alludes to early 
signs of degeneration, it is unclear whether this is necessarily the case (Loesch et al. 2005). In a 
similar way to the MCP sign, thinning of the corpus callosum is thought to be one of the first 
radiological changes to occur in FXTAS and may precede onset of cognitive and motor symptoms, 
therefore meaning it could be a potentially useful predictor of disease onset. Changes at the amygdala 
and hippocampus are also often observed, however, interestingly, despite these areas intuitively being 
involved in premutation pathology, they do not seem to be as significantly affected as other regions of 
the brain. At the hippocampus, some groups have identified the region to be significantly increased in 
volume, whereas other groups have reported it to be not significantly different to control subjects. 
Similarly, volumetric studies into the amygdala have seen changes, but these were not statistically 
significant upon analysis (Loesch et al. 2005; Adams et al. 2010; Cohen et al. 2006).   
Diffusion tensor studies are highly supportive of the notion that progressive loss of white matter 
structural integrity is fundamental to FXTAS disease pathology. Increases in radial and axial 
diffusivities at the MCPs in both asymptomatic carriers and those with FXTAS are further 
confirmation that changes at the MCPs are an early sign of degeneration that is likely to precede the 
outward manifestation of FXTAS (Hashimoto, Srivastava, et al. 2011). In addition, evidence suggests 
that only individuals with lesions at the MCPs and corpus callosum have significantly decreased 
structural connectivity at a whole brain level, again indicative of the MCPs and corpus callosum being 
potentially important areas for early disease pathology (J. Y. Wang et al. 2012).   
Functional MRI research studies have indicated that in addition to structural changes, functional 
abnormalities of the brain also form part of the premutation and FXTAS phenotype. During 
associative memory recall tasks, increases in activation at the parietal cortex is suggestive of 
compensatory mechanisms within premutation carrier groups, given that performance in the task was 
not significantly different to control subjects (Koldewyn et al. 2008). This type of neural 
compensation may be important in the carrier phenotype, allowing individuals to counteract 
processing deficiencies and appear outwardly asymptomatic. Findings of reduced activation in the 
limbic system of carriers is also further evidence of the higher incidences of social and psychiatric 
problems in carrier populations, and may indeed be linked to structural findings, such as volume loss 
at the amygdala (Hessl et al. 2011). Additionally, during a scanner task that involved the presentation 
of neutral faces to participants, premutation carriers were observed to respond to this type of stimuli 
with greater overall brain activation, which again may be reflective of social difficulties and 
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neuropsychological abnormalities (Hessl et al. 2007). On the whole, fMRI in Fragile X premutation 
carriers has shown a reduction in the BOLD signal at multiple different brain regions in response to 
varied stimuli. However, the literature is not without conflicting results, and some research groups 
have demonstrated no significant differences in comparison to control groups during functional 
testing (J. M. Wang et al. 2012). This absence of differences between groups may arise for many 
different reasons, one such important reason being that the heterogeneity of the premutation 
phenotype and percentage of FXTAS penetrance may cause studied groups of carriers to vary 
considerably. In addition, groups using asymptomatic carriers require larger numbers of participants 
to allow for a more sensitive measure of what are likely to be small effect sizes, and given that known 
premutation carriers are infrequent within the general population, this is often difficult to achieve. 
Moreover, type of task used in the scanner, pre-scan training or practice and variation in the methods 
of analysis are all likely to affect results between groups of researchers.  
Review of the current neuroimaging and premutation literature here establishes that there is a 
significant space for development in the research. Structural imaging has demonstrated both global 
brain changes in FXTAS and focal changes such as the possible early identifier of thinning of the 
corpus callosum and the frequently seen FXTAS hallmark, the MCP sign. DTI has moreover has 
shown reduced structural integrity in various brain regions of premutation carriers, both with and 
without FXTAS. The MCPs, motor tracts and limbic tracts appear to be the most highlighted regions 
of changes in diffusivity in DTI studies to date. Existing functional MRI studies have used emotional 
and working memory tasks in carriers both with and without FXTAS, establishing changes in BOLD 
response commonly at the amygdala, hippocampal formation, parietal regions and the inferior frontal 
cortex. An important part of the progression of the research into the FMR1 premutation and FXTAS 
will be to replicate these results in larger populations and aim towards longitudinal multi-modal study 
of premutation carriers prior to and after the onset of illness. A combination of various neuroimaging 
techniques, out of scanner measurements of symptomatology and molecular measurements of FMR1 
gene products may be useful in linking the premutation genotype to FXTAS and other carrier 
phenotypes. Through this type of study, it may also be possible to further define the nature of FXTAS 
development and additionally to distinguish neurodevelopmental changes in carriers from later-life, 
neurodegenerative changes.    
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Chapter 3: Introduction to experimental sections 
3.1 Introduction to current study  
Reviewing of the existing neuroimaging literature on FMR1 premutation carriers revealed that an 
important future study in the premutation and FXTAS field would be a longitudinal imaging study of 
premutation carriers without FXTAS with follow-up until possible development of 
neurodegeneration. Such a study would provide cross-sectional age-related insights into the 
premutation and using future follow-up investigation would allow for the mapping of phenotypes 
across time. Most pertinent to this investigation would be to delineate stable, neurodevelopmental 
traits of carriers from the degenerative processes of FXTAS. Cross-sectional and longitudinal data 
will also be important to further characterise the biological mechanisms and clinical presentation of 
FXTAS development and prognosis.  
The first step towards such a study is to clarify whether premutation carriers show differences to brain 
function which predate the onset of frank FXTAS.  In addition, it is possible to use cross-sectional 
data to provide preliminary evidence of a change over time, by examining whether there is a 
relationship between age and neuroimaging differences in carriers comparative to a control group.   
We therefore set out to examine using fMRI whether premutation carriers without showed differences 
compared to controls even when they had not developed FXTAS.  We also aimed to examine whether 
some features of the FXTAS phenotype were neurodevelopmental, such as psychiatric 
symptomology, social difficulties and autistic traits and whether some were neurodegenerative in 
nature, such as motor function.  We chose to utilise two fMRI tasks, one hypothesised to relate to a 
neurodevelopmental feature of the premutation state (an emotional processing task) and another 
hypothesised to relate to a neurodegenerative characteristic of the premutation state (a finger-tapping 
task). In tandem with fMRI investigation, outside scanner measurements of these premutation 
characteristics were chosen to examine the presence and extent of clinical or neuropsychological 
phenotypes. Molecular measurements of FMR1 gene products were also included in the study 
protocol, to allow insight into possible molecular influence on carrier phenotypic variables.      
3.2 Neurodegeneration in the Fragile X premutation: Hypotheses 
Part of the clinical presentation of FXTAS is the progressive loss of normal motor functioning (such 
as balance problems, tremor and ataxia). As mentioned, in the present study, the premutation carrier 
group will be asymptomatic for FXTAS to allow for examination of differences in carriers that exist 
in the absence of overt disease. We set out to utilise an fMRI based finger-tapping motor task to 
identify possible functional differences in the motor areas that are likely to be age-dependant in 
premutation carriers which may precede the overt clinical changes associated with FXTAS. In this 
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way, we would predict to observe mild functional differences that are synonymous to the early stages 
of FXTAS manifestation.  
Previous literature in typically developing people utilising fMRI based finger-tapping tasks  of 
variable complexity and frequency show main activations at the primary motor cortex, supplementary 
motor area and the superior parietal cortex (Minkova et al. 2015). When regressed against finger-taps, 
fMRI data also indicated a main significant cluster at the motor cortex (Murta et al. 2016) . When 
considering healthy aging, it appears qualitatively that older individuals exhibit different activation 
patterns during fMRI when performing simple movements compared to younger individuals 
(Hutchinson et al. 2002). Evidence also suggests that more of the brain is recruited during motor tasks 
in older individuals, including non-motor areas, which is suggestive of a necessity for higher 
processing and compensatory mechanisms (Zapparoli et al. 2013; Sharma & Baron 2014). Motor 
training and motor imagery or cognition also play a key part in differential functional brain responses 
to finger-tapping tasks in older cohorts, with training-specific BOLD response increases at the 
premotor cortex in individuals who performed motor training and increases at the secondary visual 
cortex in individuals who performed mental training (Boraxbekk et al. 2016). These findings highlight 
the importance mental processing, attentional regulation and changes during healthy aging suggestive 
of compensatory mechanisms during finger-tapping tasks.  
There are currently no fMRI studies using motor tasks in FXTAS; however, considering such tasks in 
clinical neurodegeneration populations more generally, investigations into Huntington’s disease have 
revealed a critical role for the dorsal premotor cortex in functional motor control in carriers of the 
Huntington gene without disease. Additionally, this research has indicated that impairment in the 
premotor cortex may cause compensatory recruitment of the parietal cortex in overt Huntington’s 
disease, marking the premotor areas and compensatory activations as points of interest in early 
pathology (Bartenstein et al. 1997). In patients nearing clinical onset of Huntington’s disease, 
involvement of the supplementary motor area has also been shown to be caudally over-recruited 
during higher frequencies and more demanding finger-tapping movements (Kloppel et al. 2009). In 
Parkinson’s patients with tremor, cerebello-thalamo-cortical circuitry dysfunction is implicated in the 
development of tremor symptoms, with a poor suppression of tremor being linked to lower cerebellar 
neural activity (Deiber et al. 1993). Neuroimaging studies also suggest compensatory activity in the 
cerebellum in Parkinson’s disease (Lewis et al. 2011). Lower cerebellar activation has also been 
implicated during a variable frequency finger-tapping task in Spinocerebellar Ataxia Type 3 (Duarte 
et al. 2016; Cleary & Ranum 2014). 
Given evidence based on studies into healthy aging and neurodegenerative diseases, we would expect 
to see group differences in the fMRI finger-tapping task in this study at the premotor cortex, 
supplementary motor area and the cerebellum, in addition to other regional involvement of 
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compensatory mechanisms, possibly at more diffuse areas of higher function. Random finger-tapping 
driven by choice, compared to learned sequential tapping, has been shown to elicit stronger activation 
in classical motor regions as well as recruit areas of higher cognitive functioning, such as the 
dorsolateral prefrontal cortex (Gountouna et al. 2010). The chosen focus of finger-tapping task design 
for this study will therefore be centred around sequential and random finger-tapping to produce a 
similar variance in brain activation and task demand. By using a task design of this type, we hope to 
contrast the random and sequential tapping conditions to probe differences between asymptomatic 
carriers and controls concerning brain regions responsive to changes in task demand. This contrast 
between the sequential and random conditions, also focuses analysis on the compensatory activity and 
mental imagery that have been previously noted as sensitive to age (Boraxbekk et al. 2016). In 
addition to a classic between group imaging analysis, we  will also consider whether the effect of age 
on brain activation during the finger tapping task differs between carriers and control individuals, 
which may implicate brain areas that are vulnerable to early development of FXTAS pathology.        
In accordance with previous findings, we also expect molecular measurements of FMR1 mRNA 
derived from peripheral blood samples to be higher in Fragile X premutation carriers (Tassone, 
Hagerman, Taylor, Gane, et al. 2000; Jacquemont et al. 2003a). It is also expected that due to altered 
RNA metabolism, FMR1 mRNA may accumulate over time and higher levels may be associated with 
increasing age in carriers, which is supported by FMR1 mRNA-mediated intranuclear inclusions in 
the brain becoming larger over time in individuals with FXTAS (Tassone, Hagerman, Taylor, Gane, 
et al. 2000; Sellier et al. 2010). Given the RNA toxic gain-of-function model for FXTAS, we would 
also expect to see functional brain changes that are likely neurodegenerative in nature to correlate 
with increasing FMR1 mRNA levels in the carrier group. 
Presence of sub-clinical levels of motor symptoms in carriers without overt FXTAS have been found 
to be variable, which is likely to be dependent on differences in sample age and future FXTAS 
penetrance (Allen et al. 2008a; Leehey et al. 2008; Tassone, Adams, Elizabeth M Berry-Kravis, et al. 
2007). However, we expect to see some mild changes in tremor, co-ordination and balance, especially 
in older individuals. Previous research in premutation carriers has employed a computerised system 
called the CATSYS-2000 system to establish that carriers without FXTAS exhibit worse co-
ordination scores and to generate estimates of age-related prevalence of tremor and ataxia in carriers 
(Allen et al. 2008b; Aguilar et al. 2008). Given this robust history of use in premutation carriers, the 
CATSYS-2000 system will be used in the present study to obtain measurements of participant tremor, 
balance and co-ordination and we would expect to see a subtle group differences in carriers of 
increased, yet not clinically significant motor symptomology in line with FXTAS development before 
frank clinical onset.   
3.3 Neurodevelopment in the Fragile X premutation: Hypotheses 
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As previously discussed, premutation carriers are known to have an increased risk of psychiatric 
problems, such as depression, obsessive-compulsiveness and autistic traits. We therefore predict that 
carriers will show differences in emotional processing that link to these disorders (Jacquemont et al. 
2004; Cornish et al. 2005). Moreover, we predict that these changes arise from the 
neurodevelopmental aspects of the Fragile X premutation, and as such will represent a stable trait as 
opposed to one that is involved in the neurodegenerative processes of FXTAS. We therefore aim in 
the present study to utilise an emotional processing fMRI task that uses photographic stimuli sourced 
from the International Affective Picture System (IAPS) to probe possible between group differences 
in emotional function. Multiple previous fMRI studies have used Ekman face-based tests using fearful 
faces, so the present study will use an IAPS-based paradigm with the aim of establishing novel 
emotional processing differences in premutation carriers on a more complex emotional spectrum than 
can be examined using fearful and neutral face tasks (Hessl et al. 2007; Hessl et al. 2011).  
The pictures from the IAPS are defined according to valence and arousal parameters, in keeping with 
the dimensional model of emotion, which specifies that all emotions fall on spectra of valence 
(pleasant to unpleasant) and arousal (calm to excited) (Bonnet et al. 2015). Functional imaging using 
IAPS stimuli has shown that the intensity and extent of BOLD activation at the right and left 
amygdala is closely correlated to the increasing emotional intensity (arousal rating) of positive 
valence pictures (Bonnet et al. 2015). Additionally, only pictures deemed to be arousing (both 
unpleasant and pleasant) produced clusters of activity in certain regions, such as the occipital gyrus, 
the right fusiform gyrus and the superior parietal lobes (Lang et al. 1998). Positive linear relationships 
have also been found between activation in the amygdala and the arousing quality of visual stimuli 
and activation in the insula and prefrontal cortex and IAPS arousal ratings (Prehn et al. 2015; 
Sabatinelli et al. 2005). Distinct findings have also demonstrated that pleasurable visual stimuli 
preferentially activate the nucleus accumbens and medial prefrontal cortex (Sabatinelli et al. 2007). 
When grouped against neutral pictures, affective pictures of either pleasant or unpleasant stimuli were 
observed to produce more extensive activation in the visual cortex, especially the secondary 
association areas (Brodmann Areas 18 and 19) (Bradley et al. 2003). Unpleasant IAPS stimuli was 
observed to elicit positive peak BOLD responses that were greater relative to neutral stimuli at the 
primary visual cortex, the bilateral amygdalae and the right ventrolateral prefrontal cortex. This type 
of emotional discrimination was also found to follow a typical region-specific time course, whereby 
right amygdala responsiveness precedes that of the left amygdala, which in turn precedes that of the 
ventrolateral prefrontal cortex (Kohno et al. 2015). Another study identified significant BOLD 
activation during presentation of pleasant stimuli at the ventromedial prefrontal cortex, bilateral 
middle temporal gyrus and the right precuneus, whereas aversive stimuli prompted significant 
activation at the left amygdala and bilateral middle temporal gyrus. These patterns of valence 
associated activations were observed consistently across a range of healthy subjects and individuals 
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with various psychiatric disorders, including major depressive disorder and panic disorder, however 
there was no evident interaction between psychiatric diagnostic group and whole brain significant 
responses (Hägele et al. 2016). The occipito-temporal cortex and the amygdala-hippocampal complex 
were also highlighted as areas of non-specific emotion related activation, which increased in intensity 
during negative valence stimuli from the IAPS compared to pleasant stimuli (Radua et al. 2014). 
Taken together, findings of task-based fMRI using the IAPS stimuli have identified the amygdala, 
hippocampal complex, the ventrolateral and ventromedial prefrontal cortex, the insula and the 
orbitofrontal cortex as brain regions associated with both high and low valence emotional processing, 
with associative links between some areas of regional BOLD intensity and image arousal ratings. 
fMRI studies using IAPS task design and psychiatrically affected groups have indicated that overall, 
BOLD responses are elevated in the limbic regions and prefrontal cortex, particularly during low 
valence conditions, and amygdala-prefrontal functional connectivity is attenuated in individuals with 
psychiatric disorders. Given that the previous literature utilising the IAPS demonstrates brain 
activation patterns in multiple populations that involve a connectome of brain regions that are likely to 
reflect an emotional processing system, we can hypothesise that the premutation group in this study, 
given their higher incidences of psychiatric problems, may show attenuated or heightened BOLD 
responses in areas previously described as altered in psychiatric populations. In keeping with previous 
commonalities in fMRI IAPS based tasks, the task to be utilised in the present study will be centred 
around spectra of valence and arousal in an event-related design. To ensure engagement with the task, 
participants will also be asked to indicate an arbitrary measure of picture content that does not 
explicitly involve ratings of either pleasure or arousal. 
As previously mentioned, Fragile X premutation carriers are a high risk group for the development of 
autism spectrum disorder (ASD) and psychiatric symptomatology (Cornish et al. 2005; Dorn et al. 
1994). In concordance with previous findings therefore, we would expect to see significantly different 
measurements of neuropsychological or psychiatric symptoms in carriers when compared to controls 
in tests conducted outside of the scanner. In studies of premutation carrier males, the self-report 
psychiatric questionnaire Symptom Checklist -90- Revised (SCL-90-R) (Pearson) has been used to 
characterise symptomatology of the following: somatization, obsessive-compulsiveness, interpersonal 
sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism and global 
severity index. Males without FXTAS were observed to have worse scores in obsessive-
compulsiveness and global severity than controls as scored by the SCL-90-R (Hessl et al. 2005). 
Using this measure we would therefore hope to replicate these previous psychiatric findings. 
Symptoms of autism spectrum disorder in adults of normal intelligence can be self-reported using the 
Autism Quotient (AQ) and the Empathy Quotient (EQ) (Baron-Cohen et al. 2001). The AQ 
questionnaire involves assessment of participant social skills, attention switching, attention to detail, 
communication and imagination and has an 83% accuracy in positively predicting the presence of 
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autism spectrum disorder above a score of 26 (Woodbury-Smith et al. 2005; Baron-Cohen et al. 
2001). The EQ assesses ability for empathic awareness in participants, and has an 81% accuracy of 
correctly identifying individuals on the ASD spectrum with scores lower than 30 (Baron-Cohen & 
Wheelwright 2004). EQ scores are also predictive of AQ scores (Wheelwright et al. 2006). Previous 
studies into ASD and the FMR1 premutation have revealed that the incidence of ASD is significantly 
higher in premutation males (Saul & Tarleton 1993). Therefore, the use of the AQ and the EQ in the 
present study is hoped to reflect these previous findings. Other neuropsychological measurements,  
the Ekman Faces and Social Judgement tests, will also be included, to allow more thorough 
investigation of social and emotional processing and ability in tandem with the MRI scanner-based 
emotional task. Additionally, it will be of interest as to whether these psychiatric and 
neuropsychological variables exhibit correlational significance when regressed against data from 
between group brain imaging analyses from the emotional processing task. 
In terms of possible molecular changes driving emotional and psychiatric differences in carriers, it is 
theorised that FMR1 protein levels are key. FMRP is densely concentrated at the post-synaptic 
density, and is essential for healthy brain development, as is demonstrated by marked 
neurodevelopmental problems in Fragile X Syndrome and animal knock-out studies (Penagarikano et 
al. 2007). It therefore seems probable that slightly lowered levels of FMRP in carriers compared to 
controls may be causing subtle neurodevelopmental differences which manifest in the 
neuropsychological and psychiatric symptoms found in previous studies (Tassone, Hagerman, Taylor, 
Gane, et al. 2000; Allen et al. 2005). This study therefore aims to establish first whether FMRP is 
indeed lower in this male premutation population, and second whether levels of FMRP are associative 
with fMRI BOLD responses, as has been identified previously, where amygdala dysfunction was 
found to correlate with lower levels of FMRP in carriers (Hessl et al. 2011). Overall, we aim to use 
this combination of methodology to investigate the existence of carrier/control differences and to 
establish whether FMRP levels and symptomatology are associated with possible changes in BOLD 
response.   
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Chapter 4: Neurodegeneration in the Fragile X premutation: Methods 
4.1 Participants and recruitment 
Male carriers of the premutation and a group of healthy male age-matched control subjects were 
recruited. The age range for inclusion in the study was 20-70 years. Recruitment was carried out using 
the Patrick Wild Centre and Fragile X Registry email lists, which are contactable lists of potential 
participants held by the affiliated centre for Fragile X related clinical studies and 1000 mailings were 
sent out through the existing Fragile X family database held by the Fragile X Society. Potential 
premutation carrier participants were required not to have received a diagnosis of FXTAS and to have 
been genetically confirmed as a carrier prior to taking part in the study. Participants were not 
permitted to take part in the study if they were a member of a family with an identified individual with 
the Fragile X premutation or Fragile X Syndrome, but had not had a genetic test to confirm or deny 
carrier status. This was to minimise unexpected findings, and the ethical issues surrounding diagnosis 
of carrier status during the study. Both carrier and control participants were also not permitted to take 
part if they fell out with the age range of 20-70 years. All participants were given an Information 
Sheet at least 48 hours prior to taking part in the study, were given the opportunity to ask any 
questions they may have had and gave fully informed written consent on the day of testing. All 
participants were also screened for MRI eligibility and safety prior to taking part. 
A power calculation was used to define an ideal sample population of 80 (40 controls and 40 
premutation carriers). Dividing age in a 5-level factor (20-29, 30-39, 40-49, 50-59, 60-69) with group 
as a 2-level factor (control, carrier) and assuming an effect size for the interaction of eta sq = 0.18 
(estimated from Cornish et al. 2008 and Cornish et al. 2009, who report findings consistent with an 
effect size of >0.18) a total sample of 60 participants would be required to give 80% power to detect 
an age interaction difference at a significance level of p<0.05. In addition, two previous 
neuropsychological studies in this area (Cornish et al. 2008, Cornish et al. 2009) examined 40 
premutation carriers and identified differences between them and controls in terms of the relationship 
between age and cognitive function. Neuroimaging studies generally require smaller sample sizes than 
neuropsychological studies, therefore a sample size of 80 was deemed preferable and sufficient. 
However, recruitment of male premutation carriers for the study yielded a low response rate (<2% of 
Fragile X families contacted). Causes for this plausibly included the likely requirement for significant 
travel for participants, unwillingness or inability to take time off work, anxiety about an MRI scan and 
a relatively large length of testing time. In addition, male carriers of the premutation who have been 
genetically diagnosed are rare, and due to ethical issues surrounding confirming carrier status during 
the study, recruitment was unable to include individuals who were suspected to have the premutation 
but had not undergone genetic counselling. The sample size for the current study therefore was not as 
large as originally predicted.  
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The protocol was approved by the South East Scotland Research Ethics Committee and NHS Lothian 
Research and Development Office.   
 
4.2 Imaging methods 
All MRI data was acquired on a 3 Tesla Siemens MRI scanner using an 8 channel head coil. For the 
acquisition of functional images the TR was 1560ms, the TE (echo time) was 26ms, the flip angle was 
66 degrees, the FOV (field of view) was 220mm, slice thickness was 5mm and slice number per 
volume was 26. Slice order was interleaved and bottom up in the axial orientation. Each participant 
also underwent a T1-weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) 
sequence, for the purpose of image preprocessing. For the MPRAGE acquisition the TR was 2300ms, 
the TE was 2.98ms, the flip angle was 9 degrees, the FOV was 256mm, slice thickness was 1mm and 
slice number per slab was 160. Each participant also underwent a 12 minute DTI sequence which is 
not considered further in this thesis. The scanning protocol in total was approximately 50 minutes for 
each participant.  
 
The finger-tapping motor task used for this study utilised a block design and consisted of three 
conditions (Fig. 4.1). In the sequential tapping condition, participants were asked to tap their thumbs 
and index fingers in a predetermined sequence in time with a flashing symbol. In the random tapping 
condition, participants were asked to tap their thumbs and index fingers in a random order in time to a 
flashing symbol. The final condition consisted of a flashing fixation cross, where participants were 
asked to simply rest and watch the screen. The flashing symbol appeared once every second, for a 
duration of 0.5 seconds. Each condition block had a total duration of 30 seconds (including a 2 second 
prompt screen) and was repeated 4 times during the task. The task was designed and ran using 
PresentationTM software. Participants were given written instructions for all of the tasks before 
entering the MRI scanner (Appendix 4.1), shown an example of each task on a laptop screen and 
given the chance to ask any questions they may have had. The tasks were visually presented to 




Figure 4.1 Finger-tapping task behavioural conditions and block design.
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This task was behaviourally piloted prior to use in the scanner (Table 4.1). Five individuals who were 
not potential participants for the main study carried out the task on a laptop. The task was presented 
using PresentationTM software, in the exact same manner as it was to be presented in a scanner 
environment. Button presses of the scanner triggers were replaced by keyboard presses. Each 
individual subsequently filled out an evaluation form of the task (Appendix 4.2), which focussed on 
the clarity of task instructions, ease of carrying out the task and engagement in the task. Individuals 
were also asked to comment on the sequential and random conditions separately. The majority of 
individuals rated this task as very simple and very engaging. Four out of five individuals also did not 
make a differentiation based on easiness between the sequential and random conditions. It was 
therefore deemed the task was suitable for participants to carry out in an MRI scan. 
 
Table 4.1. Finger-tapping task behavioural pilot data 
Individual  Clarity rating (1=confusing, 
5=simple) 
Engagement rating (1=not engaged, 
5=very engaged) 
1 4 2 
2 2 2 
3 5 5 
4 5 5 
5 5 5 
 
Table 4.1 Finger-tapping task self-reported evaluation form data from behavioural piloting 
  
4.3 fMRI analysis 
Statistical analysis on fMRI data was carried out using Statistical Parametric Mapping software 
(SPM12) (Wellcome Department of Clinical Neurology).  
The functional images from all participants were preprocessed according to the following steps: 1) 
firstly images were realigned, estimated (for optimal transformation from individual images to the 
reference using SPM12 default quality, separation, smoothing, num passes, interpolation, wrapping 
and weighting parameters) and resliced 2) images were then slice timed, adjusting for interleaved and 
bottom up slice order 3) subsequent functional images were coregistered with the source structural 
image from the T1 MPRAGE anatomical scan 4) coregistered images were segmented into grey 
matter, white matter and CSF outputs 5) images were normalised to MNI space, and 6) finally the 
normalised images were smoothed with a 8mm FWHM (full-width at half maximum) Gaussian 
smoothing kernel.  
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Movement was controlled for by adding realignment parameters for each participant as a multiple 
regressor into the first level model. First level analysis was carried out for each participant for each 
task. For the finger-tapping motor task, the sequential and random conditions were contrasted using a 
[1 -1] contrast. This type of contrast investigates the linear effect of one condition minus the linear 
effect of another condition.  
For the second level analysis, explicit masking was used to exclude voxel data outwith the brain 
tissue. This explicit mask was comprised of an average binarised image created from the combined 
grey matter and white matter segmented images from all participants. Both within and between group 
analyses were completed. Within group analysis used a one-sample t-test for each task and first level 
contrasts to look at significant activation for the control and premutation group separately. Within 
group second level contrasts were defined as either [1] or [-1] to look at linear increase and linear 
decrease of activation patterns. The between group analyses used a full factorial design to examine the 
differences between the control and premutation groups. The groups were compared using [1 -1] and 
the reverse [-1 1] contrasts. An example design matrix is presented in figure 4.2, showing the between 
group analysis for controls and carriers. In addition, age was added into the full factorial design as a 
regressor and group x age interactions at a whole brain level were examined in SPM for both the 
control and the premutation group using [1 -1] and the reverse [-1 1] contrasts. All second level 
contrasts were calculated using an initial height threshold of p < 0.005. Family-wise error correction 




Figure 4.2 Design matrix displaying a control>premutation between group contrast for the finger-
tapping second-level analysis. Controls are represented in column 1, premutation carriers are 
represented in column 2 and age is represented in columns 3 and 4. 
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4.4 Clinical measurements 
The CATSYS-2000 PC-based system was used to assess movement variables in all participants. The 
CATSYS system groups movement performance into three categories: tremor, balance and co-
ordination. For tremor measurements, participants were asked to hold a stylus as they would a pen, 
vertically in front of their chest with their arm bent. They were then asked to remain as still as 
possible during the 8 second testing period, where movement parameters were obtained in two 
dimensions by the stylus accelerometer (m/s2). Both left and right hands were tested. For balance 
measurements, each participant was asked to stand on a computerised sway board, without shoes, with 
feet hip-distance apart, arms straight by their side and head facing forwards. Once standing on the 
board, participant sway was then measured for 1 minute, using the Pythagorean sum of transversal 
and sagittal sway (mm). Co-ordination measurements were carried out first using tapping 
measurements and then reaction time measurements. During tapping assessments, participants were 
asked to tap their hand on a computerised drum, using a pronation-supination movement to a rhythmic 
beat that is set by an auditory beep. Measurements were taken for each participant at a slow beat (1 
beep per second, 20 second duration), fast beat (2 beeps per second, 10 second duration) and 
increasing frequency beat (1 beep per second-5 beeps per second, 20 second duration) for both the 
right and left hands. Participants were also asked to repeat the same measurements on the drum 
tapping with their index finger, with wrist and thumb resting on the table. Reaction time co-ordination 
scores were obtained for both the right and left hands for each participant using a hand-held click 
button. For a duration of 40 seconds, participants were asked to click the button using their thumb as 
soon as they heard an auditory stimulus. This stimulus was a beep which sounded randomly over the 
duration of the test. Co-ordination scores were produced from deviation in rhythmic tapping and 
reaction time with respect to stimulus time (msec).     
The CATSYS system then produced performance indices for overall tremor, balance and co-
ordination as values between 0 and 2, relating the participant performance to average human 
performance as determined by the CATSYS normative material (Danish Product Development Ltd.). 
Indices for performance better than typical human performance are higher than 1.0, indices below 
typical human performance are less than 1.0. Formulae relating performance indices to average 
human performance are exponential equations using a Gauss distribution function (Appendix 4.3).  
4.5 Molecular measurements 
DNA was isolated from blood samples for both control and carrier participants. The assay for CGG 
repeat length in the FMR1 gene was carried out using a PCR-only approach based on Triplet Repeat 
Primed PCR design (AmplideX® PCR/CE FMR1 reagents).   
Whole blood was collected from all participants and processed to isolate total RNA. Total RNA was 
then reverse transcribed into cDNA, using Real Time (RT) PCR methodology. RT reactions were 
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performed in 25µl aliquots containing 10µl of patient total RNA sample, 12.5µl 2x RT buffer and RT 
enzyme mix (Invitrogen Superscript). RT thermal cycling conditions were as follows: 25ºC for 10 
minutes, 50ºC for 30 minutes, 85ºC for 5 minutes and 4ºC for 15 minutes. 1µl of RNase H was 
subsequently added to each aliquot and the samples were incubated at 37ºC for 20 minutes. Each 
sample was then diluted to a cDNA concentration of 6ng/µl. These dilutions were then used to 
quantify FMR1 mRNA using quantitative PCR (qPCR). Once an FMR1 primer pair was designed and 
validated (R2 =-0.998, efficiency = 101.01%), aliquots were prepared in triplicate for each sample, 
with each aliquot containing 0.6µl 300nM forwards primer, 0.6µl 300nM reverse primer, 10µl SYBR 
Green (Qiagen), 11.8µl H2O and 1µl 6ng/µl cDNA sample. An additional control was run in triplicate 
on each plate with cDNA replaced by H2O. Thermal cycling conditions for the qPCR were as follows: 
95ºC for 15 minutes, (94ºC for 20 seconds, 59ºC for 30 seconds and 32ºC for 30 seconds) x 35 cycles, 
then 95ºC for 1 minute, 60ºC for 30 seconds and 90ºC for 30 seconds.  
All FMR1 mRNA measurements were averaged per participant and normalized to 18 sRNA 
measurements from the same samples (primer efficiency = 91.28%, R2 = -0.994), which were also ran 
in triplicate on the same qPCR plate as the FMR1 mRNA probes. All samples underwent qPCR 
analysis on the same plate as their age-matched counterpart. Carrier FMR1 mRNA was then 
additionally normalized to age-matched control. Outlier FMR1 mRNA or 18 sRNA measurements 
within the triplicate were discarded and qPCR was repeated for these samples.  
 
4.6 Statistical analysis 
Further statistical analyses were carried out in SPSS Statistics 22. Parametric testing of group means 
was deemed appropriate considering the assumed normal distribution of the data. A two-tailed t-test 
was used to discern differences between the premutation and control groups for the tremor, balance 
and coordination measurements, in addition to the FMR1 mRNA data. Simple linear regressions were 
also performed on extracted raw voxel values from significant clusters against the movement and 
molecular variables. All significance levels were assumed at p<0.05.  
CGG repeat analysis revealed that some individuals in the sample were mosaic or borderline for the 
full mutation. To ensure this was not causing a bias in the results, mosaic and borderline carriers were 
separated from the sample, creating three participant groupings: control, premutation and 
mosaic/borderline. A one-way ANOVA of 3 age-matched groups, followed by a Tukey post-hoc test 
was performed on extracted voxel data from the maximum voxel of the significantly different 
between group cluster. An analysis of covariance with age as a covariate, including group, age and 
group x age interaction in the model was performed on extracted voxel data from the age interaction 
significant cluster on these 3 age-matched groups using age as an interacting variable.  
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Chapter 5: Neurodegeneration in the Fragile X premutation: Results 
5.1 Participants and recruitment 
Male premutation carriers without FXTAS (n=17, mean age 50.4 years, SD=15.1) and a group of age-
matched healthy male controls n=17, mean age 47.6 years, SD=12.9) were recruited for this study. A 
parametric two-sample t-test of age carried out in SPSS revealed participant age in the premutation 
and control groups not to be significantly different (p=0.570). Level of education was comparable 
between groups. CGG repeat testing revealed that 12 carriers were within the premutation range, 1 
carrier was in the intermediate range, 3 carriers were mosaic for repeat size and one carrier was 
borderline for the full mutation. All control subjects were within the normal CGG repeat length range. 
Main CGG repeat length value by group is plotted in figure 5.1. All participants were right handed, 
apart from one control and two carriers, and all participants had composite IQ >80, as measured by 
the KBIT Second Edition Intelligence Test (Pearson) (Table 5.1). When compared using a parametric 
two-sample t-test in SPSS, verbal IQ and composite IQ as measured by the KBIT-2 were not 
significantly different between the groups (p=0.604, p=0.053), although composite IQ could be seen 
to exhibit a trend towards being lower in carriers. Non-verbal IQ was identified to be significantly 





Figure 5.1 Main CGG repeat values by group, excluding secondary mosaic values in carriers. Mean 
CGG repeat length in the control group was 27.76 repeat units (SD=6.49), and mean for the carrier 




Table 5.1: Participant data 
 
  
Participant ID  Age Premutation status Composite IQ 
1 26 Normal (40 repeats) 129 
2 24 Normal (20 repeats) 123 
3 33 Normal (22 repeats) 110 
4 30 Normal (38 repeats) 103 
5 52 Normal (19 repeats) 107 
6 41 Normal (20 repeats) 128 
7 58 Normal (23 repeats) 112 
8 53 Normal (30 repeats) 110 
9 48 Normal (32 repeats) 110 
10 55 Normal (32 repeats) 111 
11 64 Normal (31 repeats) 108 
12 52 Normal (31 repeats) 105 
13 45 Normal (31 repeats) 121 
14 68 Normal (23 repeats) 126 
15 58 Normal (30 repeats) 127 
16 55 Normal (20 +/-1 repeats) 122 
17 47 Normal (30 repeats) 126 
18 46 Premutation (91 +/-3 repeats) 139 
19 67 Premutation (82 +/- 3 repeats) 106 
20 24 Premutation (82 +/-2 repeats) 119 
21 50 Premutation (88 +/- 3 repeats) 144 
22 54 Premutation (85 +/- 5 repeats) 108 
23 57 Premutation (185 +/- 10 repeats) 101 
24 26 Premutation (mosaic 150 +/- 5; ~200 +/- 10 repeats) 86 
25 33 Premutation (74 +/- 2 repeats) 111 
26 68 Premutation (118 +/- 8 repeats) 104 
27 68 Premutation (88 +/- 3 repeats) 97 
28 43 Premutation (71 +/- 2; 119 +/- 5 repeats) 107 
29 66 Premutation (mosaic 133, 156; 198 +/- 10 repeats) 109 
30 52 Premutation (58 repeats) 94 
31 30 Premutation (mosaic 148 +/- 5; ~200 repeats) 102 
32 67 Premutation (80 +/- 2 repeats) 108 
33 58 Premutation (91 +/-3 repeats) 125 
34 47 Intermediate (50 repeats) 117 






Figure 5.2 IQ scoring by group, analysed statistically using a parametric two-sample t-test in SPSS a) 
Verbal IQ by group. Mean verbal IQ in the premutation group was 111.1 (SD=15.8), mean verbal IQ 






Figure 5.2 IQ scoring by group, analysed statistically using a parametric two-sample t-test in SPSS b) 
Non-verbal IQ by group. Mean non-verbal IQ in the premutation group was 108.1 (SD=13.7), mean 







Figure 5.2 IQ scoring by group, analysed statistically using a parametric two-sample t-test in SPSS c) 
Composite IQ by group. Mean composite IQ in the premutation group was 110.4 (SD=14.9), mean 
composite IQ in the control group was 116.4 (SD=9.1).
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5.2 Within group imaging analysis 
Within group one sample t-test analysis revealed that when contrasting the sequential tapping and the 
random tapping conditions, controls exhibited a large cluster of activation (FWEcorr<0.001, T=8.62) at 
the bilateral lobules VI of the cerebellum, right Brodmann Area (BA) 17 of the primary visual cortex 
and right lobule V of the cerebellum. The maximum of the cluster was located at [14,-48,-16] (Fig. 
5.3a). The premutation group exhibited a similar, smaller cluster of BOLD response at the right 
lobules VI and V of the cerebellum, although this did not reach significance (FWEcorr=0.491, T=6.05). 






Figure 5.3 Within group functional brain imaging analysis carried out in SPM12 a) Within group 
analysis of the control group. Significant cluster of activation (FWEcorr <0.001, T=8.62) at the bilateral 
lobules VI of the cerebellum, right BA17 of the primary visual cortex and right lobule V of the 
cerebellum in the sequential>random condition contrast. Cluster co-ordinate of maximum voxel: 14,-






Figure 5.3 Within group functional brain imaging analysis carried out in SPM12 b) Within group 
analysis of the premutation carrier group. Cluster of BOLD activation, not reaching significance 
(FWEcorr <0.491, T=6.05) at the right lobules VI and V of the cerebellum in the sequential>random 





5.3 Between group imaging  
Between group full factorial analysis carried out in SPM12 revealed that the premutation group had a 
significantly lower cluster of BOLD response (FWEcorr<0.001, T=5.59) at the bilateral lobules VI of 
the cerebellum, left lobule V and the left hippocampus (subiculum) compared to controls. The 
maximum of the cluster was located at [-12,-36,-12] (Fig. 5.4a).  
As analysis of FMR1 CGG repeat length revealed a number of carriers in the sample to be mosaic or 
borderline for the full mutation, a third group was created of mosaic and borderline carriers to ensure 
that anomalies in CGG repeat length were not skewing the imaging results, and that these individuals 
were not driving the between group differences. The ANOVA analysis was carried out in SPSS and 
the groups were defined as the following: control (n=17), premutation (n=13) and mosaic/borderline 
carriers (n=4). A statistically significant between group difference in BOLD response at the 
significant cluster maximum voxel [-12,-36,-12] was identified by one-way ANOVA 
(F(2,31)=14.249, p<0.001). A Tukey post-hoc test revealed that BOLD response for this cluster was 
significantly different in controls compared to carriers (p<0.001) and controls compared to 
mosaic/borderline carriers (p=0.026), but not significantly different between carriers and 





Fig. 5.4 Between group functional brain imaging analysis carried out in SPM12 a) Premutation group 
significantly less activated (FWEcorr <0.001, T=5.59) at the bilateral lobules VI of the cerebellum, left 
lobule V and the left hippocampus (subiculum) in the sequential>random condition contrast. Cluster 






Fig. 5.4 Between group functional brain imaging analysis carried out in SPM12 and subsequently 
plotted using SPSS b) Mean extracted voxel response by grouping at the bilateral lobules VI of the 




5.4 Group x age interaction  
In the analysis of age related differences, carried out at a whole brain level in SPM12, a significant 
group x age interaction was seen in a cluster that included the left inferior parietal cortex, the left 
Brodmann Area (BA) 17 in the primary visual cortex, the left hippocampus (cornu ammonis) and the 
left temporal lobe (FWEcorr<0.001, T=5.22). The maximum of the cluster is located at [-26,2,36] (Fig. 
5.5a).  Subsequently plotting extracted values from this cluster using SPSS indicated there was a 
negative relationship between age and activation in this cluster in the premutation group, while the 
relationship was positive in the control group. Within group regression analysis revealed both of these 
relationships to be significant (Table 5.2).  
A univariate analysis of variance was also carried out on this significant cluster in SPSS to ensure 
anomalous CGG repeat lengths were not causing a bias in the imaging results. The groups for the 
univariate analysis of variance analysis were defined as the following: control (n=17), premutation 
(n=13) and mosaic/borderline carriers (n=4). A statistically significant group x age interaction was 
identified in BOLD response at the significant cluster maximum voxel [-26,2,36] (p<0.001), and 
plotting of group x age extracted voxel data demonstrates that both the premutation and the 
mosaic/borderline group differ significantly to controls but not to each other (Fig. 5.5b).  
Table 5.2:  Within group age/BOLD activation regression analyses 
Group DV IV β Standard 
error 
Adjusted R2 P value 
Control Age BOLD response 
at [-26,2,36] 
0.763 0.001 0.554 <0.001 
Premutation Age BOLD response 
at [-26,2,36] 
-0.595 0.001 0.312 0.012 
 
Table 5.2. Statistical results of within group regression analyses between participant age and BOLD 
activation at the left inferior parietal cortex, the left Brodmann Area (BA) 17 in the primary visual 







Fig. 5.5 Group x age interaction analysis carried out at a whole brain level in SPM12 a) Significant 
group x age interaction (FWEcorr <0.001, T=5.22) at the left BA17, left hippocampus (CA), left 
inferior parietal cortex and left temporal lobe in the sequential>random condition contrast. Cluster co-








Fig. 5.5 Group x age interaction analysis carried out at a whole brain level in SPM12 and voxel data 
subsequently analysed and plotted in SPSS b) Fit linear regression lines comparing positive control 
BOLD response and age relationship compared to negative premutation carrier BOLD response and 
age relationship at maximum cluster voxel [-26,2,36], located at the left BA17, left hippocampus 
(CA), left inferior parietal cortex and left temporal lobe.
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5.5 Clinical measurements  
Although none of this population of carriers had been diagnosed with FXTAS, using parametric two-
sample t-testing in SPSS, the CATSYS-2000 system identified carriers to have significantly worse 
tremor and co-ordination (p=0.002, p=0.001), although not balance (p=0.931) compared to controls 
(Fig. 5.6). Both populations had mean performance indices of better than normal human performance 







Figure 5.6 CATSYS-2000 movement data analysed using parametric two-sample t-testing in SPSS a) 
Participant tremor score by group. Mean tremor score for the premutation carrier group was 0.325 




Figure 5.6 CATSYS-2000 movement data analysed using parametric two-sample t-testing in SPSS b) 
Participant balance score by group. Mean balance score for the premutation carrier group was 1.73 






Figure 5.6 CATSYS-2000 movement data analysed using parametric two-sample t-testing in SPSS c) 
Participant co-ordination score by group. Mean co-ordination score for the premutation carrier group 








Tremor SD Mean 
balance 
score 






Control 0.43 0.72 1.719 0.156 1.311 0.154 
Premutation 0.325 0.106 1.730 0.130 1.088 0.191 
 
Table 5.3 Comparison of mean tremor, balance and co-ordination measurements obtained from the 
CATSYS-2000. 
5.6 Molecular measurements 
Quantative PCR analysis revealed that this population of asymptomatic premutation carriers do not 
have significantly higher levels of FMR1 mRNA relative to 18 sRNA when measured from peripheral 
blood samples (p=0.3223). However, normalization of carrier FMR1 mRNA relative to 18 sRNA to 
age-matched control data suggests there is a higher mean level than controls and some carriers have 
up to a 7-fold increase in FMR1 mRNA when compared directly to an age-matched control (Fig 5.7a). 
To examine again whether the borderline or mosaic carriers were causing anomalies in the data, these 
individuals were separated from the analysis. One-way ANOVA analysis revealed no significant 
difference in borderline or mosaic carrier FMR1 mRNA level relative to 18 sRNA compared to 




Fig. 5.7 FMR1 mRNA quantification data analysed using parametric two-sample t-testing in SPSS a) 











Fig. 5.7 FMR1 mRNA quantification data analysed using parametric one-way ANOVA testing in 
SPSS b) Carrier and mosaic or borderline carrier FMR1 mRNA amount relative to 18 sRNA 
normalised to age-matched control.
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5.7 Linear regression analyses 
Simple linear regression analyses were carried out in SPSS on the imaging and clinical variables 
(Table 5.4). Extracted raw voxel data from the cluster global maxima originating from the between 
group analysis, located at the bilateral lobules VI of the cerebellum, left lobule V and the left 
hippocampus (subiculum) was regressed against measures of tremor, co-ordination and balance. No 
significant association was found between these variables and the between group significant cluster in 
either carriers or controls. Extracted raw voxel data from the global maxima of the significant cluster 
from the age interaction analysis, located at the left BA17, left hippocampus (cornu ammonis), left 
inferior parietal cortex and left temporal lobe, was also regressed against participant tremor, co-
ordination and balance data. None of the linear regression analyses showed an association between 
age-related functional brain changes and these variables in either carriers or controls. 
Simple linear regression analyses were also carried out on the imaging data and measurements of 
FMR1 mRNA (Table 5.4).  Neither the between group imaging significant cluster or the significant 
group x age cluster revealed a significant relationship with FMR1 mRNA. 
Table 5.4:  Within group regression analysis 
Group DV IV β Standard 
error 
Adjusted R2 P 
value 
Control BOLD response 
at [-12,-36,-12] 
Tremor -0.196 0.009 -0.026 0.452 
  Balance -0.027 0.004 -0.066 0.917 
  Co-
ordination 
-0.053 0.004 -0.064 0.839 
  FMR1 
mRNA 
0.105 34399.317 -0.055 0.689 
Premutation BOLD response 
at [-12,-36,-12] 
Tremor -0.054 0.006 -0.064 0.838 
  Balance -0.311 0.005 0.036 0.225 
  Co-
ordination 
0.322 0.003 0.044 0.207 
  FMR1 
mRNA 
-0.024 19615.590 0.066 0.926 
Control BOLD response 
at [-26,2,36] 
Tremor -0.100 0.003 -0.056 0.702 





-0.010 0.001 -0.067 0.970 
  FMR1 
mRNA 
0.359 9677.064 0.071 0.157 
Premutation BOLD response 
at [-26,2,36] 
Tremor -0.202 0.002 -0.023 0.438 
  Balance -0.007 0.002 -0.067 0.978 
  Co-
ordination 
0.217 0.001 -0.017 0.403 
  FMR1 
mRNA 
0.048 6058.494 -0.064 0.354 
 
Table 5.4 Statistical results of within group regression analyses between extracted BOLD activation 
data from the significant cluster, located at the bilateral lobules VI of the cerebellum, left lobule V and 
the left hippocampus (subiculum) in the classic between group analysis, cluster maximum co-ordinate 
[-12,36,-12], and the significant cluster in the group x age interaction analysis, located at the left 
BA17, left hippocampus (CA), left inferior parietal cortex and left temporal lobe, cluster maximum 
co-ordinate [-26,2,36], with clinical and molecular variables. 
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Chapter 6: Neurodegeneration in the Fragile X premutation: Discussion 
6.1 Within group imaging  
Within group one sample t-test analysis revealed a large significant cluster of BOLD activation in the 
control group, centred at the lobules VI and V of the cerebellum and extending into BA17 of the 
primary visual cortex, when contrasting the sequential and random finger-tapping conditions. A 
smaller cluster centred in the same region, but not reaching statistical significance, was evident in the 
premutation group within group analysis. These BOLD responses in the anterior lobe of the 
cerebellum (lobules I-VI) is consistent with both the cerebellar homunculus and previous reported 
findings (O’Reilly et al. 2010a). In a similar manner to the present study, an fMRI investigation into 
patients with essential tremor revealed within group activation during blocks of upper limb movement 
of cerebellar lobule V in both controls and patients (Broersma et al. 2016). Functional topography 
studies report cerebellar lobule V in particular as being activated in response to finger-tapping, and 
lobule VI is reported as being involved during more cognitively demanding tasks (Stoodley et al. 
2012). The involvement of both lobules V and VI in the present within group analysis is in line with 
these previous reports of differential activation and demand responses, as contrasting two finger-
tapping conditions here was hypothesised to provide activation patterns consistent with a change in 
task demand, given that choice-driven, random tapping is known to elicit higher peak and more 
diffuse activation patterns than sequential tapping (Gountouna et al. 2010). 
Although both the control and premutation group separately exhibited a cluster of activation centred 
at the anterior lobe of the cerebellum, the cluster was significant in the control group but not in the 
carrier group. It is possible that an increased heterogeneity of activation patterns in the carrier group 
may have contributed to no significant clusters being identified, given that it is a high-risk group for 
neurological disease. However, the within group analyses robustly indicate an overall reduction in 
BOLD response in the carrier group when contrasting sequential and random finger-tapping 
conditions. The regional activation specificity of this finger-tapping task is also reflective of previous 
findings into fMRI motor-based tasks and the cerebellar topography.  
6.2 Between group imaging  
Consistent with the primary hypothesis, differences between carriers and controls were identified 
when contrasting random and sequential finger-tapping conditions in this fMRI task in the bilateral 
lobules VI of the cerebellum, left lobule V and the left hippocampus (subiculum), reflective of the 
within group analysis.   
The cerebellum is a brain region which is strongly associated with movement initiation and 
processing, as well as being a site of degeneration in FXTAS (Berry-Kravis, Abrams, et al. 2007). 
Cerebellar involvement is a key part of FXTAS, with generalised loss of cerebellar volume 
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disproportionate for age being commonly reported in patients and hyperintensity at the middle 
cerebellar peduncles seen in T2 and FLAIR acquisitions, known as the MCP sign, forming part of the 
primary diagnostic criteria for FXTAS (Capelli et al. 2010). The MCP sign is reported in 
approximately 60% of FXTAS patients, and diffusion tensor tractography has revealed that the middle 
cerebellar peduncles exhibit weaker structural connectivity compared to controls (Wang, Hessl, et al. 
2013; Apartis et al. 2012). In addition, other cerebellar tracts, such as the superior cerebellar 
peduncles, showed weaker structural connectivity than normal in FXTAS, and these measurements 
exhibited a correlation with motor functioning across the control, FXTAS and asymptomatic carrier 
groups (Wang, Hessl, et al. 2013). It is therefore not unexpected that a between group difference has 
been identified at the cerebellum, extending into the hippocampus, during a finger-tapping task in a 
premutation population. Sensorimotor mapping of the cerebellum labels lobule V as primarily related 
to movements of the hand, and finger-tapping tasks have previously been found to reliably activate 
cerebellar lobule V, with more cognitively demanding tasks also recruiting lobule VI (Stoodley et al. 
2012; Grodd et al. 2001). Our finding of significantly lower activation at lobule VI of the cerebellum 
may well reflect deficits in recruitment during higher levels of demand during the task, in addition to 
a lower level of basic sensorimotor processing at lobule V. The hippocampus is not routinely cited as 
being significantly activated during within group analyses of fMRI motor tasks, however the 
extension of the significant between group cluster to the hippocampal subiculum may also indicate a 
deficit in more diffuse recruitment in response to a change in task demand (De Guio et al. 2012; Berns 
et al. 1999). This type of evidence of significant differences between carriers without FXTAS and 
controls during a motor task is suggestive of neurological vulnerability to disease prior to onset.   
Our results also indicate parallels with other neurodegenerative diseases. Interestingly, cerebellar 
lobule VI has previously been highlighted as an area of significantly different BOLD response during 
self-cued finger-tapping in Parkinson’s patients when compared to healthy controls (Mak et al. 2016). 
Lobule V of the cerebellum has also been indicated in functional connectivity analysis to be 
associated with tremor variation in both its intrinsic activity and extrinsic connectivity to the thalamus 
in patients with an essential tremor (Buijink et al. 2015). These links to functional changes at 
cerebellar lobules V and VI with other neurodegenerative diseases or movement disorders tie to 
FXTAS symptomology, given the presence of both tremor and Parkinsonism in most FXTAS patients, 
and here we demonstrate for the first time functional imaging evidence of similar motor processing 
differences in premutation carriers. 
6.3 Group x age interaction  
A significant group x age interaction was also identified that revealed that, compared to controls, 
carriers showed a significantly more negative association between age and activation in the left BA17, 
left hippocampus (cornu ammonis), left inferior parietal cortex and left temporal lobe. Involvement of 
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the cerebrum is a major part of FXTAS development, with generalised cerebral atrophy being 
reported in virtually all FXTAS patients studied (Brunberg et al. 2002; Jacquemont et al. 2003b; 
Greco et al. 2002; Leehey et al. 2003). Volumetric studies revealed significant loss of volume in the 
thalamus, amygdalo-hippocampal complex and cerebral cortex in patients with FXTAS, and in 
particular, reduction in hippocampal volume was correlated with more advanced clinical staging of 
FXTAS (Adams et al. 2007; Loesch et al. 2005; Moore et al. 2004). Given that the cerebrum has been 
globally implicated in FXTAS pathology, moreover in a progressive manner, it is pertinent that 
imaging results of this group x age interaction analysis reveal a cluster that involves the hippocampal 
formation, visual cortex and other areas of the cerebrum.  
Within group regression analysis of the voxel data from this significant cluster revealed that both the 
positive age-related correlation in the control group and the negative age-related correlation in the 
premutation group were significant. In normal elderly populations, finger-tapping has been seen to 
elicit over-recruitment of the occipito-temporo-parietal regions, suggesting an increased level of 
visual or mental strategizing (Zapparoli et al. 2013). This idea of compensatory activity is reflected in 
our regression analysis, with activation in the temporo-parietal cluster identified in this analysis 
showing a positive linear relationship with increasing age in the control population. However, this 
cluster shows significant deactivation in relation to age in the premutation group, suggesting that there 
is degeneration affecting the functional compensatory response to changes in movement demands. 
Additionally, links to other types of neurodegeneration can me made here, as the hippocampus and 
medial temporal lobe, areas identified as significantly different between groups in their interaction 
with aging, have long been known to be areas of early neurodegeneration, being particularly 
vulnerable to the development of molecular and cellular pathology (Braak & Braak 1991; Serrano-
Pozo et al. 2011; Hochgräfe et al. 2013). The parietal lobe has also exhibited significant grey matter 
reduction in Spinocerebellar Ataxia Type 3 patients, a disease often likened to FXTAS in its 
molecular and radiological development (Duarte et al. 2016). In Huntington pre-symptomatic carriers, 
another useful disease parallel for FXTAS and premutation carriers, a fMRI finger-tapping task 
revealed an inhibitory effect on the connection from the parietal cortex to premotor areas during 
dynamic causal modelling analysis (Minkova et al. 2015). In addition, cognitive decline in FXTAS is 
of a mixed subcortical pattern, much like other neurodegenerative diseases that implicate the 
hippocampal formation as an area of early pathology (Seritan et al. 2008; Berry-Kravis, Goetz, et al. 
2007; Brega et al. 2008). These parallels of neurodegeneration may be useful in further characterising 
the nature and progression of FXTAS. 
6.4 Clinical measurements  
In addition to imaging data, the present study utilised clinical measurements of tremor, co-ordination, 
balance using the CATSYS-2000 computerised system to further characterise the participant sample. 
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Independent two-sample T-tests revealed that performance on the tremor and co-ordination 
measurements were significantly worse in carriers, suggesting subtle motor symptoms in the absence 
of a diagnosis of FXTAS. CATSYS measurements in female carrier populations both with and 
without FXTAS also exhibited significantly worse tremor and co-ordination, and a study of high CGG 
repeat size and low CGG repeat size asymptomatic carriers identified tremor in 23% of men who did 
not self-report tremor symptoms, and ataxia in 30% of men who did not report ataxic symptoms 
(Allen et al. 2008b; Narcisa et al. 2011). Interestingly however, in the present study, both the control 
and carrier groups performed worse than normal human performance on average on the tremor 
measurements, but better than normal human performance on average on the co-ordination 
measurements. Other studies utilizing CATSYS measurements in carriers have not reported indices 
relating to normal human performance, and therefore there are difficulties in reconciling these results 
with other findings. One possible explanation however may be that other CATSYS studies in 
premutation carriers have described the exclusion of outlying data due to concerns about instrument 
malfunction, which was not replicated in this study (Allen et al. 2008b; Narcisa et al. 2011). In 
addition, age may be a confounding factor here, given the cross-sectional nature of this study and 
unknown concordance of subject age with the original CATSYS normal material (Danish Product 
Development Ltd.). Independent T-test analyses did not reveal balance to be significantly different in 
carriers than in controls, and this may be explained by balance being affected later on during FXTAS 
progression, as falls are not often reported in early disease stages, meaning that balance 
symptomatology is not present in this asymptomatic or pre-clinical sample. Again, balance indices on 
average were higher than normal human performance in both the control and carrier groups, which 
may possibly be explained by the same confounds as described for the tremor and co-ordination 
CATSYS measurements.  
6.5 Molecular measurements 
FMR1 mRNA has frequently been reported as higher in premutation carriers and is theorised to be 
one of the primary molecular driving forces behind the development and progression of FXTAS. 
However, results have been inconsistent as to whether these differences reach statistical significance 
(Hagerman & Hagerman 2013; Garcia-Arocena & Hagerman 2010; Jacquemont et al. 2003a). 
Independent two-sample T-test analysis of the FMR1 mRNA amount relative to control 18 sRNA 
amount does not reveal levels of FMR1 mRNA to be significantly higher in carriers compared to 
controls. Nevertheless, when each carrier FMR1 mRNA amount relative to 18 sRNA was normalised 
to counterpart age-matched control data, carrier levels were often higher, with some carriers 
exhibiting up to 7-fold increases compared to age-matched control. These results are in line with 
previous data, with evidence of higher FMR1 mRNA in carriers when normalised to control data and 
the fold increase of RNA being comparable to previous findings (Kenneson et al. 2001; Tassone, 
Hagerman, Taylor, Gane, et al. 2000).  
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6.6 Linear regression analyses 
None of the tremor, balance or co-ordination index variables exhibited an association with the raw 
voxel data extracted from the between group analysis at the cluster at the bilateral lobules VI of the 
cerebellum, left lobule V and the left hippocampus (subiculum). It is possible in this case that a 
relatively small sample size for this study may have led to these results not reaching significance. 
Additionally, in the absence of overt FXTAS, it may be that symptomatology and functional brain 
changes are not yet developed enough to display a significant relationship. Tremor, co-ordination and 
balance as measured by the CATSYS-2000 system also did not prove to be significantly associated 
with raw voxel data extracted from the age-related significant cluster at the left BA17, left 
hippocampus (cornu ammonis), left inferior parietal cortex and left temporal lobe. This may be due to 
the likelihood of this predominantly limbic cluster being more relevant to compensatory activity and 
motor imagery, instead of overt motor processing and associated deficits, in addition to the 
aforementioned limitations regarding power to detect a small effect size and the present study’s cross-
sectional design.    
Measurements of FMR1 mRNA from peripheral blood samples did not show any relationship with 
significant differences in BOLD response, in either the between group or age-related analysis. FMR1 
mRNA levels are thought to be one of the main molecular causes of neurodegenerative processes in 
FXTAS, and it is therefore somewhat surprising that FMR1 mRNA amount is not related to these 
functional imaging changes. Previous studies have found hippocampal volume to be correlated with 
FMR1 mRNA and IQ scores in premutation carriers, which is supportive of the hypothesis that brain 
changes that are most likely early signs of FXTAS should be associated with changes in mRNA levels 
or metabolism (Cohen et al. 2006; Adams et al. 2007). It can be theorised from the findings of the 
present study, in addition to some inconsistent findings in the literature pertaining to FMR1 mRNA 
levels and associated variables in carriers, that using peripheral blood samples to ascertain RNA 
measurements may be only a loose estimate and reflection of brain expression profiles (Tassone, 
Adams, Elizabeth M Berry-Kravis, et al. 2007; Cohen et al. 2006; Leehey et al. 2008). It is possible 
however that statistical power may be a contributing factor to the discrepancies in the findings into 
FMR1 mRNA levels in carriers, in addition to variation in asymptomatic premutation carrier 
populations in terms of future FXTAS penetrance. To elucidate this further, work in the field should 
attempt to strive towards methodology that can more directly identify molecular changes in the brain 
in vivo or post mortem. 
6.7 Limitations and conclusions 
Here, we report neuroimaging and clinical evidence of possible early, pre-FXTAS neurodegeneration, 
however, limitations of the present study should be considered. The future FXTAS penetrance of the 
sample may be a confounding factor of the study. As previously mentioned, 40-60% of males with the 
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premutation will go on to develop FXTAS later in life (Sébastien Jacquemont et al. 2004). Firstly, 
when using a sample of FMR1 carriers without FXTAS, the reality of this penetrance within the 
sample is unknown. Additionally, the study utilised a cross-sectional design to allow the investigation 
of age as a regressor. A cross-section of participants aged between 20-70 years without FXTAS may 
introduce a bias in the sample therefore towards older carriers who are less at risk or will not develop 
FXTAS. Unfortunately, without longitudinal data, the impact of FXTAS penetrance on this sample 
cannot be established, although this is something possible to achieve in future follow-up 
investigations.     
Another notable limitation in the methodology of the present study is using peripheral blood 
measurements of FMR1 mRNA with the aim of reflecting brain expression levels. Firstly, it is known 
that expression profiles of FMR1 mRNA are variable across regions of the brain, with relative isoform 
transcripts varying by as much as two orders of magnitude. Different biochemical properties are 
inferred by different isoforms, and isoform expression patterns in the hippocampus and olfactory bulb 
are reported to differ from patterns of dominant isoform types elsewhere in the brain (Brackett et al. 
2013). Region specific expression patterns in the brain therefore are unlikely to be reflected in a 
relative FMR1 mRNA average measurement derived from peripheral blood mononuclear cells. 
Additionally, studies into FMR1 mRNA isoforms have revealed differential expression between 
human carriers and controls, which do not remain statistically consistent between brain tissue and 
peripheral blood mononuclear cells (Pretto et al. 2015). However, blood sample derived molecular 
measurements remain the safest, least invasive and most ethically sound methodology to use in a 
clinical research setting. In addition, blood-based molecular analyses promise the potential scope for 
easily accessible future biomarkers.     
Here we show for the first time in asymptomatic FMR1 premutation carriers evidence of significantly 
lower cerebellar activity during an fMRI motor task. The neuroimaging analyses also revealed a 
cerebral and limbic cluster where the group x age interaction differed significantly between carriers 
and controls. These findings of deviation from normal BOLD activation patterns during a movement-
orientated task and activation changes differing significantly from normal aging are likely to be 
indicative of a functional vulnerability to FXTAS in the anterior lobe of the cerebellum and 
hippocampal formation. Longitudinal follow-up investigations into this cohort may confirm a 
susceptibility to FXTAS and indeed progression of symptomatology in some individuals.  
Additionally, we also identify in this sample premutation carriers without FXTAS demonstrating 
significantly worse measurements of sub-clinical tremor and co-ordination. These subtle movement 
phenotypes in carriers indicate that motor problems are present before the onset of diagnosable 
FXTAS, and may even be present from a young age. Again, longitudinal study of this sample may 
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allow formation of a third FXTAS group, which can then be compared against non-FXTAS carriers 
and the stability of movement symptoms over long periods of time may be mapped.  
Consistent with previous reports, we also find that relative FMR1 mRNA levels in carriers are 
increased, although this does not reach statistical significance. Further insights into the molecular 
pathology of FXTAS may be gained through using existing RNA aliquots to probe specific FMR1 
isoforms, with the aim of replicating isoform abundance levels as previously reported in carrier 
populations, and building on clinical understanding by using regression analyses to establish any 
possible relationships between isoform expression profiles and movement symptomatology or 
functional brain responses. 
Regression analyses carried out within this study revealed no association of clinical or molecular 
variables to significant second level clusters of brain activation. Given the strong hypothetical links 
between a functional MRI motor task, movement symptoms, the FMR1 mRNA gain-of-function 
toxicity model and FXTAS phenotypes, we may have expected to see a significant relationship 
between some of these measurements. However, a higher level of power may allow for such 
relationships to reach significance in future studies, or indeed, establish that such associations do not 
exist in carriers without FXTAS. 
Overall, these novel neuroimaging findings, replication of previous molecular findings and insights 
into sub-clinical movement problems in asymptomatic premutation carriers provide new 
understanding of the development of FXTAS-related neurodegeneration. 
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Chapter 7: Neurodevelopment in the Fragile X premutation: Methods 
7.1 Participants and recruitment 
The same 34 individuals who took part in the investigation into neurodegeneration in the premutation, 
also took part in this neurodevelopmental part of the study. The recruitment process, inclusion and 
exclusion criteria are described in Chapter 4.1.  
 
7.2 Imaging methods 
All MRI data was acquired in the same scanning session and image acquisition is described in 
Chapter 4.2. 
 
The emotional processing task used in the scanning protocol was designed and ran on Presentation™ 
software. The task utilised 120 pictures sourced from the International Affective Picture System 
(IAPS), which differentiates images based on arousal and valence (pleasure) ratings, as defined by 
IAPS normative data. Arousal and valence are rated on a scale of 1-10, with higher scores indicating 
higher levels of arousal or pleasure. Normative affective ratings were obtained to form this material 
from approximately 50 male college students (Lang et al. 2005). In the present task, 20 pictures for 
each of the following conditions were used: high pleasure/low arousal, high pleasure/high arousal, 
low pleasure/low arousal, low pleasure/high arousal, neutral pleasure/high arousal and neutral 
pleasure/low arousal. Pictures that were judged to be too distressing, disturbing or graphic were 
removed from the task, meaning that arousal rating of the pictures was not above 7.02. Neutral images 
were chosen based on a median valence range of 4.5-5.5. Selected IAPS images for this study are 
plotted according to valence and arousal ratings in figure 7.1 and image details are listed in Appendix 
7.1. The task utilised an event-related design, with each trail duration comprising of stimulus 
presentation and an inter-stimulus interval. Order of the presentation of stimulus condition was 
randomised, without variation between participants. Jittering of the stimuli relative to the TR was 
achieved by varying inter-stimulus interval length at upper and lower truncation points of 1.5 and 2.5 
seconds. Mean inter-stimulus interval for each condition was 2 seconds. All stimuli presentation 
durations were 1.5 seconds, and mean trial duration was 3.5 seconds for each condition. A 2 second 
fixation period was presented every 10 trials. Each total condition duration was 1 minute 10 seconds. 
Participants were asked to indicate using left and right trigger buttons in the scanner whether or not 
there was a face in each of the pictures – i.e. “Face” or “No face” – as a measure of engagement with 
the task. Participants were given written instructions for all of the tasks before entering the MRI 
scanner (Appendix 4.1), shown an example of each task on a laptop screen and given the chance to 
ask any questions they may have had. The tasks were visually presented to participants using goggles 
that fit onto the scanner head coil. 
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The IAPS emotional processing task used here was designed specifically for this study and was 
behaviourally tested on 5 individuals who were not prospective participants for the main study (Table 
7.1). The task was presented exactly as it would be in the scanner on a laptop using Presentation™ 
software, using keyboard buttons in the place of trigger buttons. Each individual taking part in the 
behavioural testing filled out an evaluation form of the task (Appendix 7.2) which focussed on clarity 
of the task instructions and engagement in the task. Subjects were also asked whether choosing 
“Face” or “No Face” for each picture during the task distracted them from the picture content, and 
whether they found the images emotional. The majority of individuals rated the task as simple and 
engaging. None of the individuals behaviourally testing this task rated that choosing “Face” or “No 
Face” for each picture as distracting from the picture content, and the majority found that indicating 
“Face” or “No Face” was not confusing or difficult. It was therefore deemed that the task was suitable 




Figure 7.1 Selected images from the IAPS that form the fMRI emotional processing task: 
Mean valence and arousal scores for male subjects from the IAPS normative data set. 
Reference line for arousal indicates differentiation between ‘high’ and ‘low’ arousal images 
and reference lines for valence indicate differentiation between ‘high’, ‘neutral’ and ‘low’ 
valence images. 
 















1 4 5 3 4 5 
2 1 5 3 2 4 
3 4 4 3 2 5 
4 5 5 3 3 4 
5 5 5 2 1 4 
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Table 7.1. IAPS task self-reported evaluation form data from behavioural testing. Clarity rating 
(1=confusing, 5=simple), engagement rating (1=not engaged, 5=very engaged), “Face”/”No Face” 
distraction rating (1=not distracting, 5=very distracting), “Face”/”No Face” confusion/difficulty rating 
(5=not confusing or difficult, 1=very confusing or difficult) and picture emotionality rating (1=not 
emotional, 5=very emotional) 
7.3 fMRI analysis 
Statistical analysis on fMRI data was carried out using Statistical Parametric Mapping software 
(SPM12) (Wellcome Department of Clinical Neurology).  
The functional images from all participants were preprocessed according to the following steps: 1) 
firstly images were realigned, estimated and resliced 2) images were then slice timed, adjusting for 
interleaved and bottom up slice order 3) subsequent functional images were coregistered with the 
source structural image from the T1 MP RAGE anatomical scan 4) coregistered images were 
segmented into grey matter, white matter and CSF outputs 5) images were normalised to MNI space, 
and 6) finally the normalised images were smoothed with a 8mm FWHM (full-width at half 
maximum) Gaussian smoothing kernel.  
For first-level analysis of the IAPS emotional processing task, the images were split into high/low 
arousal combined conditions. The high and low arousal conditions across the whole task where then 
compared using a [1 -1 1 -1 1 -1] contrast, and the reverse [-1 1 -1 1 -1 1] contrast. This type of 
contrast investigates the combined brain activation effects of high arousal versus low arousal 
conditions, irrespective of valence. 
For the second level analysis, explicit masking was used to exclude voxel data outwith the brain 
tissue. This explicit mask was comprised of an average binarised image created from the combined 
grey matter and white matter segmented images from all participants. Both within and between group 
analyses were completed. Within group analysis used a one-sample t-test for each task and first level 
contrasts to look at significant activation for the control and premutation group separately. Within 
group second level contrasts were defined as either [1] or [-1] to look at positive and negative 
activation patterns in the high/low arousal contrast. The between group analyses used a full factorial 
design to examine the differences between the control and premutation groups. The groups were 
compared using [1 -1] and the reverse [-1 1] contrasts. In addition, age was added into the full 
factorial design as a regressor and group x age interactions were examined for both the control and the 
premutation group using [1 -1] and the reverse [-1 1] contrasts between age data and group BOLD 
response. The design matrix for this task is presented in figure 7.2. All second level contrasts were 
calculated using a height threshold value of p=0.005 and a voxel threshold of 0 to allow for the 
detection of spike activations. Family-wise error correction was then carried out, with significance 




Figure 7.2 Design matrix displaying a control>premutation between group contrast for the emotional 
processing second-level analysis. Controls are represented in column 1, premutation carriers are 
represented in column 2 and age is represented in columns 3 and 4 
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7.4 Clinical measurements 
Each participant completed several clinical and neuropsychological measurements outside of the 
scanner linking to neurodevelopmental and psychiatric symptoms. The Symptom Checklist 90 
Revised (SCL-90-R®) (Pearson) was used to evaluate participant psychiatric symptomatology. The 
SCL-90-R is a self-report questionnaire comprising of 90 questions asking participants to rate how 
much they were distressed by various psychiatric symptom manifestations on a scale of 0-4, 0 being 
not at all distressed and 4 being extremely distressed. The SCL-90-R is a measure of current 
psychiatric symptomatology, and so participants are asked to rate their distress in response to certain 
problems within the context of the last 7 days, including the day of testing. Symptoms measured in the 
SCL-90-R are somatization, obsessive-compulsiveness, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoid ideation and psychoticism. These symptoms are scaled by dividing 
total additive score by number of question responses and adding 0.005 to the result. Combined scores 
also produce measurements of global severity index, which is the severity of all symptoms combined, 
positive symptom total, which is the total number of questions responded to above a 0, and positive 
symptom distress index, which is a measure of how severe symptoms were when reported as positive. 
Normative sample data for the SCL-90-R is comprised of 3 major cohorts applicable to this research: 
1,002 heterogeneous psychiatric outpatients, 947 non-patients and 423 psychiatric inpatients. Raw 
score means and standard deviations for the nine primary symptom dimensions and three combinative 
indices for males, as is applicable to the present study, in these three normative cohorts are 
summarised in Table 7.2. 
The Ekman 60 Faces Test (Version 1.0, Thames Valley Test Company) was carried out by all 
participants on a laptop (Young et al. 2002). The Ekman 60 Faces Test asked participants to correctly 
identify the facial emotion in 60 pictures of males and females, which were presented for a duration of 
5 seconds each in a random order. The facial emotions used in the test are anger, disgust, fear, 
happiness, sadness and surprise and 10 of each were presented during the test. Scores are reported as 
number of correctly identified images out of 10 per emotion, and a total of correctly identified images 
out of 60. Each participant was given verbal instructions and given a short practice run of the test. 
Normative material based on a cohort of 227 individuals aged between 20-70 years old with IQ scores 
above 90 is summarised in Table 7.3.  
A neuropsychological, laptop based test of social judgement was also carried out by all participants, 
known as the Social Judgement Test (Hall et al. 2004). Here, participants were asked to identify 
pictures of faces based on a series of variables, which were age, approachability, attractiveness, 
distinctiveness, intelligence and trustworthiness. In each of the 6 test conditions, the pictures were 
designed to exhibit an overt socially recognisable trait in a binary manner, for instance, in the age 
variable individuals in the image stimuli were either young or old, and in the trustworthy variable 
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individuals in the image stimuli stereotypically appeared to be either trustworthy or not trustworthy. 
For each variable, 32 images were presented for a duration of 5 seconds each. Scores for each social 
variable are therefore number of images correctly identified out of a maximum of 32.  
All participants also completed the Autism Quotient (AQ) and Empathy Quotient (EQ) self-report 
questionnaires, which report levels of autistic traits (Baron-Cohen et al. 2001). Scores over 26 in the 
AQ correctly identify autism spectrum disorder in 83% of cases, and scores below 30 in the EQ 
correctly report autism spectrum disorder in 81% of cases (Woodbury-Smith et al. 2005; Baron-
Cohen & Wheelwright 2004). A maximum score in the AQ is 50, indicating high levels of ASD 
symptoms (difficulty with social skill, attention switching, attention to detail, communication and 
imagination) and a minimum score is 0, indicating absence of autistic traits. A maximum score in the 
EQ is 80, indicating a very high level of empathy and low level of autistic traits, and a minimum score 
is 0, indicating a very low level of empathy and high level of autistic symptomatology. The scores of 
the AQ and the EQ are also highly correlative (Wheelwright et al. 2006). 
Table 7.2. SCL-90-R normative sample raw score means and standard deviations (males only) 
 Psychiatric outpatient 
cohort 
Non-patient cohort Psychiatric inpatient 
cohort 
Dimension Mean SD Mean SD Mean SD 
Somatization .70 0.67 0.29 0.33 0.82 0.78 
Obsessive-
compulsive 
1.41 0.89 0.34 0.39 1.22 0.96 
Interpersonal 
sensitivity 
1.36 0.90 0.25 0.32 1.03 0.87 
Depression 1.59 0.92 0.28 0.32 1.41 1.02 
Anxiety 1.30 0.83 0.22 0.27 1.22 0.95 
Hostility 1.00 0.89 0.29 0.37 0.73 0.76 
Phobic anxiety 0.65 0.74 0.08 0.19 0.71 0.88 
Paranoid 
ideation 
1.07 0.90 0.34 0.40 1.08 0.84 
Psychoticism 0.90 0.65 0.13 0.22 0.91 0.78 
Global 
severity index 









47.64 19.22 16.37 13.85 43.90 22.95 
Table 7.2. Raw score means and standard deviations for the SCL-90-R primary symptom dimensions 
and global indices for males in three normative sample groups      
Table 7.3. Ekman 60 Faces Test normative sample means and cut-offs for impairment 
  Total 
Score 
Anger Disgust Fear Happiness Sadness Surprise 
Whole 
sample 
Mean 50.64  7.86 8.59 7.19 9.87 8.33 8.55 
 Cut-off 42  5 6 4 9 6 6 
Age 20-40 Mean 51.43  8.21 8.38 7.82 9.90 8.59 8.54 
 Cut-off 45 5 6 4 9 6 6 
Age 41-60 Mean 51.20 8.17 8.77 7.23 9.84 8.53 8.61 
 Cut-off 43 5 6 4 9 6 6 
Age 61-70 Mean 49.41 7.33 9.00 6.47 9.93 8.03 8.66 
 Cut-off 41 4 6 3 9 5 6 
 Table 7.3. Raw score means and cut-off scores indicating the boundary between normal range and 
impaired scores for the Ekman 60 Faces Test. All total scores are out of 60, all individual emotion 
scores are out of 10 
7.5 Molecular measurements 
Protein quantification was carried out by Western blotting analysis. All participants provided a blood 
sample, part of which was purified to peripheral blood mononuclear cells using Histopaque layering. 
Protein was then extracted from the samples by firstly quickly thawing the peripheral blood 
mononuclear cell samples at 37˚C and spinning them at 5000 rpm for 5 minutes at 4˚C. The 
supernatant was then carefully removed and discarded. Pellets were then re-suspended in 100µl lysis 
buffer (RIPA buffer: 50mM Tris-HCl, 150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS and 1mM EDTA made up with ddH2O with an additional protease inhibitor tablet) and 
lysed on ice for 30 minutes. The samples were then centrifuged again at 11,000 rpm for 15 minutes at 
4˚C, and the supernatant was aliquoted 1:1 with 95:5 laemmli sample buffer:2-mercaptoethanol. An 
aliquot without sample buffer per sample was retained for protein quantification analysis. The protein 
aliquots with added sample buffer were then boiled for 5 minutes at 100˚C to kill the proteases, 
vortexed and centrifuged for ten seconds. Samples were stored at -80˚C before use for protein 
quantification or Western blotting. 
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Total protein concentration for each sample using the RC/DC Protein Assay (BioRad, United States). 
SDS-PAGE electrophesis was then used to separate 25µg of sample loaded into each well of Mini-
PROTEAN® TGX™ Precast Gels, 4-20% polyacrylamide. The gels were run in 1 x running buffer 
(0.1% SDS, 25mM Tris base and 190mM glycine made up with ddH2O) for 25 minutes at a constant 
of 100V, and then 30 minutes at a constant of 200V. Each sample was ran three times in total, on the 
same gel as counterpart age-matched control. Protein was then transferred from the gel to a 
nitrocellulose membrane in 1 x transfer buffer (25mM Tris base, 190mM glycine and 20% methanol 
made up with ddH2O) on ice for 2 hours at a constant of 85V. The membranes were then blocked 
using a 1:1 blocking buffer and PBS-T solution for one hour at room temperature and then probed 
with Ab17722 rabbit anti-FMRP polyclonal antibody (ABCAM, Cambridge, UK) at a dilution of 
1:1000 and ab6276 mouse anti-beta actin (ABCAM, Cambridge, UK) at a dilution of 1:5000, 
overnight at 4˚C. The membranes were then washed once in ddH2O and then three times for 5 minutes 
in PBS-T. An IRDye goat anti-rabbit 800CW secondary antibody at a dilution of 1:5000 and an 
IRDye goat anti-mouse 680CW secondary antibody at a dilution of 1:5000 were then incubated with 
the membranes at room temperature for 1 hour. The membranes were subsequently washed again 
once with water and three times for 5 minutes in PBS-T. Beta actin bands were then imaged at 169µm 
resolution in the 700 channel and FMRP bands were imaged at 169µm resolution in the 800 channel 
using the Odyssey infrared scanner following manufacture recommendations. Analysis was performed 
using densitometry methodology using Image Studio version 2.0.      
7.6 Statistical analysis  
Further statistical analyses were carried out in SPSS Statistics 22. Independent two-tailed t-tests were 
used to discern differences between the premutation and control groups for the clinical, 
neuropsychological and molecular data. For the Ekman 60 faces test, data was statistically analysed 
using an (M)ANOVA to investigate group by emotion interactions. Simple linear regressions were 
also performed on extracted raw voxel values from significant neuroimaging clusters against the 
psychiatric, neuropsychological and molecular variables. All significance levels were assumed at 
p<0.05.  
CGG repeat analysis revealed that some individuals in the sample were mosaic or borderline for the 
full mutation. To ensure this was not causing a bias in the results, mosaic and borderline carriers were 
separated from the sample, creating three participant groupings: control, premutation and 
mosaic/borderline. A one-way ANOVA of 3 groups, followed by a Tukey post-hoc test was 




Chapter 8: Neurodevelopment in the Fragile X premutation: Results 
8.1 Participants and recruitment 
The same participant group who took part in the neurodegenerative section of the study took part in 
the neurodevelopmental section of the study. As described in Chapter 5, section 5.1, the group of male 
premutation carriers (n=17) had a mean age of 50.4 years old (SD=15.1), and the age-matched male 
control group had a mean age of 47.6 years old (SD=12.9). Independent two-sample t-testing revealed 
that age did not differ significantly between the groups (p=0.507). CGG repeat length testing 
indicated that 12 carriers were in the premutation range, 1 carrier was in the intermediate range, 3 
carriers were mosaic for repeat size and one carrier was borderline for the full mutation. It was 
confirmed that all control subjects were within the normal CGG repeat length range. Main CGG 
repeat value by group is plotted in figure 5.1. All participants were right handed, excepting one 
control subject and two carrier subjects, who were left handed. All participants had a composite IQ 
>80, as measured by the KBIT Second Edition Intelligence Test (Pearson) (Table 5.1). Two-sample t-
testing of IQ data revealed that composite and verbal IQ as measured by the KBIT-2 were not 
significantly different between the groups (p=0.053, p=0.604), although composite IQ exhibits a trend 
towards being lower in carriers. Non-verbal IQ as measured by the KBIT-2 was significantly lower in 
carriers (p=0.015) (Fig. 5.2).   
8.2 Within group imaging  
One sample t-test within group analysis revealed that when contrasting the combined low arousal and 
high arousal conditions, controls exhibited four significant clusters of activation. The first and largest 
significant cluster (FWEcorr<0.001, T=10.17) incorporated the right intraparietal cortex and the right 
human intraparietal areas 1 and 3. The maximum of the cluster was located at [48,-48,34]. A second 
significant cluster (FWEcorr<0.001, T=7.37) was located at the left cerebellar lobule VIIa Crus I, left 
cerebellar lobule VI and the right human occipital cortex 3 dorsal (hOC3v) with the co-ordinates of 
the cluster maximum at [-18,-76,-26]. A third significant cluster (FWEcorr<0.001, T=6.90) was located 
at the bilateral superior parietal lobes, with the co-ordinates of the cluster maximum at [12,-62,40] and 
a final significant cluster (FWEcorr=0.001, T=6.18) was located at the right middle and superior frontal 
gyri, with the co-ordinates of the cluster maximum at [22,54,30] (Fig. 8.1a). In contrast, a one sample 




a)     
 
Figure 8.1 Within group functional brain imaging analysis carried out in SPM12 a) Within group 
analysis of the control group for the high arousal-low arousal contrast. Significant cluster 1 
(FWEcorr<0.001, T=10.17) at the right intraparietal cortex and the right human intraparietal areas 1 
and 3. Cluster co-ordinate of maximum voxel: 48,-48,34, k=1321, normalised voxel size: 2mm3. 
Significant cluster 2 (FWEcorr<0.001, T=7.37) at the left cerebellar lobule VIIa Crus I, left cerebellar 
lobule VI and the right human occipital cortex 3 dorsal (hOC3v). Cluster co-ordinate of maximum 
voxel: -18,-76,-26, k=2102, normalised voxel size: 2mm3. Significant cluster 3 (FWEcorr<0.001, 
T=6.90) at the bilateral superior parietal lobes. Cluster co-ordinate of maximum voxel: 12,-62,40, 
k=1070, normalised voxel size: 2mm3. Significant cluster 4 (FWEcorr=0.001, T=6.18) at the right 
middle and superior frontal gyri. Cluster co-ordinate of maximum voxel: 22,54,30, k=754, normalised 
voxel size: 2mm3. 
90 
 
b)    
  
Figure 8.1 Within group functional brain imaging analysis carried out in SPM12 b) Within group 
analysis of the carrier group for the high arousal>low arousal contrast. No significant clusters of 
activation.   
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8.3 Between group imaging  
Full factorial between group analysis revealed that the premutation group had two clusters of 
significantly lower BOLD response when compared to the control group. The first, largest cluster of 
significantly lower activation (FWEcorr=0.001, T=4.77) was located at bilateral BA17 of the primary 
visual cortex, right BA18 of the visual association area and the right superior parietal lobe. The 
maximum of the cluster was located at [16,-88,14]. The second cluster of significantly lower 
activation in the carrier group (FWEcorr=0.021, T=4.26) was located at the bilateral superior parietal 
lobes, right BA2 of the primary somatosensory cortex and right human intraparietal area 1. The 
maximum of the cluster was located at [34,-40,42] (Fig. 8.2a).  
As analysis of the length of the FMR1 CGG repeat island revealed a number of carrier individuals in 
the sample to be mosaic or borderline for the full mutation, an additional group was created of these 
mosaic or borderline carriers to ensure that anomalous CGG repeat length data were not skewing 
imaging results and that these individuals were not driving significant between group differences. The 
groups for the ANOVA analysis were defined as the following: control (n=17), premutation (n=13) 
and mosaic/borderline carriers (n=4). A statistically significant between group difference in BOLD 
response at significant cluster 1 maximum voxel [16,-88,14] was identified by one-way ANOVA 
(F(2,31)=11.737, p<0.001). A Tukey post-hoc test revealed that BOLD response for this cluster was 
significantly different in controls compared to carriers (p=0.001) and controls compared to 
mosaic/borderline carriers (p=0.003), but not significantly different between the premutation group 
and mosaic/borderline carriers (p=0.726). Representative group means are presented in figure 8.2b. A 
statistically significant between group difference in BOLD response at significant cluster 2 maximum 
voxel [34,-40,42] was also identified by one-way ANOVA (F(2,31)=8.459, p=0.001). Tukey post-hoc 
showed that BOLD response for this cluster was significantly different in controls compared to 
carriers (p=0.012) and controls compared to mosaic/borderline carriers (p=0.004), but not 
significantly different between the premutation group and mosaic/borderline carriers (p=0.345). 





Figure  8.2 Between group functional brain imaging analysis carried out in SPM12 a) Cluster 1 of 
significantly lower BOLD activation in carriers compared to controls (FWEcorr=0.001, T=4.77) at 
bilateral BA17 of the primary visual cortex, right BA18 of the visual association area and the right 
superior parietal lobe. Cluster co-ordinate of maximum voxel: 16,-88,14, k=938, normalised voxel 
size 2mm3. Cluster 2 of significantly lower activation in the carrier group compared to controls 
(FWEcorr=0.021, T=4.26) at the bilateral superior parietal lobes, right BA2 of the primary 
somatosensory cortex and right human intraparietal area 1. Cluster co-ordinate of maximum voxel: 




Figure  8.2 Between group functional brain imaging analysis carried out in SPM12 and subsequently 
plotted using SPSS b) Cluster 1, located at bilateral BA17 of the primary visual cortex, right BA18 of 
the visual association area and the right superior parietal lobe, mean extracted voxel response by 






Figure  8.2 Between group functional brain imaging analysis carried out in SPM12 and subsequently 
plotted using SPSS c) Cluster 2, located at bilateral superior parietal lobes, right BA2 of the primary 
somatosensory cortex and right human intraparietal area 1, mean extracted voxel response by 
grouping at cluster maximum, co-ordinate [34,-40,42].
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8.4 Group x age interaction  
In the analysis probing presence of age related group differences, no significant group x age clusters 
were identified at a whole brain level (Fig. 8.3). Within group regression analyses also confirmed that 









8.5 Clinical and neuropsychological measurements 
The psychiatric symptomatology checklist, SCL-90-R, revealed that premutation carriers had 
significantly worse obsessive-compulsiveness (p=0.006), anxiety (p=0.028), global severity index 
(GSI) (p=0.033) and positive symptom distress index (PSDI) (p=0.002) scores compared to controls. 
Somatisation, interpersonal sensitivity, depression, hostility, phobic anxiety, paranoid ideation, 
psychoticism and positive symptom total (PST) were not significantly different between the groups 
(p=0.212, 0.389, 0.135, 0.187, 0.171, 0.161, 0.122, 0.202 respectively). Mean carrier and control 
scores of the SCL-90-R are plotted with normative mean material of non-patients in figure 8.4 and 





Figure 8.4 SCL-90-R psychiatric data analysed using parametric two-sample t-testing in SPSS a) 
Mean scores of somatization, obsessive-compulsiveness, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoid ideation, psychoticism and global severity index as measured by 
the SCL-90-R for the control group and premutation group with mean scores from SCL-90-R 










Figure 8.4 SCL-90-R psychiatric data analysed using parametric two-sample t-testing in SPSS b) 
Mean scores of positive symptom total (PST) and positive symptom distress index (PSDI) as 
measured by the SCL-90-R for the control group and the premutation group with mean scores from 
SCL-90-R normative non-patient data.
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Table 8.2: SCL-90-R psychiatric symptomatology data with normative material 
Group Variable Mean Standard deviation 
Control Somatization 0.26 0.34 
Carrier  0.41 0.41 




Carrier  1.33 1.02 




Carrier  0.6 0.71 
Non-patient norm  0.25 0.32 
Control Depression 0.39 0.35 
Carrier  0.88 0.83 
Non-patient norm  0.28 0.32 
Control Anxiety 0.21 0.26 
Carrier  0.6 0.54 
Non-patient norm  0.22 0.27 
Control Hostility 0.29 0.24 
Carrier  0.67 0.76 
Non-patient norm  0.29 0.37 
Control Phobic anxiety 0.16 0.35 
Carrier  0.24 0.32 
Non-patient norm  0.08 0.19 
Control Paranoid ideation 0.18 0.27 
Carrier  0.50 0.59 
Non-patient norm  0.34 0.40 
Control Psychoticism 0.12 0.19 
Carrier  0.40 0.55 
Non-patient norm  0.13 0.22 
Control Global Severity 
Index (GSI) 
0.31 0.23 
Carrier  0.68 0.55 
Non-patient norm  0.25 0.24 
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Control Positive Symptom 
Total (PST) 
21.71 13.19 
Carrier  31.71 19.18 
Non-patient norm  16.37 13.85 




Carrier  1.75 0.51 
Non-patient norm  1.31 0.37 
Table 8.2 Mean scores and standard deviations of SCL-90-R psychiatric symptom variables for the 
control group, premutation group and SCL-90-R normative non-patient dataset.  
The Ekman 60 Faces Test data analysed in SPSS using an (M)ANOVA indicated that carriers 
performed significantly worse than control subjects when attempting to recognise facial emotions of 
anger (p=0.045), disgust (p=0.039) and surprise (p=0.027). Controls and carriers did not perform 
significantly differently when asked to recognise facial emotions of fear, happiness or sadness 
(p=0.142, 0.08, 0.161 respectively). Carriers performed worse overall on the test than the control 
group (p=0.002). Neither group mean score for any Ekman face variable reached the cut-off for 
impairment as described by the Ekman 60 Faces Test normative sample data. Mean carrier and 
control scores of the Ekman 60 Faces Test are plotted with normative mean material in figure 8.5 and 





Figure 8.5 Ekman 60 Faces Test analysed in SPSS using an (M)ANOVA. Mean scores of correct 
recognitions of facial expressions of anger, disgust, fear, happiness, sadness, surprise and total score 
for the control group and premutation group with mean scores from Ekman 60 Faces Test normative 
sample data, including normative sample cut-off for impairment scores. 
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Table 8.3: Ekman 60 Faces Test scoring data with normative material 
Group Variable Mean Standard deviation 
Control Anger 8.0 1.2 
Carrier  6.5 2.0 
Normative sample  7.8  
Control Disgust 8.2 1.6 
Carrier  7.0 1.8 
Normative sample  8.6  
Control Fear 7.4 1.8 
Carrier  6.3 2.5 
Normative sample  7.2  
Control Happiness 9.9 0.24 
Carrier  9.7 0.46 
Normative sample  9.9  
Control Sadness 8.1 1.5 
Carrier  7.1 2.0 
Normative sample  8.3  
Control Surprise 8.8 1.2 
Carrier  7.7 1.4 
Normative sample  8.6  
Control Total 50.7 4.9 
Carrier  44.5 6.6 
Normative sample  50.6  
Table 8.3 Mean scores and standard deviations of Ekman 60 Faces Test variables for the control 
group, premutation group and Ekman 60 Faces Test normative sample dataset. 
In the social judgement test, carriers and controls did not score significantly differently on 
measurements of accurately judged age, approachability, attractiveness, distinctiveness, intelligence 
and trustworthiness (p=0.292, 0.487, 0.729, 0.521, 0.096, 0.298 respectively). Mean carrier and 




     
Figure 8.6 Social judgement data analysed using parametric two-sample t-testing in SPSS. Mean 
scores of correct social judgements of age, approachability, attractiveness, distinctiveness, intelligence 




Table 8.4: Social judgement test scoring data 
Group Variable Mean Standard deviation 
Control Age 31 0.93 
Carrier  30.2 1.8 
Control Approachability 26.5 7.2 
Carrier  26.6 4.7 
Control Attractiveness 24.9 5.7 
Carrier  25.1 4.1 
Control Distinctiveness 22.4 4.7 
Carrier  20.6 5.9 
Control Intelligence 27.6 4.6 
Carrier  26.7 2.5 
Control Trustworthiness 27.2 2.5 
Carrier  26.0 3.3 
Table 8.4 Mean scores and standard deviations of social judgement test variables for the control 
group and the premutation group. 
When investigating autistic traits in the current sample, premutation carriers were seen to display 
significantly more autistic traits in the AQ than controls (p=0.015). Scores of empathy as measured by 
the EQ were not significantly different between groups however, although a trend towards carriers 
scoring lower, indicative of less empathy, was evident (p=0.084) (Fig. 8.7a). Simple linear regression 
analyses revealed that AQ and EQ scores were significantly correlated in the control group (p=0.025), 
but not in the carrier group (p=0.104) (Fig. 8.7b, Table 8.5). Mean carrier and control scores of the 





Figure 8.7 AQ and EQ autistic trait and empathy data analysed using parametric two-sample t-testing 
in SPSS a) Mean scores of autistic traits as measured by the AQ and empathy as measured by the EQ 








Figure 8.7 AQ and EQ autistic trait and empathy data analysed using parametric two-sample t-testing 










Table 8.5:  Within group regression analysis of AQ and EQ scores 
Group DV IV β Standard 
error 
Adjusted R2 P 
value 
Control AQ EQ -0.541 0.145 0.246 0.25 
Premutation AQ EQ -0.408 0.176 0.111 0.104 
Table 8.5 Statistical results of within group regression analyses between AQ and EQ scores 
Table 8.6: AQ and EQ scoring data 
Group Test Mean Standard deviation 
Control AQ 15.7 7.2 
Carrier  21.9 7.7 
Control EQ 45.1 10.8 
Carrier  39.1 10.3 
Table 8.6 Mean scores and standard deviations of the AQ and EQ measurements of autistic traits for 
the control group and the premutation group 
8.6 Molecular measurements 
Western blots imaged in the 800 channel (FMRP only) exhibited multiple additional uncharacterised 
bands. Due to these bands of unknown identity, subsequent quantification consisted of only the 
expected 80kDa anti-FMRP band (Fig. 8.8a). Densitometry analysis revealed that carriers and 
controls did not differ significantly in FMRP levels (p=0.903). Mean carrier and control FMRP levels 











Figure 8.8 FMRP quantification data analysed using parametric two-sample t-testing in SPSS b) 
Group mean FMRP levels normalised to beta actin loading control band quantification. 
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Table 8.7: FMRP quantification data 
Group Variable Mean Standard deviation 
Control FMRP quantification 0.107 0.103 
Carrier  0.118 0.122 
Table 8.7 Mean scores and standard deviations of quantified 80kDa FMRP averaged over 3 runs and 
normalised to beta actin loading control for the control group and the premutation group 
 8.7 Linear regression analyses 
Simple linear regression analyses were carried out on extracted voxel data from the significant 
between group BOLD clusters from the imaging analysis against clinical variables of interest that 
were established to be significantly different between the groups. No significant association was 
identified between either significant cluster of BOLD response and any of these clinical or 
neuropsychological variables (Table 8.8). 
Similarly, linear regression analysis was carried out on extracted voxel data from the significant 
between group BOLD clusters against FMRP molecular data, and revealed no significant associations 
(Table 8.8).  
Table 8.8:  Within group regression analysis of BOLD response and clinical measurements, 
neuropsychological measurements and FMRP levels 










-2.34 1.85 -0.171 0.098 
 BOLD cluster 
1 
Anxiety 0.02 1.45  0.967 
 BOLD cluster 
1 
GSI 2.75 4.45  0.089 
 BOLD cluster 
1 
PSDI -1.07 2.00  0.108 
 BOLD cluster 
1 
Anger -0.24 0.50  0.782 
 BOLD cluster 
1 
Disgust 0.67 0.28  0.316 
 BOLD cluster 
1 
Surprise 0.10 0.28  0.826 
 BOLD cluster 
1 
Total -0.71 0.19  0.571 
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 BOLD cluster 
1 
AQ -0.01 0.04  0.975 




-0.38 3.53  0.452 




-2.49 1.24 0.071 0.178 
 BOLD cluster 
1 
Anxiety -0.13 2.39  0.940 
 BOLD cluster 
1 
GSI 2.00 2.90  0.373 
 BOLD cluster 
1 
PSDI 0.39 1.13  0.615 
 BOLD cluster 
1 
Anger 0.08 0.19  0.876 
 BOLD cluster 
1 
Disgust -0.14 0.20  0.781 
 BOLD cluster 
1 
Surprise -0.18 0.28  0.752 
 BOLD cluster 
1 
Total -0.01 0.09  0.987 
 BOLD cluster 
1 
AQ 0.19 0.05  0.722 




0.11 2.40  0.778 




-1.25 1.47 0.067 0.473 
 BOLD cluster 
2 
Anxiety 0.58 2.84  0.737 
 BOLD cluster 
2 
GSI 1.22 3.46  0.579 
 BOLD cluster 
2 
PSDI -0.11 1.34  0.883 
 BOLD cluster 
2 
Anger 0.21 0.23  0.689 
 BOLD cluster 
2 
Disgust 0.03 0.24  0.959 
113 
 
 BOLD cluster 
2 
Surprise 0.01 0.34  0.979 
 BOLD cluster 
2 
Total -0.70 0.11  0.409 
 BOLD cluster 
2 
AQ 0.18 0.06  0.735 




0.02 2.86  -.967 




-0.07 1.24 0.266 0.938 
 BOLD cluster 
2 
Anxiety 0.23 0.97  0.595 
 BOLD cluster 
2 
GSI 0.10 3.05  0.930 
 BOLD cluster 
2 
PSDI -0.57 1.35  0.256 
 BOLD cluster 
2 
Anger -0.42 0.34  0.547 
 BOLD cluster 
2 
Disgust 0.77 0.19  0.161 
 BOLD cluster 
2 
Surprise 0.35 0.19  0.352 
 BOLD cluster 
2 
Total -0.67 0.13  0.505 
 BOLD cluster 
2 
AQ 0.39 0.03  0.259 




0.10 2.36  0.801 
Table 8.8 Statistical results of within group regression analyses between significant between group 
clusters 1 and 2 and measures of clinical, neuropsychological and protein level variables. 
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Chapter 9: Neurodevelopment in the Fragile X premutation: Discussion 
9.1 Within group imaging 
When contrasting high and low arousal states as a means of establishing activation patterns in 
response to images that are arousing across valence ratings, the within group analysis showed no 
significant clusters of activation in the premutation group and four significant clusters in the control 
group. The clusters centred in the right intraparietal cortex, left lobules VII and VI of the cerebellum, 
bilateral superior parietal lobe and right middle and superior frontal gyrus. Previous reports of 
investigation into emotional arousal in healthy participants utilising the IAPS images have 
demonstrated similar regions of interest, providing validation of our task design. In an analysis into 
correlation between participants’ own arousal ratings and BOLD activation at a whole brain level, 
activity was identified at the right superior frontal gyrus, bilateral inferior parietal lobe and left 
dorsolateral prefrontal gyrus. These findings are indicative of significant activations in this area that 
are relevant to participants’ own judgement of the extent of arousal (Prehn et al. 2015). In addition, it 
is reported that there is greater activation in response to images with stronger emotional content in the 
right than in the left parietal regions, which is consistent with the present results exhibiting mainly 
right hemispheric parietal BOLD responses when observing images of higher arousal ratings (Bradley 
et al. 2003). The cerebellum has also been connected with social cognition and emotional processing, 
especially concerning mentalizing more abstract emotions and hypothetical events, which is 
applicable to this IAPS task presenting a variety of images portraying emotional situations (Van 
Overwalle et al. 2014). Functional topography of the cerebellum for motor and cognitive tasks 
demonstrates clear functional connectivity between cerebellar lobules VI and VII and the parietal 
cortex during cognitively demanding tasks (Stoodley et al. 2012). Moreover, resting state functional 
connectivity analyses have shown that cerebellar lobule VII is part of a supramodal zone of the 
cerebellum, which exhibits overlapping connectivity maps for the prefrontal and parietal cortices 
(O’Reilly et al. 2010b). It is possible that the origin of the cerebellar cluster here in response to high 
arousal compared to low arousal conditions may have arisen from a strong connectivity between the 
parietal lobe and lobules VI and VII of the cerebellum and additional mentalizing processing of 
emotional stimuli.  
The two fMRI emotional processing tasks utilised to date in premutation carrier samples have been a 
fearful and neutral faces paradigm and a facial emotion matching task, both utilising Ekman face 
images (Hessl et al. 2007; Hessl et al. 2011). The former study carried out a within group analysis 
comparing fear and control conditions that exhibited significant clusters of activation centring at the 
orbital gyrus, middle temporal gyri, occipital sulcus, cerebellar lobule VI and middle and inferior 
frontal gyri in controls. This contrast of fear-control conditions may be seen to somewhat align with 
the high arousal-low arousal contrast of interest for this study, and clusters at the cerebellum and 
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middle frontal gyri are concurrent. Also, in a similar manner to the present analysis of emotional 
processing, the premutation within group analysis of the fear-control contrast exhibited both markedly 
less overall activation and different activation patterns, with smaller significant clusters than the 
control group only at the angular gyrus, the bilateral cuneus and the middle occipital gyrus (Hessl et 
al. 2007). The other fMRI emotional processing study carried out in carriers however did not find 
overt inconsistency in the within group analysis, with both carriers and control exhibiting robust 
activations bilaterally in the insula, mid cingulate gyrus, fusiform gyrus, parietal lobe, superior frontal 
gyrus and middle frontal gyrus (Hessl et al. 2011). Despite the lack of significant clusters in the within 
group analysis for premutation carriers in the present study, our results are consistent with many of 
these regions of activation during an emotional processing task. Overall, the results of our within 
group analyses tally well with some of the previous findings, showing robust areas of emotion-related 
activation in response to arousing stimuli in controls and exhibiting marked attenuation of BOLD 
response in carriers. The novelty of the use of an IAPS based task in premutation carrier imaging 
research and population variance may be a causative factor in the moderate disparity of the present 
results with previous fMRI findings of emotional processing in premutation groups.           
9.2 Between group imaging  
Between group analysis of the high arousal-low arousal contrast of interest revealed that premutation 
carriers showed significantly less activation in a cluster located bilaterally at BA17 (primary visual 
cortex), right BA18 (visual association area) and the right superior parietal lobe, and another cluster 
located bilaterally at the superior parietal lobes, right BA2 (primary somatosensory cortex) and right 
intraparietal area. In previous studies utilising the IAPS, an increase in the extent of visual cortex 
activation has been found when viewing emotional images that are both pleasant and unpleasant 
compared to low arousal images (Bradley et al. 2003; Lang et al. 1998). The basis of such increased 
metabolism at the visual cortex is thought to reflect increased attention towards perceived threat or 
positive stimuli. Our findings of between group differences at the primary visual cortex and visual 
association area indicate that this response to high arousal stimuli is significantly attenuated in 
premutation carriers. The parietal cortex has also been implicated as an area of interest in an IAPS-
based fMRI task, with images portraying sadness prompting clusters of BOLD activation at the 
bilateral parietal cortices including the angular and supramarginal gyri compared to neutral images 
(Radua et al. 2014). It is possible therefore that extensive clusters of significantly lower activation in 
carriers at the superior parietal areas is reflective of deficits in the emotional processing of arousing 
images of a more negative valence.  
Like the current study, the two neuroimaging studies to date utilising fMRI emotion-based tasks in 
premutation carriers, carried out by Hessl et al., demonstrate the existence of between group 
differences in BOLD response concerning emotional processing (Hessl et al. 2011; Hessl et al. 2007). 
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In one study, when contrasting fearful and neutral face conditions, the control group showed 
significantly greater activation at the bilateral amygdalae, bilateral insula, left superior temporal 
sulcus, bilateral intraparietal sulcus and regions of the left basal ganglia (Hessl et al. 2007). The other 
study demonstrated no significant differences at a whole brain level when comparing facial stimuli to 
inanimate stimuli, however subsequent region of interest (ROI) analysis revealed significantly lower 
activation in the carrier group compared to controls at the left amygdala (Hessl et al. 2011). The 
present study tallies with these previously identified between group differences in that activation in 
that carriers exhibited significantly lower activation clusters, not significantly higher. This replicated 
lower level of activation is indicative of significantly attenuated response to or recognition of 
emotional stimuli in premutation carriers. Moreover, in the present study there is concurrence with 
previous findings of the location of between group activation differences at the intraparietal regions 
during emotional processing contrasts.  
However, both previous studies into functional responses to emotional processing in premutation 
carriers highlight activation differences in the amygdala (Hessl et al. 2007; Hessl et al. 2011). 
Additionally, multiple studies utilising the IAPS in fMRI investigations show that the amygdala plays 
an important role in emotional processing, particularly involving arousal and fear. BOLD signal 
changes have been identified at the amygdala to correlate with participant ratings of arousal for IAPS 
images at a whole brain level (Prehn et al. 2015) and the amygdala and insula bilaterally demonstrated 
enhanced responsivity to negative IAPS images of balanced arousal ratings in individuals with social 
phobia (Shah et al. 2009). Using volume of interest (VOI) analysis in an fMRI study utilising the 
IAPS, the amygdala was also seen to be involved in emotional discrimination, with amygdala 
activation preceding activation of the ventrolateral prefrontal cortex, consistent with theories of 
emotional stimulus detection and integration of information in these areas (Kohno et al. 2015). In the 
present study however, no differences at the amygdala were discerned in carriers. This disparity may 
originate from the known heterogeneity of emotional, psychiatric, neuropsychological and autistic 
trait phenotypes in FMR1 premutation carriers, therefore causing sample groups to be variable 
between studies. In addition, our findings indicate that amygdala dysfunction may not be a robustly 
replicable phenotype of male premutation carriers. 
Overall, our results indicate significant between group differences that demonstrate attenuation of the 
functional response to arousing stimuli in carriers. The locations of the clusters of significantly 
different activation, at BA17 (primary visual cortex), BA18 (visual association area), the superior 
parietal lobes, BA2 (primary somatosensory cortex) and intraparietal areas, converge with the results 
from both other fMRI based emotional processing tasks in carriers and other IAPS based tasks in 
healthy or psychiatrically affected cohorts.               
9.3 Group x age interaction  
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When group x age interactions were examined at a whole brain level for this emotional processing 
task, the analysis showed no significant clusters of BOLD activation. This indicates that no areas of 
the brain differ significantly between the groups in their reactivity to arousing stimuli when 
considering their interaction with age. It can be drawn from these results therefore, that the lower 
functional brain response in premutation carriers when contrasting high and low arousal conditions of 
varying valence is not sensitive to the effects of age. Moreover, not only are the significant 
differences in BOLD response at BA17 (primary visual cortex), BA18 (visual association area), the 
superior parietal lobes, BA2 (primary somatosensory cortex) and intraparietal areas not susceptible to 
age-related changes, neither is any region of the brain’s emotional functional response to arousing 
stimuli.  
This is the first study investigating emotional processing in carriers using fMRI that has a cross-
sectional design incorporating age as a variable factor, allowing for the collection of neuroimaging 
evidence supportive of the idea that premutation carriers exhibit neurodevelopmental changes that 
remain stable over time. Previous findings have indicated the existence of these neurodevelopmental 
traits in carriers. Most of these findings however concern out of scanner measurements, such as 
evidence of elevated risk for ASD in carrier populations and increased prevalence of associated 
seizures (Chonchaiya et al. 2012). Developmental delay, attention problems, aggressiveness, and 
anxiety have also all been identified as being significantly more common in young carriers than 
controls (Bailey et al. 2008). However, in previous neuroimaging studies investigating emotional 
processing in premutation carriers, the participant samples were relatively young, with mean age-
matched premutation carrier ages of 32.9 years and 42.9 years (Hessl et al. 2007; Hessl et al. 2011). 
These sample ages, regarded as low-risk ages for FXTAS onset, combined with the samples being 
asymptomatic for FXTAS as confirmed by neurological examination, suggest that significantly 
different BOLD responses during Ekman face-based tasks are both separate from FXTAS and present 
long prior to expected onset of neurodegeneration. The analysis in the present study probing age-
related changes in premutation carriers, is therefore in accord with previous evidence of emotional 
processing disparities in carriers and we present here novel evidence of FMR1 premutation carrier 
phenotypic changes in arousal that may be stable and separate to onset of neurological disease.   
9.4 Clinical and neuropsychological measurements  
Consistent with the hypotheses of increased levels of psychiatric symptoms and neuropsychological 
problems in premutation carriers compared to neurotypical individuals, our results show significant 
differences in carriers pertaining to neurodevelopmental traits. Psychiatric symptomatology as 
measured by the SCL-90-R self-report questionnaire, facial emotion recognition as measured by the 
Ekman 60 Faces Test and autistic traits as measured by the AQ all revealed significant deviation from 
control group norms. Although some measurements did not show any significant differences between 
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groups, such as the social judgement test and EQ, it is clear that psychiatric and neuropsychological 
differences exist between carriers and controls.  
Here, we report significantly higher neuropsychiatric symptomatology of obsessive-compulsiveness, 
anxiety, global psychiatric severity and positive symptom distress levels as measured by the SCL-90-
R in premutation carriers compared to controls. Control sample results were corroborative with the 
SCL-90-R normative sample means, suggesting that our control sample is broadly similar to the 
normative sample. Obsessive-compulsive and anxiety measurements reflect significantly higher levels 
of these specific symptoms in carriers, whereas measurements of somatization, interpersonal 
sensitivity, depression, hostility, phobic anxiety, paranoid ideation and psychoticism did not differ 
significantly between the groups. However, most of these variables did exhibit trends towards being 
more severe in carriers, which is demonstrated as the measurement of global severity of symptoms is 
significantly higher in the carrier group. In addition, the positive symptom distress index was also 
significantly higher in carriers, representing an increased level of psychological distress at the 
presence of psychiatric symptoms. These results strongly align with previous evidence of psychiatric 
symptomology in carriers, where outcomes from the SCL-90-R show that obsessive-compulsiveness 
and global symptom severity are significantly increased in male carriers without FXTAS (Hessl et al. 
2005). It is likely that within sample heterogeneity has led to the present sample also exhibiting 
significantly higher levels of anxiety and positive symptom distress. Our findings are further validated 
by previous research as higher rates of anxiety and obsessive-compulsive symptoms have been 
demonstrated in multiple studies of premutation males without FXTAS (S Jacquemont et al. 2004; 
Dorn et al. 1994).  
Participants in the present study also carried out the Ekman 60 Faces Test as an investigation into 
facial emotion recognition abilities. Our results show that carriers are significantly worse at 
identifying emotive faces of anger, disgust and surprise, and recognising emotive facial expressions 
overall as reflected by the total test score. Controls and carriers did not perform significantly 
differently when asked to recognise facial emotions of fear, happiness or sadness. The mean scores for 
all variables showed that neither the carrier or control group were reaching cut-off scores for marked 
impairment of emotive facial recognition, as dictated by the Ekman 60 Faces Test normative dataset. 
We can therefore infer that carriers are worse at identifying emotional facial expressions, but not to 
such an extent that denotes significant, clinically relevant impairment. Few prior studies have utilised 
Ekman faces in investigations into the FMR1 premutation, however carriers have been shown to 
exhibit diminished potentiation of the startle response to fearful faces as measured by skin 
conductance, despite being similar to the control group in their baseline startle responses (Hessl et al. 
2007). This lower level of skin conductance reaction to fearful faces in carriers may be a pertinent 
phenotype, and in a similar manner to the between group neuroimaging attenuated BOLD response to 
arousing stimuli in premutation carriers, it is possible that when observing Ekman face images, 
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carriers possess a weakened initial response to facial images demonstrative of heightened arousal, 
which then manifests as a reduced ability to recognise such facial emotions correctly. Our results are 
supportive of this theory, as the variables that carriers performed significantly worse on were 
primarily those that can be considered as typically more threatening or arousing.           
All participants took part in testing of social judgement, centred around variables of the perceived age, 
approachability, attractiveness, distinctiveness, intelligence and trustworthiness of individuals 
represented in images. In these measurements, mean scores of the carrier and control group were 
comparable and no significant differences existed between the groups. This is a somewhat unexpected 
finding, given that carriers have been shown to have higher levels of autistic traits than control 
populations, and part of the clinical presentation of ASD is social difficulties that may partly arise 
from lack of accurate social judgement (Shulman et al. 2012; Mathersul et al. 2013). Moreover, 
investigation into social cognition in young male premutation carriers indicated significantly 
increased levels of social deficits, particularly pertaining to interpersonal skills that necessitate 
accurate social perception, such as the recognition of complex emotions from photographs of eyes 
(Cornish et al. 2005) and our own findings report evidence of emotion processing difficulties. It is of 
note that research into social cognition in carriers has been carried out in groups of carriers that were 
younger on average than the sample in this study. It may be the case that older carriers have an 
increased aptitude for social judgement than younger carriers due to more experience, or that the 
carriers in the present study were on average more socially able, given that populations of premutation 
carriers are notably heterogenous.  
Investigation into the existence of autistic traits in premutation carriers was carried out in the present 
study using the AQ and EQ self-report questionnaires. Our results show that carriers have 
significantly higher levels of autistic traits compared to controls as measured by the AQ. This is 
supportive of the previous literature reporting FMR1 premutation carriers as a high-risk ASD cohort. 
Frequency of ASD in carrier populations has been estimated to be approximately 10-20% in males 
and 1-7% in females, which is notably elevated compared to the 1% ASD frequency estimation in the 
general population (Besterman et al. 2014). High rates of social impairment, hyperactivity, delayed 
receptive and expressive vocabulary and use of social language have also been reported in young 
males with the premutation (Aziz et al. 2003). Epidemiological data collected through a national 
survey estimates a 19.3% incidence of autism, a 33% incidence of developmental delay and a 41% 
incidence of attention problems in male carriers (Bailey et al. 2008). Our data is therefore concurrent 
with these previous reports of significantly increased ASD attributes in male premutation carrier 
cohorts. Interestingly however, EQ scores in carriers were not significantly lower than control scores 
as expected, although mean carrier EQ score was still notably lower. Comparable scores in the EQ 
between the groups indicate that lack of self-rated empathy is not  evident in this group of premutation 
carriers. Interestingly, the control group in the present study exhibited a significant correlation 
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between AQ and EQ scores, as previously reported in ASD and neurotypical cohorts (Wheelwright et 
al. 2006). The carrier group however did not show an association between AQ and EQ scores and 
deviation from this standard correlation may be indicative of a non-standard autistic presentation in 
premutation carriers. Indeed, when considering this data in tandem with the aforementioned social 
judgement scores, which were not significantly different between groups, the present results appear to 
reveal that impaired social perception and empathic feeling form part of premutation carrier ASD 
symptomatology to a lesser extent than predicted.    
Overall here, we have reported results that show premutation carriers exhibit elevated psychiatric 
symptoms in the domains of obsessive-compulsiveness, anxiety, total severity and positive symptom 
distress as hypothesised and concurrent with previous findings. Correct recognition of facial emotions 
was also seen to be impaired in carriers, particularly for expressions that may be considered as more 
arousing. Considering neuroimaging data in the present study showing attenuated response to 
arousing stimuli, it is possible that premutation carriers exhibit a phenotypic loss of response to 
arousing stimuli and facial expressions, therefore exhibiting lower levels of recognition. Our results 
also indicate higher levels of autistic traits in male premutation carriers than controls, as shown by the 
previous research, however comparable between groups results in the social judgement test and EQ 
indicate that social discernment and empathy remain neurotypical in carriers.        
9.5 Molecular measurements 
Previous research indicates that levels of FMRP are sometimes lower in premutation carriers. 
Kenneson et al. reports that reduced FMRP in premutation carriers of intermediate length repeat 
expansions is proportionally associated with CGG repeat number (Kenneson et al. 2001). Similarly, 
premutation carriers with more than 100 repeats have been reported to be more likely to possess mild 
deficits in FMRP and developmental problems than carriers with smaller repeat lengths (Tassone, 
Hagerman, Taylor, Mills, et al. 2000). Two neuroimaging studies in premutation carrier cohorts to 
date have utilised additional molecular measurements of FMRP. Both studies quantified FMRP in the 
same manner, using participant lymphocyte samples and sandwich Enzyme Linked ImmunoSorbent 
Assays (ELISA) for FMRP (Hessl et al. 2011; J. M. Wang et al. 2012). Unlike 
Immunocyctochemistry techniques, this ELISA method measures protein level, not just the proportion 
of lymphocyte cells with detectable staining (Iwahashi et al. 2009). Hessl et al. identified FMRP 
levels to be reduced by 12% in the premutation group relative to controls after log-transformation to 
achieve normality, and this difference was statistically significant (Hessl et al. 2011). Wang et al. 
however reported a 23% reduction of FMRP in carriers compared to controls which did not reach 
statistical significance, stating high variability within both groups may have been a causative factor (J. 
M. Wang et al. 2012). The present study utilised a Western blotting technique for protein 
quantification from samples of peripheral blood mononuclear cells, which revealed that premutation 
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carrier FMRP levels and control FMRP levels were not significantly different. As referred to in 
previous reporting of FMRP quantification, the variance in our results was high in both the control 
and carrier group, even within the same extracted protein sample, which may have contributed to lack 
of identification of a slight FMRP reduction. Research has previously indicated that it is often carriers 
of higher CGG repeat expansions (>150 CGG repeats) that exhibit modest reductions in FMRP, and it 
may be that lower levels of FMRP are not identified in this sample due to the majority of carriers 
being of lower CGG repeat lengths (Tassone, Hagerman, Taylor, Gane, et al. 2000). Additionally, 
Western blotting of extracted protein samples originating from peripheral blood mononuclear cell 
samples produced multiple anti-FMRP specific bands which were of unknown derivation. For this 
reason, only 80kDa FMRP bands were quantified using densitometry for the analysis, to minimize the 
chance of quantifying non-FMRP bands. However, this excluded the possibility of quantifying FMRP 
isoforms that were not 80kDa, of which several have been reported during Western blotting when 
using Ab17722 as used in the present study, and other commonly used anti-FMRP antibodies with 
human reactivity. It is likely that lack of quantification of FMRP isoforms has also impacted the 
accuracy of the present results. 
Nevertheless, our results indicate that despite a high variability in both the control and carrier group, 
that 80kDa FMRP levels equate between the groups. This lack of significant between group difference 
in FMRP level has been reported before and is therefore not unusual, however this result indicates 
that, contrary to our original hypotheses, there is no reduction in FMRP, and therefore low levels of 
FMRP do not appear to be driving neurodevelopmental deficits in premutation carriers in this case (J. 
M. Wang et al. 2012). While the present results of quantified FMRP levels shed doubt upon the 
neurodevelopmental hypotheses of FMRP-driven phenotypes, it should be stressed that the Western 
blotting assay utilised for this study was notably problematic and further limitations and 
considerations are covered in section 9.7.  
9.6 Linear regression analyses 
In the present study, no significant associations were identified between significantly decreased 
clusters of BOLD response in premutation carriers during the emotional processing task and clinical 
or neuropsychological measures of interest. It was hypothesised that differences between carriers and 
controls in out of scanner measurements of psychiatric symptoms and neuropsychological variables, 
such as recognition of facial expressions of emotion, would correlate with neuroimaging differences, 
indicating a link between functional brain processing during emotional responses and premutation 
emotional phenotypes. This was not evident however in our analyses, showing no strong connection 
between differences in BOLD response in carriers and a possible manifestation of symptoms. 
Conversely, in previous studies, associations between MRI findings and psychiatric or 
neuropsychological measures have been successfully identified, suggesting structural or functional 
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brain deficits that may underlie vulnerability to neuropsychiatric phenotypes. Reduced functional 
activation of the amygdala during an emotion-based task in premutation carriers has been shown to 
correlate with global psychiatric symptom severity as measured by the SCL-90-R, even with a small 
sample size of twelve (Hessl et al. 2007). A reduction in volume at the hippocampal complex has been 
significantly associated with anxiety symptoms in female carriers, and a sample of male carriers 
exhibited a significant association between reduced hippocampal functional BOLD response during 
memory recall and higher levels of psychiatric symptoms (Adams et al. 2010; Koldewyn et al. 2008). 
Given that carriers showed significant differences in both the in scanner and out of scanner 
measurements of emotional processing in the present study, it is somewhat surprising here that there 
is no connection between these variables. However, it is possible that the psychiatric and 
neuropsychological tests were not specific enough to be closely likened to the task contrast of high 
arousal-low arousal stimuli. In addition, previous studies identifying significant associations between 
neuroimaging and psychiatric data in carriers have been largely focussed on limbic brain regions. Our 
results indicate no differences between carriers and controls at the amygdala, hippocampus or other 
limbic region, so it is possible that significant links between MRI findings and higher levels of 
psychiatric symptomatology in carriers concerns mainly the limbic system.       
In addition, no significant link was identified between levels of FMRP and significantly different 
clusters of BOLD response during the emotional processing task in either the carrier or control group. 
It was hypothesised that given the important role of FMRP in neural plasticity and brain development, 
reported small decreases in FMRP would be a causative factor in the establishment of 
neurodevelopmental differences between premutation carriers and controls (Hagerman & Hagerman 
2013). However, this was not evident in the current sample, and no association was found between 
attenuated brain response in carriers and levels of FMRP. Previous findings have suggested that such 
links do exist, with one study in male premutation carriers showing a significant negative correlation 
between functional activity in the left parahippocampal gyrus during a memory encoding task and 
FMRP levels as measured by ELISA (J. M. Wang et al. 2012). Another study found that FMRP 
levels, also quantified by ELISA, were positively correlated with right and left amygdala BOLD 
response in premutation carriers during an emotion processing task (Hessl et al. 2011). This previous 
research is supportive of the theory that neurodevelopmental deficits in carriers is driven, at least 
partly, by FMRP expression. Our results are not supportive of this however, but it is notable in this 
case that the present study quantified FMRP levels using a different methodology to the two 
aforementioned studies, which may be reflective of different isoform and total FMRP quantification. 
Moreover, our results do not indicate any significant difference between the carrier and control group 
in FMRP expression, as has been shown in prior research, so it is possible that no association exists 
due to comparative FMRP levels in the present sample and lack of initial moderate protein reduction 
(Hessl et al. 2011; Kenneson et al. 2001). In a similar manner to the previous reports of associations 
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between clinical symptoms and neuroimaging data, FMRP and fMRI data correlations have been 
identified only in limbic regions to date. Therefore, it may be possible that it is mainly the limbic 
regions that exhibit sensitivity to lower levels of FMRP, causing aberrant BOLD responses and 
linking to vulnerability to psychiatric phenotypes.  
Overall therefore, we can surmise that in the present premutation carrier sample, FMRP levels are not 
influencing significantly lower clusters of BOLD response in response to emotional stimuli and in 
turn, these functional brain differences do not necessarily infer psychiatric or neuropsychological 
premutation phenotypes. Nevertheless, the possible influencing factors on why such associations may 
not have been statistically identified in this sample should be taken into account.  
9.7 Limitations and conclusions 
An important limitation when investigating neuropsychological and psychiatric phenotypes in any 
cohort is the large influence of environmental factors, including life stressors, traumatic life events 
and socioeconomic background (Klengel & Binder 2015; Fatori et al. 2013). In addition, drug and 
alcohol abuse can both result from and exacerbate psychiatric difficulties (Indlekofer et al. 2009). 
Environmental factors are of especial import when considering psychiatric symptoms in carrier 
populations, as both male and female carriers have been documented to have higher levels of alcohol 
abuse which may be suggestive of a heightened sensitivity to social and psychological stress (Seltzer 
et al. 2012). In a group of FXTAS patients with dementia, 21% reported alcohol abuse or dependence 
(Seritan et al. 2016). In addition to affecting individuals psychiatrically, a recent case study suggests 
that drug use, specifically narcotics, may greatly increase risk for, onset of and speed of progression in 
FXTAS, causing exacerbated white matter disease through RNA toxicity (Muzar et al. 2015). Carriers 
of the FMR1 premutation are also at increased risk for endocrinological medical conditions, which 
can contribute to the development of psychiatric disorders (Hunter et al. 2010). For example, women 
with the premutation have a 20% risk of experiencing premature ovarian insufficiency, which can lead 
to infertility and early menopause (Sullivan et al. 2011). As a result of the associated decrease in 
oestrogen and potential emotional stress, risk for mood disorders in this group is elevated (McConkie-
Rosell et al. 2012). Premutation carriers also have an increased risk for hypothyroidism, with reported 
incidence being as high as 8.84% in carriers compared to 0.93% in the general population, which 
characteristically increases risk for mood and affective disorders (Merino et al. 2016). In the present 
study of neurodevelopmental differences in premutation carriers, co-morbidities or environmental 
factors were not addressed and so could not be controlled for or investigated in the analyses. It may be 
pertinent for future study to gain complete drug histories for this sample group, and to consider more 
environmental and co-morbidity factors in prospective study design and analyses. 
Another limitation in the present study methodology is the use of peripheral blood mononuclear cell 
samples to obtain relative quantifications of FMRP with the assumption that these levels will reflect 
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brain expression levels. It is known however that FMRP levels are higher in the brain compared to 
other tissues, with moderate expression in lymphocytes, which form part of the mononuclear cell 
group, and that within brain tissue FMRP expression can also be variable between regions (Hinds et 
al. 1993). It is therefore not ideal to utilise blood-based measurements as a reflection of brain protein 
expression levels, but venepuncture and subsequent analysis of peripheral blood mononuclear cells 
remain the safest, least invasive and most ethically sound methodology for a clinical research setting. 
Moreover, some research has shown support for robust association between blood and brain measures 
of FMRP, for example, full mutation males and females exhibit a significant correlation between 
FMRP levels and full-scale intelligence quotient scores (LaFauci et al. 2013). Another study found 
that FMRP expression was similar between peripheral blood mononuclear cells and fibroblast samples 
as measured by Western blot (Pretto et al. 2014). We can therefore infer that FMRP measured from 
peripheral blood mononuclear cells can be cautiously treated as relative to brain expression levels, 
although further research should be carried out to characterise this relationship. 
Western blotting-based methodology to obtain quantifications of FMRP relative to a loading control 
has also been a limiting factor in this study. The blots revealed multiple FMRP specific bands of 
unknown origin between approximately 10-100kDa. Cross-reactivity of secondary antibodies and IgG 
reactivity was ruled out by control blots. Extensive splicing of the FMR1 gene has previously been 
reported using RT-PCR and several FMRP isoforms have been demonstrated using Western blotting 
(Ashley et al. 1993; Verheij et al. 1993; Verkerk et al. 1993). These isoforms do not appear to be 
tissue specific, with similar FMRP isoform expression profiles being seen in multiple foetal tissues, 
brain and testis (Verkerk et al. 1993). Splice variant molecular function remains unknown to date, but 
four or five isoforms of FMRP, ranging in weight from 70 to 80kDa have been identified using 
Western blotting and FMRP-specific antibodies (LaFauci et al. 2016; Verheij et al. 1995). Our blots 
did not replicate these isoform expression patterns, and variability was high both within and between 
samples. Given the unknown source of variance and the extra banding in our blots, only 80kDa FMRP 
was quantified, as the stated expected molecular weight. It is important however for future research to 
establish the identify of extra FMRP-specific bands when Western blotting peripheral blood 
mononuclear cell-derived protein samples, and for this method to be validated using additional control 
samples.  
Overall, we find in this study multiple differences in premutation carriers compared to controls in 
several modes of measurement. Our neuroimaging analysis revealed that carriers exhibit significantly 
attenuated response at bilateral BA17 (primary visual cortex), right BA18 (visual association area) 
bilateral superior parietal lobes, right BA2 (primary somatosensory cortex) and right human 
intraparietal area 1 when contrasting high arousal and low arousal images. Previous research utilising 
fMRI and the IAPS indicates that the visual system is an early regulator of arousal response, and 
exhibits localised increased BOLD response during high arousal stimuli compared to low arousal 
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(Bradley et al. 2003). Significantly lower activation in carriers at the visual cortex and visual 
association area therefore indicates diminution of this response and a possible reduction in the ability 
to heighten attentional control during arousing events. In addition, no group x age interaction was 
identified for this task, showing that changes to emotional processing concerning arousal in carriers 
are not sensitive to age in a way that deviates from the normative sample. In general, we demonstrate 
a significantly reduced functional emotional response in premutation carriers which appears to be 
stable and neurodevelopmental in nature.  
We also show that carriers have significantly increased measures of psychiatric symptomatology, 
reduced performance when recognising facial emotions and increased levels of autistic features. 
Firstly, higher levels of psychiatric features in carriers was both hypothesised and closely replicates 
previous studies. Secondly, a poorer ability for the recognition of facial expressions of emotion in 
carriers, particularly those that can be considered to be more arousing, links to the differences in 
response to arousal in the neuroimaging analysis. These combined findings imply that a reduction in 
functional brain response to arousing stimuli may cause a downstream reduction in the ability to 
correctly recognise emotionally arousing expressions, such as anger, disgust and surprise. Lastly, the 
absence of any significant differences between carriers and controls in measures of social judgement 
and EQ scores, but significantly increased levels of autistic traits as measured by the AQ, is 
suggestive of an autistic profile in carriers that may deviate from normal ASD presentation, as social 
perception and empathy remain typical.  
Analysis of FMRP levels in the present sample revealed no significant between group differences, not 
a reduction in FMR1 protein product as hypothesised and previously reported (Tassone, Hagerman, 
Taylor, Mills, et al. 2000). However, the present sample of carriers tended towards lower premutation 
allele repeat sizes, which may be an explanatory factor, as higher CGG repeat regions appear to 
produce lower FMRP expression levels (Tassone, Hagerman, Taylor, Mills, et al. 2000). Additionally, 
as discussed, the Western blotting assay used here would benefit from further protocol refinement and 
validation.   
Simple linear regression analyses of neuroimaging significant between group cluster data and clinical 
or neuropsychological measurements yielded no statistical associations, as did regression analyses of 
imaging data and FMRP levels. These findings appear to show that the functional reduction in BOLD 
response in carriers is not related to higher levels of psychiatric symptoms, autistic traits or 
performance in the Ekman 60 Faces Test, contrary to the original hypotheses. However, it is possible 
that out of scanner measurements of emotional processing were not specific enough to accurately map 
to brain responses of arousal, or that lack of limbic involvement in the fMRI analysis meant that 
previously reported results were not replicated. 
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In all, we report here evidence in keeping with neurodevelopmental symptomatology in premutation 
carriers at both a functional brain imaging and clinical level. Age-related analyses show that the 
attenuated emotional BOLD response in carriers is stable in nature, and increased levels of psychiatric 
involvement and neuropsychological differences are supportive of the hypothesis that premutation 
carriers exhibit neuropsychiatric and emotional problems throughout their life-span, regardless of 
FXTAS development.    
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Chapter 10: Study discussion 
10.1 Limitations of the study design 
The present study was designed to utilise fMRI, clinical, neuropsychological and molecular 
measurements to probe both neurodegenerative and neurodevelopmental aspects of the FMR1 
premutation phenotype. We report here new insights into both features, which are predominantly 
supportive of previous findings in the field and our original hypotheses. The study has limitations 
however, which are important to acknowledge.  
A possible limitation may be statistical power. Whilst some studies report that to reach a statistical 
power of 80% in a functional neuroimaging study, approximately 13 subjects are required when data 
is FWE corrected, other studies report that a minimum of 18 subjects are necessary to reach a 
statistical power of 80%, regardless of length of condition blocks, which when lengthened can 
increase power (Hayasaka et al. 2007; Mumford & Nichols 2008). Some studies cite even higher 
sample size requirements, despite liberal thresholding at 0.05 necessitating just 12 subjects to reach 
80% statistical power, realistic thresholds and correction for multiple comparison require double this 
sample size to reach statistical power (Desmond & Glover 2002). It seems reasonable therefore to 
infer that a sample size of 17 subjects in the present study falls somewhere in the middle of these 
estimations, and is likely to be adequately powered, although still at the lower end of the spectrum. 
When considering the present two-sample analysis, and the non-clinical nature of both the control and 
premutation group however, it is possible that the observed effect size may be relatively small. 
A cross-sectional design also is a limit to the study’s ability to establish neurodevelopmental or 
neurodegenerative aspects of the premutation. Whilst using age as a variable to investigate the 
possible existence of abnormal brain development and degeneration may be insightful, because the 
study is not longitudinal inferences of change over time cannot fully be made. In addition, factors 
such as relative compensation in older carriers and individual differences in ability level may drive or 
mask age-related associations.    
Cluster-wise inference using statistical parametric methods, as used in this analysis, has additionally 
been reported to yield high rates of Type I error in some cases (Eklund et al. 2012). Voxel-wise 
inference on the other hand has been identified as a stringent estimate of significance, with family-
wise error rates often falling below 5% (Eklund et al. 2016). Given possible limitations concerning 
power of this study, as previously discussed, and reported over-stringency of voxel-wise inference, 
the present results nevertheless remain promising.    
An additional limitation of the present study is that the design did not incorporate a neurological 
examination or a FXTAS rating scale, which could have been used to fully confirm asymptomatic 
carrier status. Although no carriers presented with any overt FXTAS symptoms, or had a diagnosis of 
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FXTAS, verification of FXTAS status would have allowed certainty of the nature of the sample 
group. It should also be acknowledged that the sample of premutation carriers taking part in this study 
had a mean age of 50.4 years, with an age range of 24-68 years old. Penetrance of FXTAS is age-
related; 40% of male carriers over the age of 50 develop the disease and FXTAS penetrance in male 
carriers over 80 years old is 75% (Sébastien Jacquemont et al. 2004). Considering that none of the 
premutation carriers in this study had a FXTAS diagnosis, it is possible that this sample had a bias 
towards a lower FXTAS penetrance, and older individuals in the sample were at a lower risk for 
FXTAS development than a group that had been selected regardless of disease status. The results 
presented from this study therefore characterise a cross-sectional group of carriers without FXTAS, 
and may not be accurately representative of a cross-section of all premutation carriers.  
10.2 Future directions 
Fragile X-associated Tremor/Ataxia Syndrome and the effects of the FMR1 premutation were only 
uncovered in the last two decades, and research into this field is quickly developing. Many 
methodologies have yet to be utilised in premutation carrier samples, and there is much room for 
advancement in the characterisation of phenotypes, with the aim of creating more effective, targeted 
treatments for FXTAS and neurodevelopmental premutation traits.  
The scanner protocol for this study involved a DTI sequence for all participants, which can be 
analysed in the future. Functional connectivity analyses may also be carried out on the existing fMRI 
data. Previous studies utilising DTI in premutation carrier cohorts have shown minimal differences 
between non-FXTAS and control groups, but robust differences between controls and FXTAS groups. 
In carriers with FXTAS, fractional anisotropy was significantly reduced in multiple white matter 
tracts, including the MCP, superior cerebellar peduncle, cerebral peduncle and the fornix and stria 
terminalis (Hashimoto, Srivastava, et al. 2011). Structural connectivity loss was identified in motor, 
limbic, association and callosal fiber tracts in carriers with FXTAS compared to controls, with greater 
age-related decline in connectivity in all tracts analysed (J. Y. Wang et al. 2012; Wang, Hessl, et al. 
2013). Premutation carriers with FXTAS also showed significantly reduced diffusion-weighted signal 
compared to controls in the bilateral thalamus, caudate, putamen and right pallidus and significantly 
reduced diffusion-weighted signal compared to asymptomatic carriers in the bilateral putamen, right 
thalamus and left caudate (Wang, Hagerman, et al. 2013). In one study, the no significant differences 
in structural connectivity were identified between non-FXTAS carriers and controls, however 
connectivity strength of the superior cerebellar peduncles in premutation carriers without FXTAS 
exhibited a negative association with CGG repeat expansion length and FMR1 mRNA levels. 
Structural connectivity measurements from the corpus callosum and superior cerebellar peduncles 
also showed a robust correlation with motor symptoms in all participants (Wang, Hessl, et al. 2013). 
Abnormalities at the MCPs were also indicated in carriers without FXTAS in a study showing 
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significant elevation in axial and radial diffusivities here, with an additional clear relationship 
between axial and radial diffusivity and CGG repeat size (Hashimoto, Srivastava, et al. 2011). 
Another study reported no significant alterations in structural fiber tractography in older carrier 
without FXTAS (J. Y. Wang et al. 2012). Given these results in carriers asymptomatic for FXTAS, 
we may expect analysis of DTI data in our sample to show no structural differences or some mild 
changes in connectivity or integrity at the MCPs. Previous correlative analyses indicate molecular and 
DTI measurement associations, so we may expect to see replication of relationships between imaging 
measurements at the MCPs, superior cerebellar peduncles and corpus callosum and CGG repeat size 
or FMR1 mRNA expression levels. Our sample indicated significantly lower functional BOLD 
response in the motor task carriers compared to controls at the cerebellum, and an age-related 
reduction in activation in the temporo-parietal region, which we may predict to see reflected in a DTI 
analysis. 
Another future investigation of interest would be into expression patterns of FMR1 mRNA isoforms. 
It has been shown that in premutation carriers compared to age-matched control tissue all groups of 
FMR1 mRNA isoforms are significantly increased in both peripheral blood mononuclear cell samples 
and derived brain tissue. The majority of isoform groups were approximately 2-fold higher in carriers, 
however isoforms 10 and 10b were disproportionately increased up to 6-fold in premutation samples. 
Isoform transcript levels were also shown to correlate positively with increasingly large CGG repeat 
lengths (Pretto et al. 2015). Additionally, the skipping of Exon 12 (isoforms 7-12) during transcription 
of FMR1 is more frequent than its inclusion (isoforms 1-6). It appears that inclusion of Exon 12 is 
greatly increased in the premutation compared to typical expression profiles. A developmental switch, 
demonstrated in the developing mouse brain, chiefly involving the presence or absence of Exon 12, is 
suggestive of a shift in the RNA-binding properties of FMRP during neural development (Brackett et 
al. 2013). A future question of interest is therefore whether isoform expression patterns, in particular 
the large relative increases in the skipping of Exon 12 and isoforms 10 and 10b, are related to 
measures related to neurodegeneration, such as loss of brain connectivity and integrity as measured by 
DTI or motor symptoms. Isoform expression profiles may also be reflective of neurodevelopmental 
traits also, given the role of developmental switching in the transcript expression patterns.    
The further development and validation of Western blotting techniques for FMRP quantification is 
also a relevant future direction of the current research. Western blotting has previously been reported 
as an effective method of measuring FMRP levels against a GAPDH loading control using peripheral 
blood mononuclear cell and lymphocyte clinical samples in the study of the Fragile X full mutation 
(Pretto et al. 2014; LaFauci et al. 2013). As previously mentioned however, the blots in the current 
study revealed multiple bands ranging from 10-100kDa molecular weight of unknown origin. To 
make steps to further validate and characterise the nature of this method, control samples should be 
run in the future under tightly controlled venepuncture and storage circumstances, where sample 
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processing and freezing is immediate. Subsequent Western blotting of these samples should reveal 
whether extra banding has resulted from partial sample degradation, and human-derived sample 
handling can be informed by this in later clinical research.  
The FMR1 premutation gene also produces RAN protein products, the most toxic among them being 
FMRpolyG, which possesses the translated CGG repeat region as a repetitive glycine amino acid 
chain in the protein (Todd et al. 2013). Large, ubiquitinated aggregates found throughout the brain 
and brainstems of FXTAS patients appear to strongly implicate a role for protein-mediated 
neurodegeneration. FMRpolyG is seen to aggregate in FXTAS fly and mouse models as well as in 
human autopsy tissue, especially in the hippocampus, frontal cortex and cerebellum, strongly 
suggesting a role in the development and progression of FXTAS pathology (Cleary & Ranum 2014). 
To date, RAN translation of the FMR1 gene has not been investigated in a clinical setting, mainly due 
to fact that the strong propensity of FMRpolyG to aggregate causes inefficient quantification using 
Western blotting and ELISA and anti-FMRpolyG antibodies are not recommended for these 
methodological uses at this time. The development of an FMRpolyG specific antibody in the future 
however that is effective in Western blotting and ELISA techniques may allow for accurate 
FMRpolyG quantification in prospective clinical research, and its role in premutation and FXTAS 
humans can be characterised more thoroughly. Alternatively, mass spectrometry is an effective 
method that may be used currently to examine the presence of FMRpolyG in human-derived samples 
(Cleary & Ranum 2014).       
Structural equation modelling is a statistical technique that has been employed in multiple 
psychiatrically- and psychologically-based studies to elucidate effect sizes and associations between 
multiple variables (Whalley et al. 2013; Hart et al. 2005). This type of analysis would fit well with the 
neurodevelopmental hypotheses of the FMR1 premutation, as here we present numerous 
neuropsychological, psychiatric and molecular measures in our sample that are likely interconnected, 
however links and effect sizes are not established between these variables. A structural equation 
model may aid in identifying which variables are associated, and whether measurements of FMRP 
and CGG repeat length influence neurodevelopmental traits. However, the sample size in the present 
study is relatively small compared to some cohorts analysed using structural equation modelling and 
the sample size requirement is not satisfied as reported by evaluations of power and bias for this type 
of investigation (Wolf et al. 2013). As addressed previously, environmental factors have a large 
influence on neuropsychiatric manifestations, and individuals with the premutation may be 
particularly vulnerable to the effects of environmental influences and stressors (Seltzer et al. 2012). 
The participant groups for this study were all consented for future follow-up contact, and it therefore 
would be possible and relatively simple to utilise self-report measures to obtain information about 
medical co-morbidities, socio-economic background and environmental stressors which could be 
added to a potential structural equation model. This would allow for a novel analysis in a premutation 
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cohort to examine the interactions between FMR1 molecular function, psychiatric and 
neuropsychological traits and environmental influence.     
Second hit hypotheses are commonly cited in the study of neuropsychiatric disorders (Bonnet-
Brilhault et al. 2016; Jozwiak & Jozwiak 2005). A recent pilot study has also revealed a possible role 
of second genetic variant hits in the manifestation of premutation carrier phenotypes. The study 
identified that additional copy number variants, both deleterious and duplicative, located at 10q26 and 
Xp22.3 and not seen in any individuals in the control group, were more commonly observed in 
carriers with neurological involvement and ASD (Lozano, Hagerman, et al. 2014). These results 
suggest that genetic hits secondary to the FMR1 CGG repeat expansion may instigate more severe 
neurodevelopmental and neurological phenotypes. Further study in this area, utilising genome-wide 
mapping or focussed investigation of psychiatrically implicated gene groups, may reveal further 
support for this hypothesis.   
10.3 Concluding remarks 
Significant differences between carrier and control groups during a finger-tapping task demonstrated 
diminished cerebellar activity when responding to increased motor-related demand. In addition, group 
x age interaction analyses for this task revealed that carriers deviate from compensatory activation in 
response to higher task demand displayed during normative aging. Motor symptom measurements 
also reveal that carriers have significantly worse but sub-clinical tremor and co-ordination than 
observed in the control group and molecular measures of FMR1 mRNA are increased in carriers but 
not significantly so. We presently report the first motor fMRI task carried out in a premutation carrier 
group, and our results show neuroimaging and clinical indications of possible neurodegeneration prior 
to overt FXTAS onset. 
Premutation carriers displayed a significantly attenuated response in the visual and superior parietal 
regions to arousing stimuli during an emotional processing task compared to controls, and group x age 
interaction analyses revealed differences to be stable in this cross-sectional sample. Moreover, 
recognition of emotive faces was significantly poorer in carriers, which is suggestive of impairment to 
the neurotypical response to and detection of emotional arousal. As expected, psychiatric 
symptomatology in premutation carriers was also significantly higher than in controls. Social 
judgement and empathy scores were comparative between the carrier and control group, despite 
carriers showing significantly more autistic traits, indicative of a non-classical ASD presentation 
without impairment of social perception and responsiveness in carriers. FMRP levels also appear to be 
similar between the groups. Overall here, we report new findings of altered emotional, 
neuropsychological and psychiatric states in premutation carriers and our results are supportive of the 




The findings of this study are in keeping with hypotheses of primarily separate mechanisms of altered 
brain development and degeneration in FMR1 premutation carriers.           
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Instructions for the scanner tasks  
1. The pictures task 
 
• This task is approximately 7 minutes long. 
• The task uses pictures from the ‘International Affective Picture System’ and is designed to 
look at your emotional responses to the pictures.  
• Please look at each picture and use the LEFT and RIGHT trigger buttons to indicate your 
responses to the pictures. The responses will be categorised as “Face” or “No Face”, where 
“Face” refers to the presence of a face in the picture. 
• In this task, animals are also classified as having faces. 
• During the task there will be some black screens with a cross-hair in the middle, please just 
focus on the cross-hair during these screens. The screen will go blank at the end of the task.  
• The pictures will stay up for approximately 3 seconds each, and will change regardless of 
whether you indicate a “Face”/”No Face” answer, so please answer within this time frame if 
you can.  
• As this task is designed to elicit emotional responses, you may find some of the images 
slightly distressing.  
2. The finger-tapping task 
 
• This task is approximately 6 minutes long. 
• The task asks you to tap your fingers (on trigger buttons in the scanner) and is designed to 
look at movement processing in the brain. 
153 
 
• There are two different types of tapping you will be asked to do, ‘sequential’ and ‘random’, 
and there are also rest periods. 
• In the ‘sequential’ condition, the task requires you to tap your fingers in a row in time 
with a flashing # symbol – ie. Left thumb, left finger, right thumb, right finger.  
• In the random condition, you will be asked to tap the buttons in a random order in 
time with a flashing ? symbol – ie. Left thumb, right thumb.  
• In the rest condition, you are asked to simply watch the flashing + symbol. There will 






Motor task behavioural test form 
This task for use in an fMRI scanner is approximately 6 minutes long. 
The task asks you to tap your fingers (on a keyboard or trigger buttons in the scanner) and is designed 
to look at movement processing in the brain. For these tests, the buttons on the keyboard that you will 
use are 1 and 2 for your left hand and 9 and 0 for your right hand. In the ‘sequential’ condition, the 
task requires you to tap your fingers in a row in time with a flashing # symbol – ie. 1, 2, 9, 0. In the 
random condition, you will be asked to tap the buttons in a random order in time with a flashing ? 
symbol – ie. 1, 9, 9, 2. In the rest condition, you are asked to simply watch the flashing + symbol. The 
screen will go blank at the end of the task.  
Your feedback from these tasks will help to determine whether they are suitable for use in an fMRI 
scan. Thank you ☺  
1. Were you clear on how to do the task, or did you find it confusing? 
(Not really, it was confusing)              1               2                 3                 4              5      (Yes, it was 
simple) 
 
2. How engaged were you in the task? 
(Not much)           1                        2                           3                          4                           5                       
(A lot) 
 
3. How did you find the ‘sequential’ tapping condition? (i.e. was it easy to do, were you able to keep 
up with the flashing symbol?) 
__________________________________________________________________________________
__________________________________________________________________________________ 
4. How did you find the ‘random’ tapping condition? (i.e. was it easy to do, were you able to keep up 






5. Did you find that you began to lose interest in the task towards the end?    Yes  /  No 
If so, to what extent? (Please describe) __________________________________________________ 
 







CATSYS formula relating performance index to performance below average: 
𝑷𝑰 = 𝟏 ÷  ℮ ((𝑷 − 𝑷𝒎) ÷ 𝒔 (𝑷𝒎))  
CATSYS formula relating performance index to performance above average: 
𝑷𝑰 = 𝟐 −  ℮ (𝟏 ÷ (𝑷 − 𝑷𝒎) ÷ 𝒔 (𝑷𝒎)) 
PI = performance index 
P = performance as measured and calculated by CATSYS 
Pm = Mean performance of large, sound population defined in the test battery 










High pleasure, low arousal 
  
1 Family 2332 7.18 4.2 
2 Children 2341 6.78 3.59 
3 Man 2357 5.33 3.06 
4 Woman 2372 5.35 3.39 
5 Band 2373 6.8 4.92 
6 Girl 2381 5.54 3.76 
7 Fish 1900 6.4 3.04 
8 Medical worker 2394 5.36 3.85 
9 Porpoise 1920 7.83 4.21 
10 Baby 2070 7.69 4.02 
11 Balloons 2791 6.02 3.58 
12 Couple 2501 6.33 2.67 
13 Woman 2506 5.8 4.14 
14 Couple 2550 7.37 4.15 
15 Shadow 2880 5.13 2.68 
16 Food basket 2980 5.48 3.09 
17 Mountains 5631 7.08 4.31 
18 Cave 5661 6.02 4.36 
19 Beach 5836 7.08 4.47 
20 Romance 4622 6.7 4.11 
 
 
Description Slide No. Valence Mean Arousal Mean 
     
 
High pleasure, high arousal 
  
1 Teens 2389 6.38 5.26 
2 Dancer 2616 6.13 5.06 
3 Woman 2030 7.51 6.24 
4 Bride 2209 7.12 5.04 
5 Erotic female 4220 7.81 6.64 
6 Attractive fem 4250 8.39 7.02 
7 Attractive fem 4275 7.51 6 
8 Couple 4598 6.55 5.25 
9 Romance 4599 7.02 5.73 
10 Romance 4606 6.37 5.1 
11 Shark 5622 6.44 5.38 
12 Windsurfers 5623 7.12 5.56 
13 Earth 5890 6.6 5.17 
14 Fireworks 5910 7.41 5.37 
15 Wedding 4626 7.36 5.45 
16 Erotic couple 4645 6.56 5.56 
17 Waterfall 5260 7.47 6 
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18 Skydivers 5621 7.28 6.96 
19 Turkey 7230 7.42 5.81 
20 Sky 5982 7.38 5.25 
 
 




Low pleasure, low arousal 
  
1 Boy 2410 4.72 3.83 
2 Sad girls 2455 3.32 4.26 
3 Elderly man 2480 4.76 2.8 
4 Toddler 2095 2.16 4.69 
5 Angry face 2100 4.3 3.77 
6 Angry face 2120 3.65 4.93 
7 Fingerprint 2206 3.91 3.56 
8 Girl 2276 3.17 4.02 
9 Mother 2312 4 3.77 
10 Disabled child 3300 3.14 4.14 
11 Erotic male 4538 4.59 2.9 
12 Beach boys 4542 4.92 3.75 
13 Police 2682 3.98 4.43 
14 Refugees 2695 4.49 4.26 
15 Woman 2700 3.33 4.52 
16 Alcoholic 2753 3.37 3.93 
17 Actor 2780 4.75 4.7 
18 Tourist 2850 4.69 2.58 
19 Crying boy 2900 2.76 4.76 
20 Tornado 5970 4.31 4.65 
 
 
Description Slide No. Valence Mean Arousal Mean 
 
Low pleasure, high arousal 
  
1 Baby 2661 3.22 5.18 
2 Open chest 3250 3.92 6.1 
3 Dental exam 3280 3.83 5.72 
4 Injury 3550 3.1 5.69 
5 Bomb 2692 4.02 5.11 
6 Sad children 2703 2.33 5.73 
7 Drug addict 2710 3.04 5.29 
8 Pipe 2716 3.48 5.21 
9 Gun 2811 2.84 6.31 
10 Deer head 2981 3.55 5.54 
11 Scream 3022 4.28 5.61 
12 Surgery 3210 4.83 5.27 
13 Medical assist 3216 3.6 5.3 
14 Lava 5940 4.79 6.42 
15 Tornado 5972 4.11 6.38 
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16 Electric chair 6020 4.1 5.23 
17 Aimed gun 6200 3.36 5.8 
18 Attack 6211 4.25 5.38 
19 Terrorist 6213 3.75 5.25 
20 Gang 6242 3.28 5.09 
 
 




Neutral pleasure, low arousal 
  
1 Men 2397 5.06 3.12 
2 Neutral girl 2441 4.95 3.48 
3 Man 2512 4.96 3.63 
4 Neutral woman 2038 5.08 2.98 
5 Woman 2830 5.09 3.93 
6 Chess 2840 4.92 2.31 
7 Plant 5740 5.07 2.36 
8 Plate 7233 5.01 2.51 
9 Mug 7009 4.96 2.69 
10 Fan 7020 5.02 2.15 
11 Baskets 7041 4.96 2.68 
12 Tool 7056 4.98 3.24 
13 Keyring 7059 5.04 2.96 
14 Book 7090 4.95 2.3 
15 Fabric 7160 4.98 3.06 
16 Pole 7161 4.99 2.79 
17 Abstract art 7184 4.94 3.44 
18 Abstract art 7186 4.98 3.48 
19 Beads 7207 5 3.31 
20 Clock 7211 4.98 3.7 
 
 
Description Slide No. Valence Mean Arousal Mean 
 
Neutral pleasure, high arousal 
 
1 Shark 1931 4.51 6.88 
2 Shark 1932 4.81 6.21 
3 Male fale 2220 5.21 5.04 
4 Sick baby 3302 5 5.69 
5 Surgery 3210 4.83 5.27 
6 Lava 5940 4.79 6.42 
7 Aimed gun 6410 4.43 5.6 
8 Freeway 7560 4.42 5 
9 Skyscraper 7640 5.31 6.21 
10 Police 6840 4.43 5.96 
11 Aircraft 6900 5.15 6.02 
12 Missiles 6930 4.46 5.17 
13 Tank 6940 4.77 5.17 
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14 Boy 9411 4.99 5.61 
15 Rock climber 8160 5.54 6.9 
16 Boxer 8231 4.6 5.17 
17 Nudists 8466 5.45 5.04 
18 Biking/train 8475 5.57 5.04 
19 Biker on fire 8480 4.5 5.83 





IAPS behavioural test form 
This task for use in an fMRI scanner is approximately 7 minutes long. 
The task uses pictures from the ‘International Affective Picture System’ and is designed to look at 
your emotional responses to the pictures. Please look at each picture and use the LEFT and RIGHT 
arrow buttons on the keyboard to indicate your responses to the pictures. The responses will be 
categorised as “Face” or “No Face”, where “Face” refers to the presence of a face in the picture. In 
this task, animals are also classified as having faces. During the task there will be some black screens 
with a cross-hair in the middle, please just focus on the cross-hair during these screens. The screen 
will go blank at the end of the task. The pictures will stay up for approximately 3 seconds each, and 
will change regardless of whether you indicate a “Face”/”No Face” answer, so please answer within 
this time frame if you can.  
Your feedback from these tasks will help to determine whether they are suitable for use in an fMRI 
scan. Thank you ☺  
1. How much did you focus on the content of the pictures during the task? 
 
(Not much)              1               2                 3                 4                 5                        (A lot) 
 
2. Did you find that choosing “Face” or “No Face” distracted you from looking properly at the 
images? 
(No, not at all)              1               2                 3                 4                 5                        (Yes, a 
lot) 
 
3. Did you find choosing “Face” or “No Face” at all confusing or difficult? 
(No, not at all)              1               2                 3                 4                 5                        (Yes, a 
lot) 






4. Were you clear on how to do the task, or did you find it confusing? 
(Not really, it was confusing)              1               2                 3                 4              5      (Yes, it was 
simple) 
 
5. Did you think that some of the images were quite emotional? 
(No, they were not emotional)          1          2            3           4             5        (Yes, they were 
emotional) 
 
6. Did you find any of the pictures that were shown particularly disturbing?        Yes  /  No 
If so, which ones? (Please describe) 
_____________________________________________________ 
 
7. Would you object to being shown these particular pictures without first being informed of their 
nature?                                                                                                                               Yes  /  No 
 
8. Did you find that you began to lose interest in the task towards the end?    Yes  /  No 
If so, to what extent? (Please describe) __________________________________________________ 
 
9. Do you have any other comments? 
__________________________________________________________________________________
__________________________________________________________________________________ 
